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Translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor (PBR), 
is a mitochondrial outer membrane protein highly conserved from bacteria to humans. TSPO is found to 
be upregulated in many pathological conditions, making it an attractive target for both diagnostic and 
therapeutic purposes in human medicine. However, the exact molecular function of TSPO remained 
unclear. For the past 25 years, TSPO was depicted to transport cholesterol from the cytosol to the inner 
mitochondrial membrane, the rate-limiting step in steroid hormone biosynthesis. Its critical role in 
survival and development was reinforced by a report that claimed TSPO knockout (Tspo-/-) mice were 
embryonic lethal. Therefore, there had been no genetic models to study the function of TSPO and all 
functional interpretations of TSPO were based on in vitro experiments using pharmacological tools. Our 
lab generated the first global Tspo-/- mice which surprisingly were healthy with no apparent abnormalities. 
Deletion of TSPO in different steroidogenic cell lines also did not affect cell viability. Furthermore, 
steroid hormone production was not affected in Tspo-/- mice or in steroidogenic cells lacking TSPO 
compared to the controls, indicating that TSPO is not involved in steroidogenesis. The stimulating effect 
of some TSPO binding chemicals on steroid hormone production that formed the early basis for linking 
TSPO and steroidogenesis was also found to be inaccurate. Using the TSPO knock out MA-10 Leydig 
cancer cells, I demonstrated that PK11195, the prototypical ligand of TSPO, could modestly induce 
steroid hormone production to the same extent regardless of the presence or absence of TSPO. This result 
indicated that the effect of PK11195 is nonspecific and not mediated by TSPO. 
My studies subsequently made the first correlation that TSPO is enriched in all tissues rich in 
 lipid droplets including adipose tissues, suggesting a role of TSPO in lipid metabolism. Using both TSPO 
knockout MA-10 cells and Tspo-/- mice as the models, I demonstrated that deletion of TSPO increased 
mitochondrial fatty acid oxidation (FAO). However, co-immunoprecipitation result showed that TSPO 
did not have any interacting partners involved in FAO but formed a dimer, which could be induced by 
protoporphyrin IX (PPIX), the endogenous ligand of TSPO. Levels of free PPIX were found to be high in 
tissues rich in lipid droplets and directly regulated by TSPO. I also provided the first evidence for a novel 
function of PPIX in inhibiting FAO, which forms the basis for TSPO in regulation of FAO. 
Overall, my studies helped amend the current model of steroidogenesis by removing TSPO from 
its core machinery, and paving the way for the precise cholesterol transport mechanism to be identified. 
The function of TSPO in PPIX sequestering instead of steroidogenesis urges careful reinterpretation of 
previous studies using TSPO binding chemicals, and rigorous reevaluation of their applications in human 
medicine. Studying biological functions of PPIX is poised to uncover potentially new pathways with 
broad implications in biology, and remains a core topic for future investigation.   
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CHAPTER 1 
Introduction and Literature Review 
Selvaraj, V., Stocco, D. M., & Tu, L. N. (2015). Minireview: translocator protein (TSPO) and 
steroidogenesis: a reappraisal. Molecular endocrinology, 29(4), 490-501. 
 
Selvaraj, V., & Tu, L. N. (2016). Current status and future perspectives: TSPO in steroid 
neuroendocrinology. J Endocrinol, 231(1), R1-R30. 
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OVERVIEW OF THE TRANSLOCATOR PROTEIN 
Translocator protein (TSPO), also known as the peripheral benzodiazepine receptor (PBR), was first 
identified in 1977 based on its distinct pharmacology with high affinity binding to benzodiazepines in peripheral 
tissues (Braestrup et al., 1977; Braestrup and Squires, 1977; Davies and Huston, 1981; Regan et al., 1981). The 
term ‘peripheral’ was used to distinguish it from the plasma membrane ‘central’ benzodiazepine receptor, a 
complex together with the γ-aminobutyric acid type A (GABAA) receptor that is important for inhibitory 
neurotransmission in the central nervous system (Macdonald and Barker, 1978; Takahashi et al., 1958). In 
comparison, TSPO/PBR is present in the mitochondria and its structural and functional properties have been a 
topic of active research for the past 25 years (Gatliff and Campanella, 2012; Gavish et al., 1999; Rupprecht et al., 
2010).  
Comparisons of TSPO/PBR amino acid sequence show a high degree of conservation throughout 
evolution (Yeliseev and Kaplan, 1995). Both human and mouse Tspo genes translate to a 169 amino acid protein 
with 81% sequence homology (Bucan et al., 1993; Riond et al., 1991). Sequence examination of the Tspo promoter 
region revealed a GC-rich region that binds specific protein transcription factors (Sp1/Sp3/Sp4) (Batarseh et al., 
2012). Sequences in the promoter region that bind the v-ets erythroblastosis virus E26 oncogene homolog (Ets), 
and activator protein 1 (AP1) have also been reported (Giatzakis et al., 2007; Giatzakis and Papadopoulos, 2004). 
In addition, a recent study showed the existence of a non-transcription factor-mediated gene regulation for TSPO 
via an intron-based short interspersed repetitive element (SINE) B2 natural antisense transcript (Fan and 
Papadopoulos, 2012). It appears that signaling via protein kinase C ε (PKCε) could induce TSPO expression 
(Batarseh et al., 2008; Batarseh and Papadopoulos, 2010), however, the precise mechanisms that control Tspo 
gene regulation remain unclear (Batarseh and Papadopoulos, 2010). Expression of TSPO has been reported in 
different tissues including heart, brain, lung, spleen, testis, ovary, adrenal, kidney, bone marrow, salivary gland, 
platelets, adipose tissue, skin and liver (Anholt et al., 1985b; Tu et al., 2014; Wang et al., 2012); and within these 
tissues, TSPO expression is regional and/or cell type specific (Morohaku et al., 2013). 
In eukaryotic cells, sub-cellular fractionation and detection using TSPO-binding chemicals showed that 
TSPO/PBR was enriched in outer mitochondrial membrane (OMM) (Anholt et al., 1985b; Anholt et al., 1986; 
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Basile and Skolnick, 1986). To a lesser extent, binding sites were also detected in the plasma membrane of 
erythrocytes (Olson et al., 1988). Antibody-based labeling also confirmed the predominant presence of TSPO in 
the mitochondria, but also indicated localization in plasma membrane of adrenocortical cells (Oke et al., 1992), 
and nuclear labeling was observed in adult male germ cells (Manku et al., 2012) and in some cancer cells 
(Hardwick et al., 1999; Venturini et al., 1998). However, a rabbit monoclonal antibody against TSPO recently 
released in the market (Cat# ab109497; Abcam, Cambridge, MA) allowed for TSPO detection with high 
specificity; using this antibody, TSPO expression in adult male germ cells was not detected (Morohaku et al., 
2013). Therefore, studies using polyclonal antisera against TSPO for immunolocalization may need to be 
interpreted with caution. In addition, non-specific signal from TSPO binding chemicals have been detected in vivo 
(Owen and Matthews, 2011), and several non-TSPO mediated effects have been recorded in vitro (Gonzalez-Polo 
et al., 2005; Hans et al., 2005; Walter et al., 2005). Therefore, the existence of non-mitochondrial forms of TSPO 
remains to be definitively established. 
TSPO structure 
The structure of murine TSPO was initially described as a five transmembrane alpha helix (Murail et al., 
2008). This was followed by a low-resolution structure of Rhodobacter sphaeroides TSPO constructed using 
electron cryo-microscopy, showing the possibility of a channel-like structure with an interior surface for potential 
substrate translocation (Korkhov et al., 2010). However, it was not possible to assign amino acid sequences to this 
low-resolution TSPO structure (Korkhov et al., 2010) and any functional prediction was largely speculative. In 
1998, a putative cholesterol recognition amino acid consensus (CRAC) sequence was identified at the C terminal 
region of TSPO, suggesting cholesterol binding property (Li and Papadopoulos, 1998). These structural features 
contributed to the modeling of TSPO as a membrane-associated cholesterol transport protein (Lacapere et al., 
2001; Rupprecht et al., 2010). A more recent high-resolution NMR structure of murine TSPO confirmed the 
structure of a five alpha helix fold but showed that side chains of the CRAC motif essential for cholesterol binding 
are located on the outside of the TSPO pointing towards the membrane environment (Jaremko et al., 2014) (Figure 
1.1), suggesting that previous model of TSPO transporting cholesterol through the interior core was not accurate. 
Instead, the CRAC motif could function in associating TSPO with raft microdomains in the membrane (Morohaku 
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et al., 2014). Binding of PK11195, a prototypical ligand of TSPO, does not involve the CRAC motif (Figure 1.1) 
and appeared to stabilize its 3D structure (Jaremko et al., 2014).   
TSPO has been reported to exist in several forms of oligomers as multiple bands were detected in a 
western blot using TSPO polyclonal antisera (Delavoie et al., 2003). However, these extra bands are likely 
nonspecific as they have not been reported in studies using the rabbit monoclonal antibody recognizing the last 
amino acids at the C-terminus of TSPO (Morohaku et al., 2013). Crystallographic studies of bacterial TSPO 
concluded that purified TSPO formed a highly stable dimer (Guo et al., 2015; Li et al., 2015) but the NMR 
structure of murine TSPO was found to be a monomer (Jaremko et al., 2014). Moreover, the dimerization interface 
was described completely different between Bacillus cereus and Rhodobacter sphaeroides TSPO (Guo et al., 
2015; Li et al., 2015), raising questions why the dimerization sites are not conserved and whether the dimerization 
itself is an artifact due to hydrophobic aggregation of TSPO during purification and/or crystallization. Therefore, 
the conclusion of TSPO oligomerization still needs further investigation for more definitive experimental 
evidence.  
 
Figure 1.1. Structure of TSPO in outer mitochondrial membrane. (A) Side view: TSPO has a five α-helix 
transmembrane structure. The CRAC motif (in red) is at the C terminus (residues 147 to 159). Side chains of 
Tyr152, Tyr153 and Arg156, essential for cholesterol binding are located on the outside of the TSPO structure and 
point toward the membrane environment.  PK11195 binding pocket (in purple) is formed by residues Ala23, Val26, 
Leu49, Ala50, Ile52, Trp107, Ala110, Leu114, Ala147 and Leu150, that do not involve side chains of CRAC motif amino 
acids. Binding site for Ro5-4864 (in green) is distinct from that of PK11195 and was identified to include residues 
Glu29, Arg32, Lys39 and Val154 (Farges et al., 1994). (B) Top view: Cholesterol binding side chains of the CRAC 
motif pointing outside of the TSPO structure and do not interfere with internal PK11195 binding site. From high-
resolution NMR structure PDB ID: 2MGY (Jaremko et al., 2014). 
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TSPO pharmacology 
Pharmacology of benzodiazepines provided most of the early information about TSPO. Benzodiazepine 
Ro5-4864 (4’-chlorodiazepam), and a non-benzodiazepine PK11195 (an isoquinoline carboxamide derivative) 
were initially established as prototypical TSPO binding chemicals (Le Fur et al., 1983a; Le Fur et al., 1983b), as 
they bind to TSPO but not to GABAA (Benavides et al., 1983a; Benavides et al., 1983b). This ability to detect 
TSPO using binding chemicals with reasonable accuracy, and the pathological TSPO upregulation seen at sites of 
inflammation led to the development of TSPO as a diagnostic target (Chen and Guilarte, 2008). TSPO-binding 
chemicals linked to tracers could be used to detect inflammatory lesions in vivo in a variety of human diseases 
using positron emission tomography (Banati et al., 2000; Chauveau et al., 2008). Therefore, many classes of TSPO 
binding chemicals have been developed and used in both basic and clinical research across multiple fields of 
human medicine (reviewed in (Kim and Pae, 2016)). Clinical trials for different TSPO binding drugs for this 
application are either in progress or have been recently completed (clinicaltrials.gov; Identifiers: NCT02181582, 
NCT01547780, NCT01527695, NCT01428505, NCT02086240, NCT02062099, NCT01613703), and this 
remains an area of active research. 
Beyond this use as a diagnostic tool, several functional interpretations of TSPO based on responses to 
chemical binding have been documented. These implicated a primary role for TSPO in steroid hormone production 
(Mukhin et al., 1989; Papadopoulos et al., 1990), and additional roles in mitochondrial respiration (Larcher et al., 
1989; Rosenberg et al., 2013), cell proliferation (Takai et al., 2012; Wu and Gallo, 2013), production of reactive 
oxygen species (Lehtonen et al., 2012; Zeno et al., 2012) and execution of apoptosis via modulating the 
mitochondrial permeability transition pore (MPTP) (Sileikyte et al., 2011; Zulian et al., 2011). Moreover, 
beneficial pharmacological effects were observed in treatments using TSPO binding chemicals in preclinical 
models across a variety of diseases/disorders. As a result, there has been immense interest in promoting different 
TSPO binding chemicals as drugs for treatment of a variety of conditions that include: neurological disorders 
(Rupprecht et al., 2010), neurotrauma (Papadopoulos and Lecanu, 2009), multiple sclerosis (Daugherty et al., 
2013), cancer chemotherapy (Austin et al., 2013), cardiovascular disease (Qi et al., 2012), and Alzheimer’s disease 
(Barron et al., 2013). Therapeutic benefits from use of TSPO binding chemicals were explained by their putative 
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ability to induce steroid hormone production in these different conditions (Rone et al., 2009). This link was made 
due to the prevailing model at the time that proposed an indispensable role for TSPO in steroid hormone 
production (Papadopoulos and Miller, 2012). 
It is important to note that there are reports in the literature of TSPO-independent actions of several 
putative binding chemicals, although specific cellular targets other than TSPO have not been characterized. TSPO 
ligands like PK11195 can insert themselves into lipid bilayers affecting membrane properties (Hatty et al., 2014), 
a phenomenon that could modulate cholesterol availability to the steroidogenic machinery. PK11195 has also been 
demonstrated to target the F1F0-ATPsynthase and inhibit mitophagy without the involvement of TSPO 
(Seneviratne et al., 2012). In another study, an apoptosis-sensitizing effect for PK11195 was observed even after 
TSPO was completely knocked down (Gonzalez-Polo et al., 2005). The anti-tumor effect of TSPO binding 
chemicals Ro5-4864 and FGIN-1-27 was identical irrespective of the presence or absence of TSPO in different 
tumors (Hans et al., 2005). In hematologic cancers, PK11195 showed broad inhibition of adenosine triphosphate 
(ATP)-binding cassette transporters by binding to plasma membrane sites without involvement of TSPO (Walter 
et al., 2005). In cells of mesenchymal origin, PK11195 and Ro5-4864 could inhibit cell proliferation through 
decreases in activation of ERK and c-Jun independent of TSPO (Kletsas et al., 2004). Therefore, interpretations 
of biological effects mediated by TSPO binding chemicals require caution as they might not translate to the true 
function of TSPO.  
Human TSPO polymorphism 
Mutations/polymorphisms for TSPO were previously sought and excluded in lipoid congenital adrenal 
hyperplasia patients (Lin et al., 1993). However, a common human polymorphism in TSPO (rs6971, leading to 
amino acid change Ala147Thr) has been demonstrated to cause differences in affinity of TSPO binding chemicals 
used for diagnostic imaging (Mizrahi et al., 2012; Owen et al., 2012). Ala147 is considered part of the TSPO 
PK11195 binding pocket (Jaremko et al., 2014), suggesting that a change to Thr147 could affect binding properties 
of PK11195 and other chemicals that bind to this region. Functionally, this rs6971 polymorphism was linked to 
adult separation anxiety in patients with depression (Costa et al., 2009b). This same polymorphism was 
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subsequently associated with decreased pregnenolone production by immune cells in both Thr147 homozygous 
and heterozygous individuals (Costa et al., 2009a). 
TSPO homolog 
 Due to Tspo sequence conservation from bacteria to humans, there has been some interest in studying the 
functional evolution of this gene (Fan et al., 2012). Tspo2 (PBRL/Peripheral benzodiazepam-like) was identified 
as a gene that emerged from a duplication event preceding speciation of reptiles, birds and mammals (Nakazawa 
et al., 2009). TSPO2 expression appears restricted to the bone marrow (Fan et al., 2009; Nakazawa et al., 2009), 
and has not been detected in steroidogenic tissues [confirmed in (Morohaku et al., 2014; Tu et al., 2014)]. 
Subcellular localization of TSPO2 using specific antibodies has not been performed; localization based on 
overexpression studies using C-terminal GFP/DsRed-TSPO2 fusion proteins (chicken, mouse and human) in cell 
lines have led to conflicting proposals. The group who studied chicken TSPO2 demonstrated mitochondrial 
localization (Nakazawa et al., 2009), and the group who studied mouse and human TSPO2 proposed that TSPO2 
is localized to the endoplasmic reticulum and the nuclear membrane (Fan et al., 2009). These studies have 
demonstrated functional disparities as well. Based on the study in the chicken, a strict co-regulation of TSPO2 
expression but not TSPO expression with genes involved in hematopoiesis was demonstrated (Nakazawa et al., 
2009). This led to the conclusion that TSPO2 may be involved in heme availability for the assembly of hemoglobin 
(Nakazawa et al., 2009). In contrast, the study with mouse and human TSPO2 was an extrapolation of previous 
work on TSPO and steroidogenesis from the same authors, and suggested that TSPO2 is involved in cholesterol 
uptake and trafficking in erythroid cell types (Fan et al., 2009). At the present time, there are no gene knockout 
models to study loss-of-function resulting from TSPO2 deletion, and understanding of its function remains 
rudimentary. Nevertheless, what we do know is that distinct tissue localization patterns and regulation between 
TSPO and TSPO2 negates concerns of potential functional redundancy in studies that use Tspo gene-deleted 
models.  
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TSPO AND STEROIDOGENESIS 
Establishment of the model 
The first observation that chemicals that bind to TSPO could stimulate steroid biosynthesis was made in 
adrenal tumor cells in 1989 (Mukhin et al., 1989). Subsequent experiments in a variety of steroidogenic cells 
reinforced that synthetic small molecule drugs that bind TSPO could increase steroid hormone production 
(Krueger and Papadopoulos, 1990; Papadopoulos et al., 1990; Papadopoulos et al., 1991c). In support of these 
xenobiotic effects, a naturally occurring intracellular protein, the Acyl-CoA-binding protein (ACBP/ACBD1), 
previously known as the diazepam binding inhibitor (DBI) that binds TSPO, increased steroid synthesis in 
steroidogenic cells (Garnier et al., 1993; Papadopoulos et al., 1991a; Papadopoulos et al., 1991b; Papadopoulos 
et al., 1992).  Subsequent experiments using knockdown technology to inhibit TSPO expression also indicated 
that the presence of TSPO was essential for steroid synthesis (Boujrad et al., 1993; Papadopoulos et al., 1997b).  
Further, it was reported that the presence of a higher affinity ligand-binding site on TSPO was responsible for the 
constitutive biosynthesis of steroids observed in the R2C rat Leydig tumor cell line (Garnier et al., 1994). 
Supporting this mechanism, targeted disruption of TSPO in these R2C cells was shown to obliterate their ability 
to produce steroid hormones (Papadopoulos et al., 1997b). TSPO sequence also showed the existence of a 
cholesterol-binding amino acid consensus (CRAC) motif suggesting a molecular mechanism in place for 
cholesterol binding and/or transport (Li et al., 2001). All these points of evidence led to a conclusion that TSPO 
played an indispensable role in the process of cholesterol transfer to the mitochondrial inner membrane and 
steroidogenesis.  
The steroidogenic acute regulatory protein (STAR) was modeled to deliver cholesterol to the OMM and 
TSPO carried out the mitochondrial cholesterol import process. Expression of STAR in steroidogenic cells in the 
absence of hormone stimulation resulted in an increase in steroid biosynthesis (Clark et al., 1994). Mutations in 
the Star gene were responsible for the potentially fatal lipoid congenital adrenal hyperplasia (lipoid CAH), a 
disease in which severely afflicted individuals are unable to synthesize steroids (Lin et al., 1995). Mitochondrial 
cholesterol transport mediated by StAR was proposed as a shuttling event in that either StAR transfers cholesterol 
molecules, one at a time, to the IMM; or the START domain of StAR may alter the mitochondrial membrane to 
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allow for the passage of cholesterol, before reaching its final resting place in the mitochondrial matrix (Stocco, 
2001). But these models for StAR required modifications because deletion of 62 amino acids at the N-terminus 
of StAR without affecting the START domain prevented mitochondrial import, but did not affect cholesterol 
transfer and steroid production (Arakane et al., 1996; Wang et al., 1998). Moreover, Tom20-StAR fusion protein 
affixed to the OMM could induce steroidogenesis suggesting that StAR entry into the mitochondrion was not 
necessary, and that functional effects mediated by StAR are completed at the level of the OMM (Bose et al., 2002). 
Using this same model expressing OMM-affixed StAR-TOM20 fusion protein, it was demonstrated that TSPO 
knockdown using antisense oligonucleotides could reduce steroidogenic capacity (Hauet et al., 2005). These 
findings ultimately led to the conclusion that there was a functional cooperation between StAR and TSPO to 
mediate mitochondrial cholesterol transport required for steroid hormone biosynthesis. Therefore, a model in 
which StAR is considered the ‘initiator’ of cholesterol transport and TSPO is considered the ‘gate’ for cholesterol 
entry into mitochondria was established (Papadopoulos and Miller, 2012) and prevailed for the past 25 years. 
Limitations of studies linking TSPO to steroidogenic function 
Examination of previous literature on TSPO suggests that the proposed link to steroidogenesis was based 
on a complex combination of multiple interdependent indicators from a variety of methodologies, most of which 
were inconclusive, and in several cases may have been over-interpreted.  
There were two key elements that initially made a function for TSPO in steroidogenesis plausible; they 
were its localization to the OMM, and its high level of expression noted in steroidogenic cells (Anholt et al., 1986). 
However, these were just interesting associations and not direct indications. As another layer of support, often 
presented was the demonstration that hypophysectomy could decrease TSPO expression in the adrenal and testes 
(Anholt et al., 1985a). If we dissect their study, rats were examined 23 days after hypophysectomy, during which 
body weights had decreased significantly (to 55% of the control rats), and the adrenal was in a severe state of 
involution (only 28% the weight of control adrenals) (Anholt et al., 1985a). It should be noted that loss of adrenal 
weight after hypophysectomy is mainly due to shrinkage of the adrenal cortex (Deane and Greep, 1946), however 
depletion of Ro5-4864 binding (used as a measure of TSPO) in their study was calculated based on whole adrenal 
weight (Anholt et al., 1985a). It should also be noted that depletion of mitochondrial CYP11A1 activity after 
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hypophysectomy shows an almost linear drop to just 10% of control values in just 7 days, a time point when the 
adrenal weight was still 65% compared to control adrenals (Kimura, 1969). A subsequent study by another group 
demonstrated that the decrease in Ro5-4864 binding in the adrenal after hypophysectomy in rats was associated 
with mitochondrial depletion, and that changes to TSPO expression after ACTH restoration was not temporally 
related to the induction of steroidogenesis (Cavallaro et al., 1993). Although this study by Cavallaro et al. provided 
an early indication that previous evidence for TSPO was simply circumstantial, it was rarely referenced (14 
citations to date), whereas mention of previous work by Anholt et al. was very common (113 citations to date).  
Pharmacology of TSPO binding chemicals was often presented as direct evidence for the role of TSPO in 
steroid hormone production (Mukhin et al., 1989; Papadopoulos et al., 1990). Among the different TSPO binding 
chemicals tested, PK11195 was the most potent inducer of steroidogenesis followed by Ro5-4864. However, the 
response itself was very modest (maximal levels were 80-fold lower than a response seen with hCG), and transient 
(progesterone production reached maximal levels within 40 minutes, with no progressive accumulation, and levels 
remained unchanged for the next 4 hours of this experiment). Although these observations suggested a physical 
response to treatment rather than a sustained physiological response (as seen with hCG), this possibility was not 
investigated. Moreover, effects of TSPO binding chemicals were not always consistent. PK11195 and Ro5-4864 
were shown to have different thermodynamic properties, and predicted to be antagonistic and agonistic 
respectively (Le Fur et al., 1983b), even before studies linking TSPO and steroidogenesis. In agreement with this 
prediction and contrary to a stimulatory effect on steroidogenesis, it was demonstrated that treatment with 
PK11195 completely inhibited adrenal steroidogenesis stimulated by ACTH in hypophysectomized rats 
(Cavallaro et al., 1992). In another study, PK11195 was shown to inhibit brain pregnenolone synthesis in 
adrenalectomized-castrated rats, whereas another TSPO-binding chemical FGIN-1-27 was shown to increase 
pregnenolone production under similar conditions (Romeo et al., 1993). Effects consistent with an inhibitory role 
for PK11195 in steroidogenesis and other effects were reported in several other studies (Auta et al., 1993; Frye et 
al., 2009; Korneyev et al., 1993; Tsuda et al., 1998). Also, when placental explants were exposed to Ro5-4864, 
Ro5-4864 stimulated a 2.4-fold increase in progesterone levels at a low dose, but caused a significant decrease 
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compared to baseline at high doses (Barnea et al., 1989). In another study, Ro5-4864 was found to suppress 
estradiol production in vivo, whereas PK11195 had no effect on ovarian steroidogenesis (Weizman et al., 1997).  
Binding of the Acyl-CoA-binding protein (ACBP) and its processed peptides to TSPO stimulated steroid 
hormone production in isolated mitochondria (Papadopoulos et al., 1991b). In hypophysectomized rats, ACTH 
failed to acutely increase the amount of adrenal ACBP or TSPO, but increased the rate of ACBP processing and 
hormone production (Cavallaro et al., 1992). This ACTH-induced increase in ACBP processed peptides was 
interpreted as playing an important role in steroidogenesis. In support, knockdown of ACBP expression using a 
cholesterol-linked phosphorothioate oligodeoxynucleotide antisense, demonstrated decreased steroid hormone 
production in cultured Leydig tumor cells (Boujrad et al., 1993). ACBP is present in eukaryotes ranging from 
yeast to mammals (Knudsen et al., 1999), and was demonstrated to play a role in maintaining the intracellular 
Acyl-CoA ester pool size (Mandrup et al., 1993), and synthesis of very long chain fatty acids and sphingolipids 
(Gaigg et al., 2001). A spontaneous mutant mouse nm1054 cataloged at the Jackson Laboratory (Ohgami et al., 
2005a; Ohgami et al., 2005b), was subsequently identified to also contain a mutation in the ACBP gene locus (Lee 
et al., 2007). Loss of ACBP in these nm1054 mice was linked to fatty acid metabolism abnormalities in skin and 
hair (Lee et al., 2007). The subsequent generation of ACBP knockout mice (ACBP-/-) resulted in a finding that 
they were early embryonic lethal at the blastocyst stage of development (Landrock et al., 2010). However, a 
second independent ACBP-/- mouse generated showed that they were viable and fertile, and developed normally 
but with delayed metabolic adaptation to weaning (Neess et al., 2011). Further studies on this latter mouse 
(Bloksgaard et al., 2012; Neess et al., 2013) showed that metabolic abnormalities seen in skin and hair matched 
observations previously reported for the nm1054 mutation. There was no phenotypic evidence that indicated 
defects in steroid hormone production in these ACBP-/- mice. But why was there such a discrepancy between the 
two ACBP knockout mice? One explanation is that abnormal random insertional mutagenesis in embryonic stem 
cell clones could have resulted in lethality unrelated to ACBP deletion in the first ACBP-/- mouse line; validation 
to rule out this possibility was not presented (Landrock et al., 2010). Nevertheless, more recent understanding of 
ACBP function does not indicate a link to steroidogenic function as previously concluded. 
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Cholesterol is considered a natural ligand for TSPO. The CRAC motif that binds cholesterol was identified 
at the TSPO C-terminal region (Li and Papadopoulos, 1998). The CRAC motif is a sequence pattern – L/V-X1-5-
Y-X1-5-R/K – with an extremely loose definition with only one unique residue and two large variable segments. It 
was pointed out that the genome of Streptococcus agalactiae that encodes 2094 known and hypothetical proteins, 
almost all of which will have no association with cholesterol, have 5737 CRAC motifs (2.7/protein and 1/122 
amino acids) (Palmer, 2004); something that is probably true for all organisms. Therefore, predictive value of the 
CRAC motif is poor, and cannot be considered an indicator of cholesterol binding or transport function in a 
protein. For example, the CRAC motif in the nicotinic acetylcholine receptor was found in an energetically 
unfavorable location to bind cholesterol, and an alternative region of cholesterol binding was ultimately identified 
(Baier et al., 2011). But for TSPO, there is certainly evidence in the literature that cholesterol can interact with 
the CRAC motif (Li and Papadopoulos, 1998; Li et al., 2001). Most functional CRAC motifs have been described 
in proteins that associate with cholesterol-rich membrane regions called raft microdomains, for example: myelin 
P0 (Luo et al., 2007) and caveolin-1 (Yang et al., 2014). Given the new findings that TSPO is not involved in 
steroid hormone production, it is necessary to ask the question whether there is enough functional evidence for 
TSPO in mitochondrial cholesterol transport? As suggested previously (Morohaku et al., 2014), it is possible that 
the CRAC motif of TSPO could merely function in associating with cholesterol-rich raft microdomains. A 
proposed TSPO-interacting protein, voltage dependent anion channel 1 (VDAC1) on the OMM is a resident 
protein in raft microdomains (Herrera et al., 2011). Therefore, TSPO membrane raft association via the CRAC 
motif could be the basis for proximity and interaction with VDAC1. 
For demonstrating cholesterol transport, Escherichia coli DE3 bacteria that do not have TSPO or 
cholesterol were shown to gain the ability to accept cholesterol when TSPO was overexpressed (Li and 
Papadopoulos, 1998); mutations to the CRAC motif, Y153S and R156L completely abolished this cholesterol 
absorption. In this heterologous system, it was possible to demonstrate that TSPO cholesterol binding was 
reproducible. However, 3H-cholesterol acceptance by bacteria over a 120-minute period at 37˚C did not show 
saturation. This failure to saturate was considered as evidence that TSPO was a channel rather than cholesterol-
binding protein. But it was not examined if there was a pool of cholesterol that was not bound to TSPO in the 
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bacterial plasma membrane. In addition, the cholesterol-loaded bacteria were not tested for the presence of any 
inclusion bodies to suggest uptake and storage. It should be noted that the bacterial cytoplasm does not have any 
membrane-bound organelles or mechanisms to store excessive cholesterol. Moreover, bacterial proliferation and 
continued TSPO expression that could have occurred during the 120-minute incubation period was not considered. 
Therefore, this prediction of a function for TSPO in cholesterol translocation can be considered premature. 
Another piece of genetic evidence was the report that global TSPO knockout mice were early embryonic 
lethal (Papadopoulos et al., 1997a), which has been repeatedly referenced (286 citations to date). This was 
frequently presented as evidence for TSPO being important for basic cellular functions that included 
steroidogenesis. However, this review article failed to explain experimental methods covering the recombination 
strategy used and the exact stage of embryonic mortality; these specific methods/results were never published.  
 
ALTERNATIVE PERSPECTIVES FOR TSPO ACTION IN CELLS 
 As TSPO research spans multiple fields/disciplines, attempts to explain its function has resulted in rather 
divergent yet unique perspectives. Some of these perspectives lack coherence in that they do not describe a 
unifying function for TSPO that is applicable to all cell types and/or the organism as a whole. Nevertheless, we 
present evidence published in support of the different perspectives (Figure 1.2), and when appropriate, indicate 
limitations and areas that require further exploration to refine and accelerate understanding towards the precise 
function of TSPO.  
TSPO is not part of the mitochondrial permeability transition pore 
 Distinct from the purported role for TSPO in steroidogenesis, it was also thought that TSPO might play a role 
in the mitochondria-mediated cell death process called the mitochondrial permeability transition (MPT). The MPT 
refers to the opening of a non-specific pore that permits any molecule <1.5 kDa through the inner mitochondrial 
membrane allowing equilibration of the mitochondrial matrix and the cytosol leading to loss of mitochondrial 
function and cell death (Haworth and Hunter, 1979; Hunter and Haworth, 1979a; Hunter and Haworth, 1979b). 
Effects observed using TSPO binding drugs (Kinnally et al., 1993), and copurification of TSPO with other proteins 
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thought to be involved in MPT (McEnery et al., 1992), initially linked TSPO to this process. However, through 
development of conditional TspocΔ/Δ genetic models, it was recently demonstrated that TSPO plays no role in the 
regulation or structure of the MPT pore (Sileikyte et al., 2014). Implications from this recent understanding of 
TSPO and advances towards explaining the MPT process, have been critically assessed elsewhere [see review 
(Bernardi et al., 2015)]. 
TSPO as a regulator of redox homeostasis 
 There are seemingly disparate mechanisms that have been proposed for TSPO in redox homeostasis. First, a 
putative association of TSPO and the voltage-dependent anion channel protein (VDAC) is believed to induce ROS 
production. It was demonstrated that TSPO overexpression in cells induces mitochondrial ROS production, with 
a reverse trend observed after TSPO knockdown (Gatliff et al., 2014). However, there exists contrasting evidence 
that TSPO overexpression could dampen mitochondrial ROS production through an identical VDAC-dependent 
mechanism (Joo et al., 2015; Joo et al., 2012). Second, without the need for any protein interactions, it has been 
suggested that TSPO could act to neutralize ROS. According to this hypothesis, the abundance of tryptophans in 
TSPO might react with ROS to generate tryptophan radicals (Guo et al., 2015). Third, a putative TSPO-NADPH 
oxidase 2 (NOX2) association has been proposed to play a role in ROS generation. In this postulate, TSPO is 
surmised to behave as a carrier or transporter for both cholesterol and heme (Guilarte et al., 2016). 
 Although all the above mechanisms are conceivable, they are attempts to explain TSPO function in cells based 
on effects that were initially observed using TSPO binding drugs. Distinct from cells that consistently show high 
levels of TSPO expression (such as in the adrenal cortex and brown adipose tissue), these explanations almost 
always deal with cells that upregulate TSPO in response to different forms of stress. Therefore, it is possible that 
these interpretations may be confounded with cellular effects associated with the obvious link between stress and 
ROS production. The TSPO-VDAC relationship to ROS production has had contrasting results in similar TSPO 
overexpression studies (Gatliff et al., 2014; Joo et al., 2015; Joo et al., 2012). The TSPO-NOX2 association 
(Guilarte et al., 2016), remains a hypothesis. The finding that cardiac-specific TspocΔ/Δ mice did not show any 
difference in the extent of ischemia reperfusion injury (Sileikyte et al., 2014), a pathology that is partly directed 
by myocardial NOX2 (Braunersreuther et al., 2013), seems to suggest that TSPO and NOX2 may not have a 
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functional connection. Perhaps via an interaction of multiple pathways, it is not too surprising that 
pharmacological evidence have linked TSPO to a variety of mechanisms related to cardioprotection after ischemia 
reperfusion injury: preventing mitochondrial permeability (Obame et al., 2007), increasing activities of 
mitochondrial oxidative enzymes (Xiao et al., 2010), or by reducing mitochondrial cholesterol transport (Paradis 
et al., 2013). In TSPO deficient MA-10TspoΔ/Δ Leydig cells, loss of TSPO resulted in modest increases in ROS 
production (Tu et al., 2016), an observation that was linked to a shift in cellular metabolism (discussed below). 
Therefore, future studies carefully examining Tspo-/- models to observe loss-of-function are absolutely essential 
before an effect for TSPO in redox homeostasis can be confirmed. 
TSPO as an enzyme for protoporphyrin IX degradation 
 Distinct from studies involving steroid production, porphyrins, a group of cyclic tetrapyrroles involved in 
heme synthesis, are considered endogenous ligands that bind TSPO (Verma et al., 1987). This porphyrin binding 
property of TSPO appears highly conserved from bacteria to humans, but the function of this association continues 
to remain unclear. It was initially proposed that TSPO binds and transports protoporphyrin IX (PPIX), the 
precursor of heme, into the mitochondria (Wendler et al., 2003), a concept that emerged based on TSPO ligands 
being able to partially rescue cells from porphyrin-induced phototoxicity (Ratcliffe and Matthews, 1995), and 
high levels of TSPO expression seen in the bone marrow (Rampon et al., 2009; Taketani et al., 1994). Although 
the property of PPIX binding to TSPO remains true, recent studies using Tspo-/- mice and cell lines have 
established that TSPO is not a porphyrin transporter for heme synthesis (Banati et al., 2014; Zhao et al., 2016). 
Using the bacterial Chlorobium tepidum TSPO purified in detergent, it was demonstrated that TSPO could induce 
rapid spectral changes to added PPIX indicative of chemical catalysis (Ginter et al., 2013). A similar observation 
has been reported for Bacillus cereus TSPO (Guo et al., 2015). However, the reaction rate was not proportional 
to TSPO concentration, but dependent on the availability of light and oxygen. Although this photo-oxidative PPIX 
degradation mediated by purified C. tepidum and B. cereus TSPO have been discussed in broad terms, there is no 
functional evidence that this occurs in any intact biological model systems. Moreover, the relevance of this light-
dependent activity in deeper organs like the adrenal and brain remains questionable. Analysis of PPIX 
degradation/elimination as a time course in Tspo-/- mouse tissues and plasma suggests that this putative TSPO-
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mediated degradation, at least in mammalian systems is not a critical regulator of PPIX levels (Zhao et al., 2016). 
Although this observation does not validate a role for TSPO in PPIX degradation, it certainly does not discount a 
physiological function for the highly conserved TSPO-PPIX association. Use of Tspo-/- models across different 
biological systems for investigating conserved properties in future studies may offer clues to uncovering specific 
functions for this association. 
TSPO as a regulator of oxygen consumption 
 Evidence from lower organisms has indicated an oxygen-sensing function for TSPO (Yeliseev et al., 1997). 
In isolated primary microglia from Tspofl/fl and Tspo-/- mice, measurement of oxygen consumption rate (OCR) 
indicated that basal OCR was significantly lower in Tspo-/- microglia (Banati et al., 2014). In an independent study, 
OCR compared between Tspo-deficient mitochondria isolated from liver-specific TspocΔ/Δ mice and control 
Tspofl/fl mice showed no differences in OCR (Sileikyte et al., 2014). Although this contrast has been a topic of 
speculation with respect to the need for an intact cellular environment, and changes to metabolic demand in cells 
[reviewed in (Gut, 2015)], it subsequently became clear that there was also no correlation between TSPO 
expression levels and OCR deficits observed in different cell types. Measurements of OCR in embryonic 
fibroblasts that express low levels of TSPO from Tspo-/- mice showed significantly diminished values compared 
to embryonic fibroblasts from Tspofl/fl mice (Zhao et al., 2016). In contrast, measurements of OCR in steroidogenic 
MA-10 cells that express very high levels of TSPO showed no difference when compared to TSPO-deleted MA-
10 cells (Tu et al., 2016). All these studies indicate that the change in OCR is a cell-type dependent indirect effect, 
inconsistent with TSPO expression levels, perhaps reflecting on the diversity of mitochondrial types, metabolism 
and energetic status of cells, and therefore does not reveal a direct mechanism for TSPO in regulating OCR.  
 Tspo-knockout studies in another in vivo model, Drosophila melanogaster, indicated that Tspo-/- flies are 
without any abnormalities (Lin et al., 2014), similar to reports in mice (Banati et al., 2014; Tu et al., 2014). 
Interestingly, cells in Tspo-/- flies showed increased survival after hydrogen peroxide exposure or γ-irradiation 
(Lin et al., 2014). In only male Tspo-/- flies, an extended lifespan was observed compared to male wild type flies 
(Lin et al., 2014). Isolated Tspo-deficient mitochondria from these flies, irrespective of sex, showed a decreased 
rate of oxidative phosphorylation compared to Tspo+/+ mitochondria (Lin et al., 2014). Continued studies in     
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Tspo-/- D. melanogaster have linked TSPO function to ethanol-sensitivity and tolerance (Lin et al., 2015). These 
seemingly disparate effects point to general mechanisms that surround mitochondrial function and do not pinpoint 
a specific indication for TSPO function. 
 Along the lines of cellular energy metabolism, a drug screen for identifying small molecules that induce 
expression of the gluconeogenic gene, phosphoenolpyruvate carboxykinase 1 (Pck1), using a transgenic zebrafish 
reporter line, PK11195 was identified as an agent that activates a state akin to fasting metabolism (Gut et al., 
2013). Although this seems to be an exciting observation, it is unclear if the major effects observed are mediated 
through TSPO. This is because PK11195 is also known to bind the constitutive androstane receptor (CAR) 
(Anderson et al., 2011; Li et al., 2008), which can affect Pck1 transcription, together with other genes that affect 
energy metabolism (Ueda et al., 2002). The overall functions of CAR could also be linked to fasting metabolism 
(Ding et al., 2006; Maglich et al., 2004). Therefore, interpretation of PK11195 or other drug effects in the context 
of TSPO needs further affirmation using genetic models that can delineate off target effects from specific effects. 
TSPO as a regulator of lipid metabolism 
 Two independent exploratory studies identified Tspo as a candidate gene that could influence lipid 
metabolism. First, Tspo was identified as one of six novel transcripts that showed robust positive correlation with 
adipocyte differentiation in a differential display RT-PCR screen (Wade et al., 2005). Second, Tspo was identified 
as one of five genes that could influence triglyceride metabolism in an examination of quantitative trait loci 
between inbred mouse strains (Leduc et al., 2011). In agreement, recent examination of TSPO expression levels 
in different murine tissues indicated that high TSPO expression correlated with tissues active in lipid 
storage/metabolism, and was not specific for steroidogenic cells (Tu et al., 2016). As support for this correlation, 
it must be noted that steroidogenic cells also have substantial presence of lipid droplets. Measurement of energy 
metabolism in TSPO deficient MA-10TspoΔ/Δ Leydig cells that do not show any deficits in steroid biosynthesis 
revealed a metabolic shift in substrate utilization from glucose to fatty acids compared to TSPO expressing MA-
10 cells. The MA-10TspoΔ/Δ Leydig cells had higher levels of fatty acid oxidation, and modest increases in ROS 
production compared to MA-10 controls (Tu et al., 2016).  
18 
 
 
Figure 1.2. Alternative perspectives for TSPO action in cells. (1) TSPO as a regulator of redox homeostasis. 
It has been suggested that TSPO could interact with VDAC1 or NOX2 to induce production of ROS (Gatliff et 
al., 2014; Guilarte et al., 2016). On the contrary, the association of TSPO with VDAC1 (Joo et al., 2015; Joo et 
al., 2012), or TSPO by itself (Guo et al., 2015), could facilitate ROS neutralization. Although TSPO regulation of 
ROS is conceivable, at least as a secondary effect, functional evidence for the interactions and specific role of 
TSPO remains to be demonstrated. (2) TSPO as an enzyme for protoporphyrin IX degradation. Chemical 
catalysis of PPIX degradation by bacterial TSPO has been proposed as a function for TSPO (Ginter et al., 2013; 
Guo et al., 2015). The reaction rate was dependent on availability of light and oxygen. Lack of light in mammalian 
tissues that express high levels of TSPO like the adrenal glands raises question for the functional relevance and 
significance of this action. Nevertheless, conserved binding of TSPO to PPIX suggests a yet to be determined 
action in cells. (3) TSPO as a regulator of oxygen consumption. Loss of TSPO had different effects in oxygen 
consumption rate in different cell types. Decreased oxygen consumption was observed in TSPO deficient 
microglia and fibroblasts (Banati et al., 2014; Zhao et al., 2016), but no effects were observed in hepatocytes and 
Leydig cells (Sileikyte et al., 2014; Tu et al., 2016). These inconsistent effects are probably attributed to the 
diversity of mitochondrial types and energetic status of cells. Therefore, the direct mechanism remains unclear. 
(4) TSPO as a regulator of lipid metabolism. Several studies have correlated TSPO expression to functional 
changes in lipid metabolism (Leduc et al., 2011; Wade et al., 2005). It was identified that TSPO deletion could 
increase fatty acid oxidation in steroidogenic cells (Tu et al., 2016). Potential interaction of TSPO with ACBP or 
CPT1A could affects import of fatty acids into mitochondria for β-oxidation. All the above perspectives require 
additional investigation. 
 
In summary, the exact molecular function of TSPO remains unclear despite the great interest in targeting TSPO 
in human medicine. The prevalent model of TSPO and steroidogenesis appears to be inaccurate and will be 
systematically re-evaluated in my studies using both genetic and pharmacological tools. Using TSPO knockout 
mice and MA-10 cell line as the models, I will investigate the effects of TSPO loss on various cellular processes 
in order to elucidate the true function of the mammalian TSPO. 
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CHAPTER 2 
Peripheral Benzodiazepine Receptor/Translocator Protein Global Knockout Mice 
Are Viable with No Effects on Steroid Hormone Biosynthesis 
Tu, L. N., Morohaku, K., Manna, P. R., Pelton, S. H., Butler, W. R., Stocco, D. M., & Selvaraj, V. (2014). 
Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no effects 
on steroid hormone biosynthesis. J Biol Chem, 289(40), 27444-27454 
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ABSTRACT 
Translocator protein (TSPO), previously known as the peripheral benzodiazepine receptor (PBR) 
is a mitochondrial outer membrane protein implicated as essential for cholesterol import to the inner 
mitochondrial membrane, the rate-limiting step in steroid hormone biosynthesis. Previous research on 
TSPO was based entirely on in vitro experiments and its critical role was reinforced by an early report 
that claimed TSPO knockout mice were embryonic lethal. In a previous publication, we examined Leydig 
cell specific TSPO conditional knockout mice that suggested TSPO was not required for testosterone 
production in vivo. This raised controversy and several questions regarding TSPO function. To examine 
the definitive role of TSPO in steroidogenesis and embryo development, we generated global TSPO null 
(Tspo-/-) mice. Contrary to the early report, Tspo-/- mice survived with no apparent phenotypic 
abnormalities and were fertile. Examination of adrenal and gonadal steroidogenesis showed no defects in 
Tspo-/- mice. Adrenal transcriptome comparison of gene expression profiles showed that genes involved in 
steroid hormone biosynthesis (Star, Cyp11a1, and Hsd3b1), were unchanged in Tspo-/- mice. 
Adrenocortical ultrastructure illustrated no morphological alterations in Tspo-/- mice. In an attempt to 
correlate our in vivo findings to previously used in vitro models, we also determined that siRNA-
knockdown or absence of TSPO in different mouse and human steroidogenic cell lines had no effect on 
steroidogenesis. These findings directly refute the dogma that TSPO is indispensable for steroid hormone 
biosynthesis and viability. By amending the current model, this study advances our understanding of 
steroidogenesis with broad implications in biology and medicine. 
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INTRODUCTION 
The peripheral benzodiazepine receptor (PBR) was first identified as a protein with distinct 
pharmacology and high binding affinity to benzodiazepines in ‘peripheral’ sites, as opposed to ‘central’ 
sites found in brain tissue (Braestrup et al., 1977; Braestrup and Squires, 1977; Davies and Huston, 1981; 
Regan et al., 1981). The ‘central’ benzodiazepine receptor is the γ-aminobutyric acid type A (GABAA) 
receptor that has specific function in inhibitory neurotransmission (Macdonald and Barker, 1978; 
Takahashi et al., 1958). However, the function for the PBR has remained a topic of debate for decades 
(Gatliff and Campanella, 2012; Gavish et al., 1999), despite its prominence as a therapeutic target in a 
variety of diseases/disorders (Daugherty et al., 2013; Qi et al., 2012; Rupprecht et al., 2010; Vlodavsky et 
al., 2013). 
Genetic sequence comparisons show that the PBR gene is highly conserved from archea to 
metazoans (Yeliseev and Kaplan, 1995). In mammals, highly prominent PBR protein expression has been 
identified in steroidogenic tissues (Anholt et al., 1985b; Manku et al., 2012; Morohaku et al., 2013). 
Binding sites for PBR ligands have also been identified in other tissues including: heart, brain, adrenal, 
kidney, salivary gland, platelets, brown adipose tissue, skin and liver (Gavish et al., 1999). In sub-cellular 
fractions, binding sites for the PBR were identified to be present in the outer mitochondrial membrane 
(OMM) (Anholt et al., 1985b; Anholt et al., 1986). 
The transport of cholesterol from intracellular stores and the OMM to the inner mitochondrial 
membrane (IMM) forms the first and rate-limiting step in steroid hormone biosynthesis (Simpson and 
Boyd, 1967; Simpson et al., 1978). Cholesterol is then converted to the first steroid, pregnenolone, by 
CYP11A1 (cytochrome P450 side chain cleavage), an enzyme located on the matrix side of the IMM 
(Churchill and Kimura, 1979; Yago and Ichii, 1969). The initial link between PBR and steroid hormone 
biosynthesis emerged by studying the effect of a PBR-binding chemical PK11195 that triggered 
steroidogenesis in the Y1 mouse adrenal tumor cell line (Mukhin et al., 1989). In agreement, targeted 
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disruption of PBR in the R2C rat Leydig tumor cell line inhibited steroidogenesis (Papadopoulos et al., 
1997b). 
The structure of murine PBR showed a five alpha helix fold, each forming a transmembrane 
segment (Murail et al., 2008), and the possibility of a channel-like structure with an interior surface for 
potential substrate translocation (Korkhov et al., 2010). Cholesterol binding to PBR was defined by the 
identification of a cholesterol recognition amino acid consensus (CRAC) sequence at the C terminal 
region (Li and Papadopoulos, 1998). These structural features combined with functional considerations 
led to the modeling of PBR as a membrane-associated cholesterol transport protein (Lacapere et al., 2001; 
Rupprecht et al., 2010). Based on these findings, to more accurately represent its subcellular role, PBR 
was renamed as translocator protein (TSPO) (Papadopoulos et al., 2006). 
Independent of studies on PBR/TSPO, another mitochondrial protein that is expressed in rapid 
response to steroidogenic stimuli, the steroidogenic acute regulatory protein (StAR), was identified in the 
MA-10 Leydig tumor cell line (Clark et al., 1994). Induced expression of StAR resulted in increased 
steroid hormone production even in the absence of hormonal stimulation (Clark et al., 1994). Anchoring 
StAR in a mitochondria-affixed StAR-Tom20 fusion protein in MA-10 cells resulted in the constitutive 
production of steroid hormone (Bose et al., 2002). In humans, StAR mutations cause lipoid congenital 
adrenal hyperplasia that ranges from an almost complete inability to synthesize steroids (Lin et al., 1995), 
to less severe forms that retain partial StAR protein activity (Baker et al., 2006). Also in support, StAR 
gene-deleted mice showed an almost complete inability to synthesize steroid hormones underscoring its 
critical role in steroidogenesis (Caron et al., 1997). 
Two key experiments appeared to cement a functional link between StAR and PBR/TSPO. First, 
inhibition of protein synthesis that blocks StAR production and steroidogenesis (Privalle et al., 1983), did 
not affect the ability of PK11195 to trigger steroidogenesis (Krueger and Papadopoulos, 1990). Second, 
knockdown of PBR/TSPO in mitochondria-affixed StAR-Tom20 fusion protein expressing MA-10 cells 
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resulted in a reduction in their steroidogenic capacity (Hauet et al., 2005). Thus, the PBR function was 
linked to transport of cholesterol from the OMM to the IMM (Papadopoulos et al., 1990). 
In a recent study, we questioned this model showing that PBR/TSPO expression is not required 
for in vivo testicular steroidogenesis (Morohaku et al., 2014). This result has indeed raised a lot of 
questions and controversy regarding current understanding of the precise PBR/TSPO-mediated functions 
in steroid hormone production (Papadopoulos, 2014). Moving forward, there remained an absolute need 
to examine specific deficits in TSPO global knockout mice to gain additional functional understanding of 
this protein (Stocco, 2014). 
In a review article published in 1997, it was claimed that efforts to generate a PBR/TSPO gene-
deleted model failed as a result of early embryonic mortality in PBR/TSPO deficient mice (Papadopoulos 
et al., 1997a). This led to the conclusion that in addition to steroidogenesis, TSPO is involved in basic 
functions that are critically necessary for embryonic development. However, this review article failed to 
explain experimental methods covering the recombination strategy used and the exact stage of embryonic 
mortality; these specific methods/results were never published. Given the current gap in understanding 
PBR/TSPO function in vivo, we decided to revisit this global knockout question. 
With a primary objective of studying the role of PBR/TSPO in steroidogenesis and other vital 
functions (if any) that may be critical for embryonic development, we used a germ cell specific knockout 
approach to generate PBR/TSPO global gene-deleted mice. Our results are unexpected and contrary to the 
prevailing view in that we find PBR/TSPO knockout mice are viable and fertile with no effects on steroid 
hormone biosynthesis. 
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MATERIALS AND METHODS 
Generation of Tspo-/- mice  
Mice with floxed alleles for PBR/TSPO with loxP sites flanking exons 2 and 3 (Tspofl/fl) were 
generated and validated as previously described (Morohaku et al., 2014). In this study, Tspofl/fl female 
mice were crossed with Ddx4-cre+ [FVB-Tg(Ddx4-cre)1Dcas/J, (Gallardo et al., 2007)] males to generate a 
germ cell-specific deletion of Tspo (TspocΔ/+) in both male and female mice. TspocΔ/+ Ddx4cre+ 
positive offspring were then backcrossed to generate TspocΔ/Δ mice of both sexes. These sperm and 
oocyte-specific knockouts were bred to generate global PBR/TSPO null (Tspo-/-) offspring in the 
C57BL/6 background. We also observed that oocyte-specific TspocΔ/+ Ddx4-cre+ mice induced global 
recombination directly as previously described for the Ddx4-cre+ strain of mice (Gallardo et al., 2007). 
Cre was subsequently bred out from Tspo-/- mice (Figure 1). Breeding colonies for Tspo-/- and Tspofl/fl 
mice were maintained separately and offspring were genotyped for all experiments (Figure 1) using 
primers that have been previously validated (Morohaku et al., 2014). ROSA26-tdTomato (R26-tdTom) 
reporter females [B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze, (Madisen et al., 2010)] were used to confirm 
recombination, and bred to generate Tspofl/fl-R26-tdTom homozygous mice to directly mark Tspo 
deletion. Animals were maintained in accordance with the National Institute of Health Guide for the Care 
and Use of Laboratory Animals. The Institutional Animal Care and Use Committee of Cornell University 
approved all experiments in this manuscript. 
Phenotypic analysis  
Growth rate of Tspofl/fl and Tspo-/- mice were examined from postnatal day 0 to week 5. Litter 
sizes from homozygous crosses in Tspofl/fl and Tspo-/- mouse colonies were examined in at least 8 unique 
pairings. Recombination was examined in different tissues by both PCR of genomic DNA using specific 
primers as previously validated (Morohaku et al., 2014), and td-Tomato reporter expression indicating 
cre-mediated recombination as previously described (Morohaku et al., 2014). 
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Histology  
Tissues were processed for hematoxylin and eosin staining as described (Morohaku et al., 2014). 
Immunohistochemistry for PBR/TSPO was performed using a rabbit monoclonal anti-TSPO antibody 
(Abcam) that specifically recognizes amino acids 156-169 at the C-terminal of Exon 4 as described 
(Morohaku et al., 2014; Morohaku et al., 2013). For examining neutral lipid deposits, 9 µm frozen 
sections were prepared and Lipid staining was performed using Oil Red O (Matheson Coleman & Bell) in 
60% Isopropanol for 30 minutes. Fluorescent tdTomato was also visualized in 9 µm frozen sections in 
multiple tissues. Images were acquired using either a DFC365FX or an ICC50HD camera (Leica) or a 
Meta 510 confocal scope (Zeiss). Density of Oil Red O staining density was quantified using ImageJ 
(Schneider et al., 2012). 
Immunoblots  
Proteins were separated by SDS-PAGE and immunoblotted using rabbit monoclonal primary 
antibodies against TSPO (Abcam) and isocitrate dehydrogenase 2 (IDH2) (Abcam), and a rabbit 
polyclonal StAR antibody (Bose et al., 1999). Each primary antibody was multiplexed with the loading 
control β-actin (Li-Cor). Simultaneous detection was performed using IRDye 700 and 800 under a laser 
fluorescence scanner (Li-Cor) and quantified as described previously (Morohaku et al., 2014). For 
immunoblots performed in knockdown experiments, a TSPO polyclonal (Cell Signaling) and β-actin (Life 
Technologies) primary antibodies were used. Specific band intensities in knockdown experiments were 
calculated by image analysis using Quantity One Software (Bio-Rad). 
Hormone assays  
Plasma was collected from 8-10 week old Tspofl/fl and Tspo-/- mice. Levels of different steroid 
hormones were measured using radioimmunoassay: corticosterone, aldosterone and testosterone 
(Siemens), estradiol and progesterone (Serono Maia), as previously described (Beam and Butler, 1997; 
Morohaku et al., 2014). For adrenal/corticosterone stimulation test, 500 ng/g body weight (BW) of 
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adrenocorticotropin (ACTH) fragment 1-24 (Sigma) was administered subcutaneously and plasma was 
collected after 1 hr. For testis/testosterone stimulation test, 10 IU of human chorionic gonadotropin (hCG; 
EMD biosciences) was administered intraperitoneal to male mice and plasma was collected after 1 hr. 
Transmission electron microscopy  
Adrenal glands were fixed in Karnovsky’s fixative (2.5% glutaraldehyde, 2% paraformaldehyde 
in 0.08 M phosphate buffer) overnight. After fixation, tissues were processed for transmission electron 
microscopy as previously described (Daugherty et al., 2013). Stained sections were examined in a 
TecnaiTM T12 Spirit electron microscope (FEI), at 120 kV. High magnification images were acquired 
using a high-resolution CCD camera Megaview III (Olympus Soft Imaging System) to examine cellular 
and mitochondrial morphology within regions in the adrenal cortex. 
RT-PCR and quantitative PCR  
Total RNA was extracted from adrenal glands of 8-10 week old Tspofl/fl and Tspo-/- mice using 
RNeasy Lipid Tissue Mini Kit (Qiagen). For human A172 and H295R cells, total RNA was extracted 
using Trizol (Life Technologies). Reverse transcription was carried out using MultiscribeTM reverse 
transcriptase (Life Technologies). Validated Taqman gene expression assays were used for quantitative 
PCR estimation of murine Tspo (Mm00437828_m1), human Tspo (Hs00559362_m1), Tspo2 
(Mm01281420_m1), Star (Mm00441556), Cyp11a1 (Mm00490735_m1), and Hsd3b1 
(Mm00476184_g1). For all other genes, expressions were quantified by SYBR® Green detection method 
using validated primer sequences obtained from PrimerBank database (Spandidos et al., 2010). Vdac1: 5’ 
AAGTGAACAACTCCAGCC TGA 3’ and 5’ CACCAGCATTGACGTTCTTG 3’, Vdac2: 5’ 
CTCCACCCTATGCTGACCTC 3’ and 5’ CCCGCTAACTTTACCAGTGTCT 3’, Vdac3: 5’ 
CAAAGGGTATGGGTTTGGCAT 3’ and 5’ TTGGTCTCTAGGTTGCCTGAT 3’, Ant1: 5’ 
CTGGTGTCCTACCCCTTTGA 3’ and 5’ TGGCTCCTTCGTCTTTTGCA 3’, Ant2: 5’ 
CAAGACAGCGGTAGCACCC 3’ and 5’ CGC AGTCTATGATGCCCTTGTA 3’, Hxk2: 5’ GG 
GCATGAAGGGCGTGTCCC 3’ and 5’ TCTTC ACCCTCGCAGCCGGA 3’, Acbp: 5’ TTTCGG 
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CATCCGTATCACCT 3’ and 5’ TTTGTCAAAT TCAGCCTGAGACA 3’, Pap7: 5’ GAGGAGC 
TTTACGGCCTGG 3’ and 5’ CTTATGCAG TGCCACGAACTT 3’. All expressions were normalized to 
an internal control gene, Gapdh. Relative quantification of fold-change was performed using the 2-ΔΔCt 
method (Livak and Schmittgen, 2001). 
Adrenal transcriptome shotgun sequencing  
Adrenal gland total RNA from Tspofl/fl and Tspo-/- mice were extracted and polyA RNA were 
isolated using oligo(dT)25 Dynabeads (Life Technologies). Fragmentation and strand-specific RNA-seq 
library preparation was performed as described (Zhong et al., 2011). Each sample with unique bar codes 
was pooled to one lane for obtaining short single-reads in a HiSeq 2000 sequencer (Illumina). RNA-seq 
reads were first aligned to the ribosomal RNA gene database (Quast et al., 2013) using Bowtie 
(Langmead et al., 2009) and the mapped reads were discarded. The resulting filtered reads were aligned to 
the mouse genome (Ensembl) using TopHat (Trapnell et al., 2009). Subsequent to alignments, raw counts 
for each mouse gene were derived and normalized to reads per kilobase of exon model per million 
mapped reads (RPKM). Differentially expressed genes were identified using the DESeq package (Anders 
and Huber, 2010). Raw p-values of multiple tests were corrected using false discovery rate (FDR) 
(Benjamini and Hochberg, 1995). 
TSPO knockdown in different steroidogenic cell lines  
Specific small interfering RNAs (siRNAs) were used to knockdown endogenous TSPO 
expression in different steroidogenic cell lines as previously described for other genes (Manna et al., 
2013). Tspo siRNAs and the Silencer® negative control (scrambled) were obtained as annealed oligos 
(Life Technologies). Sense strand sequences for Tspo siRNAs utilized were:  (1) 5’-GGAAA 
GAGCUGGGAGGUUUtt-3’, (2) 5’-GCUCCUAC AUAGUCUGGAAtt-3’, and (3) 5’-UGGGCCUG 
CUAGUCUGUCAtt-3’. Cell lines: MA-10, Y-1, H295R, R2C and MLTC cells (from ATCC) were 
transfected with 100 nM of Tspo siRNA #1, #2, #3 or control using Lipofectamine 2000 (Life 
Technologies). Forty-eight hours after transfection, cells were examined for TSPO protein expression and 
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used to estimate steroidogenic potential with 0.5 mM dibutryl cyclic AMP [(Bu)2cAMP] as previously 
described (Manna et al., 2013). 
 
RESULTS 
Tspo-/- mice are viable and fertile  
The Tspofl/fl locus allows cre-mediated deletion of exon 2 and 3 of the Tspo gene (Figure 2.1A). 
Exon 1 does not contain any start codons. Removal of exon 2 and 3 eliminates the start codon and exon 4 
does not have any in-frame start codons. Therefore, deletion of exon 2 and 3 will completely eliminate 
TSPO protein expression (Morohaku et al., 2014). Germ cell-specific Ddx4-cre mice were used to induce 
germ cell Tspo deletion in F1 and global recombination in F2 generations. Litters from all crosses were 
genotyped and the Ddx4-cre transgene was subsequently bred out from this colony (Figure 2.1B). Using a 
Tspofl/fl-R26-tdTom reporter line, we confirmed that cre-mediated recombination occurred in all tissues 
globally (Figure 2.2 A and C). Recombination at the Tspo-/-genomic locus was also confirmed by PCR in 
different tissues (Figure 2.1C). The complete absence of TSPO protein expression in different tissues in 
Tspo-/- mice was confirmed by both Western blots (Figure 2.2B) and immunohistochemistry (not shown), 
using a monoclonal antibody that recognizes protein coded by Exon 4. This proved that no partial TSPO 
peptide was produced in mice deleted for TSPO Exons 2 and 3 as previously shown (Morohaku et al., 
2014). All Tspo-/- mice were viable and showed no apparent phenotypic abnormalities. Litter sizes from 
Tspo-/- pair mating were not different from Tspofl/fl pair litters (Table 2.1). Growth rate in Tspo-/- mice 
measured up to 5 weeks of age were quite similar to Tspofl/fl cohorts. However, when analyzed based on 
sex, Tspo-/- female mice showed a very modest (~1g) but significantly higher body weight than Tspofl/fl 
mice at 1-5 weeks of age; males body weights at this same age interval were not different between the 
two genotypes (not shown). 
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Figure 2.1. Generation of TSPO knockout mice. (A) Schematic showing genomic TSPO locus in 
wildtype (TSPO+/+), intact floxed (Tspofl/fl) and knockout (Tspo-/-) mice. Tspofl/fl mice contained exons 2 
and 3 flanked with LoxP sites (open arrow heads). Tspofl/fl female mice were bred with Ddx4-cre male 
mice to generate germ cell-specific deletion of TSPO as heterozygotes. These sperm and oocyte-specific 
knockout mice were bred to generate Tspo-/- offspring. Ddx4-cre transgene was subsequently bred out 
from this colony. (B) Panel showing genotyping for floxed alleles and cre transgene in Ddx4-cre mice, 
Tspofl/fl mice, TSPO+/- Ddx4-cre mice, Tspo-/- Ddx4-cre mice, and Tspo-/- mice. (C) Genomic DNA PCR 
for recombination at the TSPO locus detects deletion of Exon 2 and 3 in Tspo-/- mice [Product sizes: Flox-
2697 bp, Null-872 bp, Con-161 bp]. 
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Figure 2.2. Validation of Tspo-/- genotype. (A) Tspofl/fl-ROSA26-tdTomato reporter mice were used to 
examine cre-mediated recombination induced in offspring from germ-cell specific deletions. Global 
recombination was clear in R26-tdTom-Tspo-/- P3 pups. (B) TSPO monoclonal antibody specific for 
peptide corresponding to TSPO exon 4 detected a protein of expected size (18 kDa) in Tspofl/fl tissues but 
not in Tspo-/- tissues. Actin and mitochondrial IDH2 were used as controls. Scale bar: 1 cm. (C) 
Representative images of different tissues from an R26-tdTom-Tspofl/fl mouse with no tdTomato 
fluorescence in contrast to tissues from an R26-tdTom-Tspo-/- mouse showing tdTomato fluorescence 
(red) indicating recombination. Nuclei were counterstained with DAPI (blue). Scale bar: 50 µm.  
 
 
Table 2.1. Litter sizes from Tspofl/fl and Tspo-/- male and female mice 
Mating pairs  n Litter size* ± SE 
Tspofl/fl female x Tspofl/fl male 17 8.11 ± 0.44 
Tspo-/- female x Tspo-/- male  8 8.00 ± 0.53 
* No significant differences in litter size were detected between the two crosses. Sex ratios in these litters were also 
not different. 
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Figure 2.3. TSPO deletion does not affect gonadal steroidogenesis. (A) Testes sections showing TSPO 
localization in Leydig and Sertoli cells in Tspofl/fl but not in Tspo-/- testis. Functional morphology of 
seminiferous tubules was not affected in Tspo-/- testis. (B) Ovary sections showing TSPO localization in 
interstitial cells and surface epithelium, weak in theca and granulosa cells in Tspofl/fl ovary; no staining 
was observed in Tspo-/- ovary. Functional morphology was not affected in Tspo-/- ovary. (C) Baseline 
plasma testosterone levels were not different between Tspofl/fl and Tspo-/- male mice (n=24-25/group). (D) 
Increase in plasma testosterone levels after hCG stimulation was similar between Tspofl/fl and Tspo-/- male 
mice (n=6-7/group). (E) Baseline plasma estradiol levels were significantly higher in Tspo-/- compared to 
Tspofl/fl mice (p<0.05), but the difference was modest (n=12-15/group). (F) Baseline plasma progesterone 
levels were not different between Tspofl/fl and Tspo-/- mice (n=12-15/group). Scale bar: 200 µm. 
 
Gonadal steroid hormone production is not affected in Tspo-/- mice  
The lack of TSPO did not affect the functional morphology of the testis (Figure 2.3A) or the 
ovary (Figure 2.3B) in Tspo-/- mice compared to Tspofl/fl controls. In male mice, examination of plasma 
testosterone concentration showed that baseline levels were not different between Tspo-/- and Tspofl/fl mice 
(Figure 2.3C). Increase in plasma testosterone in response to hCG in vivo was not different between Tspo-
/- and Tspofl/fl mice (Figure 2.3D). Cauda epididymal sperm counts were not different between Tspo-/- and 
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Tspofl/fl mice (not shown). In female mice, examination of plasma estradiol and progesterone 
concentration showed that TSPO deletion did not decrease baseline values (Figure 2.3E-F). In actuality, 
Tspo-/- mice showed modest but significantly higher estradiol levels compared to Tspofl/fl cohorts. We did 
not observe any abnormalities in gonad size, reproductive behavior and fecundity in Tspo-/- mice (not 
shown). 
Adrenal steroid hormone production is not affected in Tspo-/- mice  
The lack of TSPO expression did not affect the functional morphology of the adrenal cortex 
(Figure 2.4A) in Tspo-/- mice. Quantitation of neutral lipid staining in the adrenal cortex did not indicate 
any major steroid transport defects in Tspo-/- mice (Figure 2.4 B-C). Baseline levels of aldosterone (Figure 
2.5A), and corticosterone (Figure 2.5B), two major hormones produced by the adrenal cortex were not 
different between Tspo-/- and Tspofl/fl mice. Increase in plasma corticosterone in response to ACTH in vivo 
was not different between Tspo-/- and Tspofl/fl mice (Figure 2.5C). There was also no evidence for 
compensatory increase in StAR expression in adrenals of Tspo-/- mice compared to Tspofl/fl mice after 
ACTH treatment (Figure 2.5 D-F). 
 
Figure 2.4. TSPO deletion has no effect on morphology and lipid deposits in the adrenal cortex. (A) 
Adrenal sections from Tspofl/fl and Tspo-/- mice showing TSPO localization in adrenocortical cells with a 
higher density in the zona glomerulosa; no staining was observed in Tspo-/- adrenal. No difference in 
adrenocortical morphology was apparent between two genotypes. (B) Oil Red O staining of adrenal 
glands showed no difference in neutral lipid deposits between Tspofl/fl and Tspo-/- adrenal glands. (C) 
Quantification of Oil Red O (ORO) labeling density was similar in both Tspofl/fl and Tspo-/- adrenal cortex 
(n=5/group; mean ± SEM). Scale bar: 200 µm. 
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Figure 2.5. TSPO deletion has no effect on adrenal steroid hormone production. (A) Plasma 
aldosterone baseline levels were not significantly different between Tspofl/fl and Tspo-/- mice (n=7/group). 
(B) Plasma corticosterone baseline levels were not significantly different between Tspofl/fl and Tspo-/- mice 
(n=24-30/group). (C) Increase in plasma corticosterone in response to ACTH stimulation was similar 
between Tspofl/fl and Tspo-/- mice (n=10-14/group). (D) Representative Western blot showing no 
compensatory increase in StAR and TSPO protein expression after ACTH stimulation in both Tspofl/fl and 
Tspo-/- mice. Quantification of (E) StAR, and (F) TSPO protein levels also showed no significant increase 
at 1 hour after ACTH stimulation (n=3). (Data are represented as mean ± SEM). 
 
Loss of TSPO does not affect steroidogenic gene expression in adrenal glands  
Comparison of gene expression profiles by transcriptome shotgun sequencing of Tspo-/- and 
Tspofl/fl adrenals revealed only a short list of differentially expressed genes (Table 2.2), none of which 
were directly associated with steroidogenesis. Mining reads representing Tspo mRNA confirmed deletion 
of exon 2 and exon 3. A majority of the differentially expressed genes were involved in immune activity. 
Validated expression of genes involved in the steroid hormone biosynthetic pathway: Star, Cyp11a1 and 
Hsd3b1 (Figure 2.6 A-C), and TSPO-interacting proteins: Vdac, Ant, Hxk2, Pap-7 and Acbp were not 
affected in Tspo-/- adrenals (Figure 2.6 E-L). Complete dataset available through NCBI-SRA SRP043599. 
To evaluate possible functional redundancy, we also examined expression levels for Tspo2, a TSPO 
paralog (Fan et al., 2009). We did not detect Tspo2 expression in both Tspofl/fl and Tspo-/- adrenal glands 
(Figure 2.6D). 
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Table 2.2. Genes differentially expressed between Tspofl/fl and Tspo-/- adrenal glands 
 
Genes* Gene Name/Description Tspo
fl/fl 
[mean] 
Tspo-/- 
[mean] 
Ratio P value 
BC018473 Unclassified non-coding RNA gene 0.01 1.86 186.33 1.77E-13 
Trim12a Tripartite motif-containing 12A 1.97 0.01 0.01 1.19E-12 
Gm12196 Predicted gene 12196 0.26 40.59 156.12 5.94E-12 
Pydc4 Pyrin domain containing 4 1.63 0.02 0.01 7.36E-10 
Gm4955 Predicted gene 4955 3.25 0.07 0.02 9.45E-09 
Gm16510 Predicted pseudogene 16510 1.19 23.5 19.81 5.15E-06 
Gm5540 Predicted pseudogene 5540 0.71 19.88 28.14 0.0018 
Prrc2a Proline-rich coiled-coil 2A 1.16 20.69 17.78 0.0084 
RP23-81C12.1 Known lincRNA 0.93 22.69 24.49 0.0084 
Atxn2l Ataxin 2-like 1.1 16.44 14.99 0.0147 
Abhd1 Abhydrolase domain containing 1 1.34 10.53 7.84 0.0157 
Ankrd52 Ankyrin repeat domain 52 0.35 5.62 15.91 0.0166 
Nxpe2 
Neurexophilin and PC-esterase domain 
family, member 2 
0.8 0.12 0.15 0.0173 
Tmem178 Transmembrane protein 178 16.36 3.04 0.19 0.0188 
Epn1 Epsin 1 0.8 9.97 12.47 0.0320 
Zbtb7b 
Zinc finger and BTB domain 
containing 7B 
0.38 5.51 14.64 0.0346 
Osgin1 
Oxidative stress induced growth 
inhibitor 1 
2.46 19.15 7.79 0.0346 
Cyp21a2-ps 
Cytochrome P450, family 21, 
subfamily a, polypeptide 2 pseudogene 
159.04 1352.39 8.5 0.0346 
Abca2 
ATP-binding cassette, sub-family A 
(ABC1), member 2 
0.41 3.38 8.24 0.0414 
*Presented in the order of significance based on P value. 
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Figure 2.6. TSPO deletion does not alter expression levels of steroidogenic genes and TSPO-
interacting proteins in the adrenal glands. Expression levels of steroidogenic genes StAR (A), 
CYP11A1 (B) and HSD3B1 (C) were similar between Tspofl/fl and Tspo-/- mice. TSPO2 expression (D) 
was not detected in both Tspofl/fl and Tspo-/- adrenal glands..  Genes encoding TSPO-interacting proteins 
VDAC1 (E), VDAC2 (F), VDAC3 (G), ANT1 (H), ANT2 (I), HXK2 (J), PAP7 (K), and ACBP (L) 
showed similar expression levels between Tspofl/fl and Tspo-/- mice. TSPO expression (M) was not 
detected in Tspo-/- adrenal glands. (n=6/group; data are represented as mean ± SEM). 
 
 
Ultrastructure of adrenal cortex remains the same in Tspo-/- mice  
Examination of steroidogenic cells of the adrenal cortex using transmission electron microscopy 
did not show any aberrations in cellular ultrastructure in Tspo-/- mice (Figure 2.7). Despite its presence in 
the OMM, TSPO deficiency did not affect mitochondrial morphology. Lipid droplet distribution was also 
identical between regions within adrenal cortex (zona glomerulosa, zona fasciculata and zona reticularis) 
in both Tspofl/fl and Tspo-/- mice. TSPO deficiency also did not affect mitochondrial volume in cells, as 
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assessed in Tspofl/fl and Tspo-/- primary fibroblasts that showed no quantitative differences between the 
two genotypes (not shown). 
 
Figure 2.7. Ultrastructure of cells in the adrenal cortex is not affected by TSPO deletion. 
Transmission electron micrographs showing cell morphology in the zona glomerulosa (A) and zona 
reticularis (B) of the adrenal cortex. Subcellular organelle morphology including mitochondria and lipid 
droplets are identical between both Tspofl/fl and Tspo-/- mice.  
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TSPO knockdown in steroidogenic cell lines does not affect steroidogenesis  
Progesterone production after (Bu)2cAMP treatment by the different murine (MA-10, Y1 and 
MLTC) and human (H295R) steroidogenic cell lines was not adversely affected by knockdown of TSPO 
expression (Figure 2.8 A-D). TSPO protein expression in murine cell lines decreased by approximately 
85%, 75% and 82% respectively; surprisingly, baseline TSPO protein expression was not detectable in 
human H295R cells, [confirmed by extremely low levels of TSPO mRNA (Figure 2.8 F-G)]. This 
observation showed that H295R cells are capable of making steroid hormones without TSPO. In all 
conditions, TSPO knockdown did not have an effect on StAR expression. In the case of MA-10 cells, 
progesterone production showed a significant increase after (Bu)2cAMP treatment in TSPO knockdown 
cells compared to scrambled controls. This is in direct contrast with another study using the same MA-10 
cells that showed significantly decreased progesterone production after just 60% knockdown of TSPO 
protein expression (Hauet et al., 2005). However, such increases were not observed in Y1 and MLTC 
cells after TSPO knockdown under identical conditions. In R2C cells that abnormally display 
constitutively high levels of steroidogenesis, TSPO knockdown showed a modest but significant decrease 
in progesterone production in conditions with and without (Bu)2cAMP treatment compared to scrambled 
controls (Figure 2.8E). Mono-allelic TSPO gene deletion in R2C cells was reported to abolish TSPO 
expression and inhibit steroidogenesis (Papadopoulos et al., 1997b). We find this hard to reconcile, as we 
do not find any evidence for allele-specific TSPO expression in our in vivo studies (Figure 2.9). 
Moreover, R2C cells are pathologically constitutive in steroid hormone production, the mechanism of 
regulation of which is not physiologically relevant. Data from TSPO knockdown experiments in 3 
different murine cell lines together with the discovery that TSPO expression is below detection levels in 
H295R cells confirm that TSPO is not essential for steroidogenesis in vitro.  
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Figure 2.8. TSPO knockdown in steroidogenic cells does not affect steroid hormone biosynthesis. 
TSPO knockdown (#1 and #2) resulted in substantial decrease in TSPO protein compared to controls 
(scrambled) in MA-10 (A), Y1 (B), MLTC (D), and R2C cells (E). No baseline TSPO was detected in 
H295R cells (C). (Bu)2cAMP treatment resulted in a similar increase in StAR protein expression in MA-
10, Y1, MLTC and H295R cells and higher progesterone production. TSPO knockdown MA-10 cells 
showed significantly higher progesterone production (p<0.05) compared to scrambled controls. 
Progesterone production in TSPO knockdown Y1 and MLTC cells was similar to the scrambled controls.  
H295R cells did not show TSPO expression but still produced progesterone upon (Bu)2cAMP treatment. 
Careful re-examination confirmed that H295R cells do not express both TSPO protein and mRNA (F and 
G). Abnormal R2C cells constitutively expressed high StAR protein levels and constantly produced high 
levels of progesterone. TSPO knockdown in R2C resulted in a modest but statistically significant 
decrease in progesterone production (p<0.05), both with and without (Bu)2cAMP treatment.  
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Figure 2.9. TSPO expression is not allele-specific. (A) TSPO monoclonal antibody detected similar 
expression levels in Tspofl/fl, maternal-transmitted heterozygous TSPO+/- and paternal-transmitted 
heterozygous TSPO+/-; no TSPO was detected in Tspo-/- adrenal glands. (B) There was no significant 
difference in TSPO mRNA expression levels between Tspofl/fl and maternal heterozygous TSPO+/-adrenal 
glands; no TSPO mRNA was detected in Tspo-/- adrenals (n=4/group; ND*-not detected). 
 
DISCUSSION 
According to existing literature, TSPO function is absolutely essential for steroid hormone 
biosynthesis (Papadopoulos et al., 1997b), and global TSPO gene deletion results in early embryonic 
lethality in mice (Papadopoulos et al., 1997a). In direct contrast to those observations, our experimental 
findings disprove these functional arguments and definitively demonstrate that TSPO is not essential for 
steroidogenesis, and that Tspo-/- mice are viable and fertile. These concrete results form a key step 
towards rectifying the prevailing model of steroidogenesis and underscore that the precise role of TSPO 
in mammalian physiology is yet to be uncovered. 
In a previous study, we demonstrated that conditional TSPO gene deletion in testicular Leydig 
cells did not affect testosterone production (Morohaku et al., 2014). At that time, the finding was met with 
skepticism that Amhr2 cre-mediated recombination may not have complete penetrance in Leydig cells, 
and criticism that it may not be the case for all steroid-synthesizing cells (Papadopoulos, 2014). But from 
observations in this present study in which TSPO has been deleted globally, it is clear that TSPO is not 
involved in physiologically relevant steroid hormone biosynthesis. This calls into question the previously 
suggested functional cooperation between StAR and TSPO for mitochondrial cholesterol import (Rone et 
al., 2009). 
49 
It could be argued that Tspo-/- mice respond to the loss of TSPO with some unknown compensatory 
mechanism. If this is the case, it is surprising that redundant mechanisms were not evident in earlier 
studies that claimed an indispensable role for TSPO in the steroidogenic machinery (Papadopoulos et al., 
1997b). TSPO2, a paralog of TSPO (35% homology) and a likely candidate for functional compensation 
is restricted to the adult bone marrow and not expressed in steroidogenic tissues (Fan et al., 2009), 
negating such a possibility. Moreover, there is no experimental evidence that multiple mechanisms are 
involved in mitochondrial cholesterol import. Based on observations in StAR knockout mice, it appears 
unmistakable that there is one rate-limiting mechanism of mitochondrial cholesterol import that is 
governed by StAR (Caron et al., 1997). Therefore, a model for TSPO in mitochondrial cholesterol 
transport is highly unlikely. 
Given these results, it is unclear how the global TSPO knockout reported in an earlier study by 
Papadopoulos et al., could be embryonic lethal (Papadopoulos et al., 1997a). As exact experimental 
details for that study were not published, we can only speculate that an error occurred in genome 
manipulation during this previous attempt. Similarly, a study from this same research group reported that 
more than 70% TSPO knockdown in cell lines resulted in cell death (Veenman et al., 2007). This is 
certainly not the case in both our in vivo and in vitro experimental observations and indicates that 
experimental conditions used in these earlier studies may have not been optimal. This conclusion is 
supported by another recent study that independently generated conditional liver and heart specific Tspo-/- 
mice and did not report any incidence of cell death after abolishing TSPO expression; TSPO was found to 
be not involved in mitochondrial permeability transition and cell death (Sileikyte et al., 2014). 
At baseline physiology, gene expression differences between Tspofl/fl and Tspo-/- adrenals were 
surprisingly few. A majority of these genes were involved in immune modulation: Tmem178 is a negative 
regulator of inflammatory cytokine production (Decker, 2012); Prrc2a is a gene within the major 
histocompatibility complex class III region and is involved in the inflammatory process (Nieters et al., 
2012); Osgin1 is an oxidative stress response protein that regulates inflammation (Li et al., 2007), Zbtb7b 
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is a regulator of T cell mediated tumor-induced immunity (Mariani et al., 2013), Pydc4 is part of a 
PYHIN domain family of proteins involved in innate immunity (Keating et al., 2011), Trim12a is a 
putative anti-viral gene (Schaller et al., 2007). Two genes were involved in vesicular transport and lipid 
sequestration: Epn1 is an endocytic adaptor involved in clathrin-mediated endocytosis (Chen et al., 2009), 
Abca2 is an endolysosomal protein with a role in intracellular lipid trafficking (Mack et al., 2007). Three 
genes expressed were of unknown function: Ankrd52, Abhd1 and Atxn2l. The remainders were 2 non-
coding RNA genes, 2 predicted genes and 3 pseudogenes. Careful consideration of these differentially 
expressed genes and the phenotype observed in Tspo-/- mice indicate that TSPO is not essential for 
sustaining physiological function. 
TSPO binding chemicals have been shown to increase steroid hormone production in isolated 
mitochondria from steroidogenic cells (Krueger and Papadopoulos, 1990), MA-10 cells (Papadopoulos et 
al., 1990), and even live rats (Chung et al., 2013). Given our current findings, we can offer two possible 
explanations for these pharmacological effects. With ligand binding, TSPO may undergo a 
conformational change [as previously suggested (Lacapere and Papadopoulos, 2003; Murail et al., 2008)], 
resulting in the release of bound cholesterol that subsequently becomes available to mitochondrial 
transport systems and steroidogenesis. Alternatively, the effect of pharmacological agents could be due to 
drug-membrane interactions resulting in TSPO-independent biological effects (Seneviratne et al., 2012). 
It has also been discovered that TSPO ligands like PK11195 can insert themselves into lipid bilayers 
affecting membrane properties (Hatty et al., 2014), something that can modulate cholesterol availability to 
the steroidogenic machinery and also the nature of TSPO-ligand interactions. Nevertheless, as TSPO is 
considered a therapeutic target for numerous inflammatory conditions (Daugherty et al., 2013; Qi et al., 
2012; Rupprecht et al., 2010; Vlodavsky et al., 2013), these properties of TSPO ligands may be important 
to assess specificity and side effects. 
The sexual disparity in body weight differences in that only female Tspo-/- mice showed subtle 
but higher growth weights than their Tspofl/fl cohorts suggests a hormone-dependent metabolic mechanism 
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(Anholt et al., 1985a). But the overall lack of phenotype in Tspo-/- mice appears to suggest that TSPO 
function could be more relevant only in pathological disease states. We have now observed Tspo-/- mice 
for up to 16 months of age with no apparent abnormalities/problems. Comparison of gene expression 
profiles after TSPO deletion also suggests potential changes to immune system function associated with 
TSPO deletion. We intend to investigate this further in future studies to gain insight into TSPO function. 
In summary, this study provides irrefutable evidence that PBR/TSPO is not essential for steroid 
hormone biosynthesis, and that Tspo-/- mice are viable and fertile. These findings form a critical step 
towards understanding TSPO function and will help rebuild a defined model for steroid hormone 
biosynthesis. In addition, this understanding also forces reevaluation of interpretations made for TSPO 
function across multiple fields including neuroscience, immunology and oncology. 
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CHAPTER 3 
PK11195 Effect on Steroidogenesis Is Not Mediated Through  
the Translocator Protein (TSPO) 
Tu, L. N., Zhao, A. H., Stocco, D. M., & Selvaraj, V. (2015). PK11195 effect on steroidogenesis is not 
mediated through the translocator protein (TSPO). Endocrinology, 156(3), 1033-1039. 
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ABSTRACT 
Translocator protein (TSPO) is a mitochondrial outer membrane protein of unknown function 
with high physiological expression in steroidogenic cells. Using TSPO gene-deleted mice, we recently 
demonstrated that TSPO function is not essential for steroidogenesis. The first link between TSPO and 
steroidogenesis was established in studies showing modest increases in progesterone production by 
adrenocortical and Leydig tumor cell lines after treatment with PK11195. In order to reconcile 
discrepancies between physiological and pharmacological interpretations of TSPO function, we generated 
TSPO-knockout MA-10 mouse Leydig tumor cells (MA-10:TspoΔ/Δ) and examined their steroidogenic 
potential after exposure to either dibutyryl-cAMP or PK11195. Progesterone production in MA-
10:TspoΔ/Δ after dibutyryl-cAMP was not different from control MA-10:Tspo+/+ cells confirming that 
TSPO function is not essential for steroidogenesis. Interestingly, when treated with increasing 
concentrations of PK11195, both control MA-10:Tspo+/+ cells and MA-10:TspoΔ/Δ cells responded in a 
similar dose-dependent manner showing increases in progesterone production. These results show that the 
pharmacological effect of PK11195 on steroidogenesis is not mediated through TSPO. 
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INTRODUCTION 
Translocator protein (TSPO), previously known as peripheral benzodiazepine receptor (PBR), is a 
highly conserved protein across kingdoms (Yeliseev and Kaplan, 1995). It was first identified for its high 
binding affinity to benzodiazepines in distinct peripheral sites, as opposed to the central benzodiazepine 
receptor (γ-aminobutyric acid type A receptor) sites in the brain (Braestrup et al., 1977; Braestrup and 
Squires, 1977; Davies and Huston, 1981; Regan et al., 1981). The isoquinoline carboxamine, PK11195 
[N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-carboxamide], was then identified as a 
selective high-affinity TSPO/PBR binding chemical (Le Fur et al., 1983), and has been widely used in 
most binding/functional studies. Binding sites of TSPO ligands have been found in multiple tissues 
including: heart, brain, adrenal, kidney, salivary gland, platelets, brown adipose tissue, skin and liver 
(Gavish et al., 1999), but were noted to be highest in steroidogenic cells (Anholt et al., 1985; Morohaku et 
al., 2013; Wang et al., 2012). 
Sub-cellular fractionation and drug displacement studies showed that TSPO was enriched in the 
outer mitochondrial membrane (OMM) (Anholt et al., 1985; Anholt et al., 1986). A putative cholesterol 
recognition amino acid consensus (CRAC) sequence was identified at the C terminal region (Li and 
Papadopoulos, 1998), distinct from its PK11195 binding site (Jaremko et al., 2014). The structure of 
murine TSPO is described as a five transmembrane alpha helix (Murail et al., 2008), that was initially 
modeled to form a hydrophobic interior core containing the CRAC domain for cholesterol translocation 
(Korkhov et al., 2010). However, a more recent  nuclear magnetic resonance structure of TSPO showed 
that the CRAC domain is located on the outside of the TSPO pointing towards the membrane 
environment (Jaremko et al., 2014). Therefore, the ability of cholesterol to dimerize has been proposed to 
induce oligomerization of TSPO leading to the potential transporter function (Jaremko et al., 2014). 
For the past 25 years, TSPO has been depicted in the steroidogenic pathway as a critical 
transporter of cholesterol from the OMM to the mitochondrial matrix (Midzak et al., 2011). Conversion of 
cholesterol to pregnenolone by the enzyme CYP11A1 is restricted to the matrix side of the inner 
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mitochondrial membrane, therefore mitochondrial cholesterol import forms the first and the rate-limiting 
step for the acute production of all steroid hormones. The very first link between TSPO and steroid 
hormone biosynthesis emerged from a pharmacological study of different high affinity TSPO-binding 
chemicals on steroidogenesis. In Y1 mouse adrenal tumor cells, three out of nine chemicals, including 
PK11195, could induce steroid production at maximum 2-fold of the baseline (Mukhin et al., 1989). A 
follow-up report using the MA-10 mouse Leydig tumor cell line showed the same phenomenon with 
PK11195 being capable of inducing a 4-fold increase in baseline steroid production (Papadopoulos et al., 
1990). These responses were independent of induction of the steroidogenic acute regulatory protein 
(STAR), a key player in mitochondrial cholesterol transport required for steroidogenesis (Caron et al., 
1997; Clark et al., 1994). A subsequent publication reported that mono-allelic targeted disruption of the 
Tspo gene by homologous recombination in the R2C rat Leydig tumor cell line abolished TSPO protein 
expression and consequently inhibited progesterone level to only ~5% of control values (Papadopoulos et 
al., 1997b); it was concluded that TSPO has an indispensable role in steroidogenesis. 
Using Leydig cell-specific TSPO conditional knockout mice, we recently demonstrated that 
TSPO does not have a role in testosterone production (Morohaku et al., 2014). In direct contrast to a 
previous study (Papadopoulos et al., 1997a), we subsequently found that global TSPO knockout mice 
were viable and fertile with no effects on steroidogenesis (Tu et al., 2014). We also showed in different 
steroidogenic cell lines: Y1, MA-10, MLTC and R2C, that TSPO knockdown did not affect their ability 
to produce steroid hormones (Tu et al., 2014). In fact, the steroidogenic human adrenocortical cell line 
H295R, is deficient of TSPO, yet is capable of making steroid hormones (Tu et al., 2014). These results 
provided compelling genetic evidence that TSPO physiology is not associated with steroidogenesis. 
However, this did not agree with TSPO pharmacology, as TSPO binding chemicals are reported to induce 
steroid hormone production (Chung et al., 2013; Mukhin et al., 1989; Papadopoulos et al., 1990). 
In order to reconcile this discrepancy, we generated TSPO-knockout MA-10 Leydig tumor (MA-
10:TspoΔ/Δ) cells and tested the ability of PK11195 to induce steroid hormone production. Our results 
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demonstrate that TSPO deletion in MA-10 cells had no effect on its ability to produce steroid hormones 
and that the pharmacological effect of PK11195 on steroidogenesis is not mediated through TSPO. 
 
MATERIALS AND METHODS 
Generation of TSPO-deleted MA-10 cells 
MA-10 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) with glutamine and 
pyruvate containing 10% fetal bovine serum as previously described (Morohaku et al., 2013). The 
clustered regularly interspaced short palindromic repeats (CRISPR) system was used to generate MA-
10:TspoΔ/Δ cells by targeting exon 2 of the Tspo gene (NCBI: Gene ID: 12257; Reference Sequence: 
NM_009775.4). The specific guide RNA sequence 5’ – GCCTACTTTGTACGTGGCGA – 3’ was cloned 
in the pX330-U6-Chimeric_BB-cBh-hSpCas9 plasmid (Cong et al., 2013), transfected into MA-10 cells 
using TransIT-X2 (Mirus Bio) and cultured for 48 hrs. Transfected cells were then seeded in 96 well 
plates at the density of ~1 cell/well for clonal selection. Clones originating from single cells were 
screened for absence of TSPO protein expression by performing Western blots using a monoclonal 
antibody (Abcam) that recognizes amino acid 156-169 coded by the TSPO exon 4. Three MA-
10:TspoΔ/Δ cell clones were identified and mutations in the Tspo gene were confirmed by sequencing 
after cloning both the respective Tspo cDNAs and Tspo exon 2 genomic DNA into TOPO-TA vectors 
(Life Technologies), and ZR Plasmid Miniprep (Zymo Research) purification. The list of primers used for 
cloning and sequencing is provided in Supplemental Table 1.  
Immunocytochemistry 
Cells were incubated with 300 nM Mitotracker® Deep Red FM (Life Technologies) in culture 
medium for 1 hour at 37˚C, washed with PBS and fixed with 2% paraformaldehyde. Cells were blocked 
with 5% horse serum in PBS to prevent non-specific binding, stained with a primary rabbit monoclonal 
TSPO antibody (Abcam) and secondary Alexa Fluor 488 antibody as previously described (Morohaku et 
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al., 2013). Images were captured using a LSM 510 confocal microscope (Zeiss) and visualized using 
Image J.  
Hormone assays 
For dibutyryl-cAMP (Bt2cAMP) stimulation experiments, 5 x 104 cells were plated per well in a 
96 well plate and allowed to attach overnight. Cells were then washed with PBS and incubated with 0.5 
mM Bt2cAMP (Sigma) in DMEM medium without serum for 6 hrs. For PK11195 stimulation 
experiments, 15 x 104 cells were plated per well in a 12 well plate and allowed to attach overnight. Cells 
were washed with PBS, changed to DMEM medium without serum, and different doses of PK11195 
(Sigma) in equal volume of vehicle (ethanol, 0.1% v/v final) was added (Treatments: Vehicle only, 100 
nM, 1 µM, and 10 µM final concentrations of PK11195), and incubated for 2 hrs. For both stimulations, 
supernatants were collected and progesterone was measured as previously described (Manna et al., 2013), 
and values were normalized to total protein in each well. 
Immunoblots 
Proteins were separated by SDS-PAGE and immunoblotted using rabbit monoclonal primary 
antibodies against TSPO (Abcam) and a rabbit polyclonal STAR antibody (Clark et al., 1994). Each 
primary antibody was multiplexed with the control for protein loading, mouse monoclonal β-actin (Li-
Cor). Simultaneous detection was performed using IRDye 700 and 800 labeled secondary antibodies 
using a laser fluorescence scanner (Li-Cor) and quantified using ImageJ as described previously 
(Morohaku et al., 2014; Morohaku et al., 2013). 
Statistics 
Numeric differences between groups were compared using a Student’s t-test; comparisons for 
more than two groups were performed using ANOVA and post hoc Tukey’s test; p<0.05 was considered 
significant. All analyses were performed using Prism 5 (GraphPad). 
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RESULTS 
CRISPR/Cas9-mediated deletion of TSPO in MA-10 cells  
Tspo has 4 exons with the translation start codon in exon 2. Using the CRISPR/Cas9 system, a 
guide RNA was used with sequence complementary to 20 nucleotides downstream of the start codon in 
Tspo exon 2 for targeting Cas9 nuclease activity (Figure 3.1A). The resulting DNA double-stranded 
breaks, which are subject to the error prone non-homologous end joining, caused random indel mutations 
that induced frame shifts and/or generated a premature stop codon in the mRNA, leading to a truncated 
and non-functional TSPO protein.  
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Figure 3.1. CRISPR/Cas9-mediated deletion of TSPO in steroidogenic MA-10 Leydig cells. (A) 
Sequence of Tspo exon 2 showing the start codon and targeted sequence followed by the protospacer 
adjacent motif (PAM). (B) After transfection with Tspo-CRISPR/Cas9 construct, MA-10 clones were 
screened for TSPO protein expression using a monoclonal TSPO antibody that recognizes amino acids 
156-169 encoded by Tspo exon 4. Western blots that identified the three TSPO-deleted clones are shown. 
Control bands are β-Actin (ACTB). (C) Sequencing results of Tspo cDNA in 3 MA-10:TspoΔ/Δ clones 
confirmed indel mutations in the target sites of expressed alleles. Regions corresponding to guide RNA 
sequences are shown in green, deletions and insertions are shown in red. Deleted regions ranged from 2 
bp in MA-10:TspoΔ/Δ1 mutation 1 to 88 bp in MA-10:TspoΔ/Δ3 mutation 2. (D) Mutations in Tspo 
induced a frame shift and/or generated a stop codon, which resulted in a truncation with fragments 
restricted to TSPO N-terminal 28 and 25 amino acids for alleles in MA-10:TspoΔ/Δ1, 21 and 28 amino 
acids for alleles in MA-10:TspoΔ/Δ2, and 23 amino acids for the one allele in MA-10:TspoΔ/Δ3. The 
second allele in MA-10:TspoΔ/Δ3 was a Gly28 mutation that induced a significant change to the short α 
helix loop (arrowhead) that connects transmembrane region 1 and 2 that ultimately led to complete loss of 
TSPO protein expression. (E) Representative light microscopy images of MA-10:Tspo+/+ and MA-
10:TspoΔ/Δ cells showed that MA-10:TspoΔ/Δ cells were healthy with no apparent morphological 
changes (Scale bar: 200 μm). (F) Immunocytochemistry confirmed complete absence of TSPO in the 
different MA-10:TspoΔ/Δ clones (Scale bar: 20 μm). 
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In this study, after transfection with the Tspo-CRISPR/Cas9 construct, we screened 36 MA-10 
cell clones derived from single transfected cells for TSPO protein expression using a TSPO monoclonal 
antibody that recognizes amino acids 156-169 at the C-terminal tail of TSPO (coded by exon 4). We 
identified three TSPO-deleted clones: MA-10:TspoΔ/Δ1, MA-10:TspoΔ/Δ2, MA-10:TspoΔ/Δ3 (Figure 
3.1B). Sequencing confirmed that deletion mutations occurred in the targeted region in exon 2 in the 
expressed alleles of the three clones resulting in loss of TSPO protein expression (Figure 3.1 C-D). In 
MA-10:TspoΔ/Δ1, truncations resulting from frame shifts resulted in fragments restricted to TSPO N-
terminal 28 and 25 amino acids respectively for expressed alleles; similarly, MA-10:TspoΔ/Δ2 resulted in 
fragments restricted to the N-terminal 21 and 28 amino acids respectively for expressed alleles. In MA-
10:TspoΔ/Δ3, one allele was truncated with a fragment restricted to TSPO N-terminal 23 amino acids, 
and the other allele showed a deletion of Gly28. No mutant clones expressed the cholesterol-binding 
CRAC domain and the PK11195 binding pocket of the TSPO protein. The Gly28 deletion in one allele of 
MA-10:TspoΔ/Δ3 was a 3 base pair deletion that could potentially allow the remainder of the TSPO 
protein to remain in frame; however, we did not detect any TSPO protein expression from this clone 
(Figure 3.1B). Based on modeling this deletion in the TSPO structure (Jaremko et al., 2014), we identified 
a significant change to the short α helix loop that connects transmembrane region 1 and 2 (Figure 3.1D), 
which could potentially trigger the misfolded protein response. However, treatment with the proteasome 
inhibitor MG132 did not recover TSPO protein detection (data not shown), suggesting that cellular 
quality control mechanisms for TSPO are yet to be understood. Sequencing the genomic DNA Tspo loci 
from the three MA-10:TspoΔ/Δ clones detected 5-6 copies of TSPO in each clone that were all mutated 
(data not shown). Although the potential possibility of multiple alleles exists, it is also possible that 
persistent or repeated cutting by Cas9 at the Tspo exon 2 loci that may have occurred during clonal 
selection, could have resulted in some minor subclonal populations. These different mutations included 
those that were detected in Tspo cDNA from these clones. All MA-10:TspoΔ/Δ cells appeared healthy 
with no morphological differences compared to the control MA-10:Tspo+/+ cells (Figure 3.1E). 
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Immunocytochemical staining confirmed that TSPO protein was not detectable in MA-10:TspoΔ/Δ cells 
(Figure 3.1F). 
Loss of TSPO does not affect progesterone production in MA-10 cells 
We examined the effect of complete TSPO protein deficiency on steroid hormone production in 
MA-10:TspoΔ/Δ cells compared to control MA-10:Tspo+/+ cells. At baseline, progesterone levels were 
not different between the three MA-10:TspoΔ/Δ clones and control MA-10:Tspo+/+ cells (Figure 3.2A). 
After stimulation with Bt2cAMP, progesterone levels increased in both MA-10:TspoΔ/Δ and control MA-
10:Tspo+/+ cells to identical levels showing no defects in steroid hormone production (Figure 3.2A). In 
fact, progesterone levels in one clone MA-10:TspoΔ/Δ3, were even significantly higher than control MA-
10:Tspo+/+ cells. Expression of the steroidogenic acute regulatory (STAR) protein, a critical player in the 
steroid hormone synthesis pathway, was similar at both baseline and after Bt2cAMP stimulation in MA-
10:TspoΔ/Δ clones and control MA-10:Tspo+/+ cells (Figure 3.2B). These results indicated that TSPO is 
not involved in the steroid hormone biosynthetic pathway in MA-10 cells. 
 
Figure 3.2. TSPO deficiency does not affect progesterone production in MA-10 cells. (A) TSPO 
deletion in the three MA-10:TspoΔ/Δ clones did not affect baseline or Bt2cAMP stimulated progesterone 
production. Bt2cAMP stimulation, increased progesterone levels to a similar extent in both intact MA-
10:Tspo+/+, and TSPO deleted clones: MA-10:TspoΔ/Δ1, MA-10:TspoΔ/Δ2, and MA-10:TspoΔ/Δ3. 
Progesterone levels after Bt2cAMP treatment in clone MA-10:TspoΔ/Δ3 were significantly higher than 
MA-10:Tspo+/+ cells. Mean values were generated from 2-3 experiments conducted in triplicate. (B) 
Western blots showing absence of TSPO and the induction of STAR after Bt2cAMP stimulation of MA-
10:TspoΔ/Δ clones and MA-10:Tspo+/+ cells. Induction of STAR expression after Bt2cAMP stimulation 
were identical in the different MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells. Control bands 
are β-Actin (ACTB). 
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Figure 3.3. PK11195 induced steroidogenesis in the absence of TSPO. PK11195 dose-dependent 
increase in progesterone production was observed in both MA-10:TspoΔ/Δ clones (1, 2 and 3) and control 
MA-10:Tspo+/+ cells. Mean values were generated from 3-4 independent experiments conducted in 
triplicate. 
 
Pharmacological effect of PK11195 on steroidogenesis is not mediated by TSPO 
Using MA-10:TspoΔ/Δ cells as a tool, we attempted to validate the specific relationship between 
PK11195 and TSPO in the induction of steroidogenesis, a pharmacological effect demonstrated in 
previous studies (Mukhin et al., 1989; Papadopoulos et al., 1990). We examined whether PK11195 would 
induce a steroidogenic response in MA-10:TspoΔ/Δ clones. Our results showed that PK11195 could 
stimulate progesterone production in a dose-dependent manner in both MA-10:TspoΔ/Δ clones and 
control MA-10:Tspo+/+ cells (Figure 3.3). In control MA-10:Tspo+/+ cells, the maximal progesterone 
levels observed at 10 µM PK11195 was about 3 to 4 fold higher than baseline; this was identical in MA-
10:TspoΔ/Δ clones 1 and 3. MA-10:TspoΔ/Δ clone 2 also showed a similar response, but the progesterone 
production was induced only about 2 fold of the baseline. These results indicated that the pharmacological 
effect of the TSPO ligand PK11195 on steroid hormone synthesis in MA-10 cells is not mediated via 
TSPO. 
 
67 
DISCUSSION 
Recent evidence that there is no physiological need for TSPO in mitochondrial cholesterol 
transport for steroid hormone biosynthesis has raised critical questions about the pharmacology of TSPO 
binding chemicals (Banati et al., 2014; Stocco, 2014; Tu et al., 2014). The core basis for TSPO 
involvement in steroidogenesis was indicated by early studies reporting that TSPO binding chemicals can 
induce steroid hormone production (Mukhin et al., 1989; Papadopoulos et al., 1990). Based on our results, 
it is apparent that the effect of PK11195 on MA-10 cells resulting in the induction of steroid hormone 
production is not mediated through TSPO. 
Hormone production by steroidogenic cells upon treatment with TSPO binding chemicals has 
been offered as proof of TSPO involvement in steroidogenesis (Mukhin et al., 1989; Papadopoulos et al., 
1990). The effect of PK11195 was previously shown to induce progesterone production in a steep dose 
response curve that plateaued at concentrations higher than 1 µM. However, it is interesting to note that 
the response itself was very modest and transient; in a time course, there was no progressive increase in 
progesterone accumulation in cell culture supernatants after the first hour of PK11195 treatment, and 
levels remained unchanged over the next 4 hours (Papadopoulos et al., 1990). This is in contrast to 
stimulation with trophic hormones, which show a progressive accumulation of progesterone in the 
supernatant over the entire 5-hour period (Papadopoulos et al., 1990). We initially interpreted this 
distinction as an indicator that the effect of TSPO binding chemicals is a physical response to TSPO 
binding rather than a physiological effect. In a recent commentary, Papadopoulos also offered such an 
explanation to address why physiological TSPO function might be different from pharmacology 
(Papadopoulos, 2014). In addition, structural evidence that PK11195-binding stabilizes TSPO also 
contributed to the logic that such an event might be possible (Jaremko et al., 2014).  
In our treatments, maximal induction of progesterone production was 2 to 4 fold higher than 
baseline at 10 µM PK11195 in both MA-10:TspoΔ/Δ and MA-10:Tspo+/+ cells, which is comparable to 
the extent of induction previously demonstrated for MA-10 cells (Papadopoulos et al., 1990). One of the 
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three clones MA-10:TspoΔ/Δ2 was less responsive and reached only about 2 fold above baseline, a 
difference that could be explained by inherent variability that exists in clonal populations within MA-10 
cells (Gocze and Freeman, 1994). Interestingly, we did not find induction of progesterone production in 
either MA-10:TspoΔ/Δ or MA-10:Tspo+/+ cells at nanomolar PK11195 concentrations; values for 
progesterone also did not seem to plateau at 1 µM for these cells as previously reported (Papadopoulos et 
al., 1990), suggesting an experimental difference in effective ranges for this steroidogenic response by 
PK11195. We observed that PK11195 ability to induce progesterone production was inversely affected by 
cell density, and a prominent response could be observed only when cells were less than 50% confluent 
(not shown). This also suggested that the PK11195 exposure did not generate a typical drug-ligand type 
response in these cells. Nevertheless, the fact that we observed a PK11195 response in both MA-
10:TspoΔ/Δ and MA-10:Tspo+/+ cells confirms that TSPO is not involved in this phenomenon. 
One possibility for this disconnect is that the pharmacological effect of PK11195 on 
steroidogenesis could be due to a chemical-membrane interaction. It has been recently demonstrated that 
TSPO ligands like PK11195 can insert themselves into lipid bilayers affecting membrane properties 
(Hatty et al., 2014), a phenomenon that could modulate cholesterol availability to the steroidogenic 
machinery. Another study reported that high concentrations of PK11195 could rapidly displace 
fluorescent NBD-cholesterol [(22-(N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino)-23,24-Bisnor-5-
Cholen-3β-Ol)] from different membrane compartments into lipid droplets, affecting intracellular 
cholesterol in astrocytes and fibroblasts (Falchi et al., 2007). Although it was not clear if this 
displacement was mediated by TSPO in these cell types, one plausible explanation for our results in 
steroidogenic cells is that a similar displacement could potentially release a limited amount of cholesterol 
from mitochondrial membranes and hence trigger a modest and transient increase in steroid hormone 
production. 
In addition, while there are reports in the literature of TSPO-independent action of several 
putative binding chemicals, specific cellular targets other than TSPO have not been extensively 
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characterized. PK11195 has been demonstrated to target the F1F0-ATPsynthase and inhibit mitophagy 
without the involvement of TSPO (Seneviratne et al., 2012). In another study, an apoptosis-sensitizing 
effect for PK11195 was observed even after TSPO was completely knocked down (Gonzalez-Polo et al., 
2005). The anti-tumor effect of TSPO binding chemicals Ro5-4864 and FGIN-1-27 was identical 
irrespective of the presence or absence of TSPO in different tumors (Hans et al., 2005). In hematologic 
cancers, PK11195 showed broad inhibition of adenosine triphosphate (ATP)-binding cassette transporters 
by binding to plasma membrane sites without involvement of TSPO (Walter et al., 2005). In cells of 
mesenchymal origin, PK11195 and Ro5-4864 could inhibit cell proliferation through decreases in 
activation of ERK and c-Jun independent of TSPO (Kletsas et al., 2004). Therefore, we can speculate that 
the effect of PK11195 on steroidogenesis may be mediated through binding to another unidentified 
cellular target in steroid hormone producing cells. 
Results in this study also contradicted the previous study on R2C cells that disruption of one Tspo 
allele dramatically reduced steroid production to only ~5% of control values (Papadopoulos et al., 1997b). 
This disruption also caused significant adverse morphological changes and 2-3 times slower cell 
proliferation in these R2C cells. We did not observe any differences in morphology, viability or 
proliferation in the three MA-10:TspoΔ/Δ clones generated in this study. Therefore, previous results from 
the solitary mono-allelic Tspo-disrupted R2C clone may require reinvestigation. 
In summary, our results show that TSPO deletion in MA-10 cells has no effect on steroid 
hormone biosynthesis and that the pharmacological activity of PK11195 on the induction of 
steroidogenesis is not mediated through TSPO. 
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CHAPTER 4 
Translocator Protein (TSPO) Affects Mitochondrial Fatty Acid Oxidation in 
Steroidogenic Cells 
Tu, L. N., Zhao, A. H., Hussein, M., Stocco, D. M., & Selvaraj, V. (2016). Translocator Protein (TSPO) 
Affects Mitochondrial Fatty Acid Oxidation in Steroidogenic Cells. Endocrinology, 157(3), 1110-1121. 
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ABSTRACT 
Translocator protein (TSPO), also known as the peripheral benzodiazepine receptor (PBR), is a 
highly conserved outer mitochondrial membrane protein present in specific sub-populations of cells 
within different tissues. In recent studies, the presumptive model depicting mammalian TSPO as a critical 
cholesterol transporter for steroidogenesis has been refuted by studies examining effects of Tspo gene 
deletion in vivo and in vitro, biochemical testing of TSPO cholesterol transport function, and specificity 
of TSPO-mediated pharmacological responses. Nevertheless, high TSPO expression in steroid-producing 
cells seemed to indicate an alternate function for this protein in steroidogenic mitochondria. To seek an 
explanation, we used CRISPR/Cas9-mediated TSPO knockout steroidogenic MA-10 Leydig cell (MA-
10:TspoΔ/Δ) clones to examine changes to core mitochondrial functions resulting from TSPO deficiency. 
We observed that, 1) MA-10:TspoΔ/Δ cells had a shift in substrate utilization for energy production from 
glucose to fatty acids with significantly higher mitochondrial fatty acid oxidation (FAO), and increased 
reactive oxygen species (ROS) production; 2) oxygen consumption rate (OCR), mitochondrial membrane 
potential (∆ψm), and proton leak were not different between MA-10:TspoΔ/Δ and MA-10:Tspo+/+ 
control cells. Consistent with this finding, TSPO deficient adrenal glands from global TSPO knockout 
(Tspo-/-) mice also showed upregulation of genes involved in FAO compared to the TSPO floxed (Tspofl/fl) 
controls. These results demonstrate the first experimental evidence that TSPO can affect mitochondrial 
energy homeostasis through modulation of FAO, a function that appears to be consistent with high levels 
of TSPO expression observed in cell types active in lipid storage/metabolism.  
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INTRODUCTION 
Translocator protein (TSPO), also known as the peripheral benzodiazepine receptor (PBR), was 
first identified in 1977 as a secondary target for diazepam-binding (Braestrup and Squires, 1977). 
Although TSPO protein sequence is highly conserved from bacteria to mammals (Yeliseev and Kaplan, 
1995), functions reported for TSPO have been variable depending on organism and sometimes even 
context (Gatliff and Campanella, 2012; Gavish et al., 1999). Hence, its exact molecular function 
continues to remain elusive. For more than two decades, mammalian TSPO was depicted as a 
mitochondrial cholesterol transporter indispensable for steroid hormone biosynthesis (Papadopoulos et 
al., 1997; Papadopoulos and Miller, 2012). Abundant expression of TSPO in steroidogenic cells, and its 
localization to the outer mitochondrial membrane (Anholt et al., 1986), appeared to support this 
functional role. However, recent genetic and pharmacological evidence has refuted this model by showing 
that TSPO has no role in steroidogenesis both in vivo and in vitro (Banati et al., 2014; Morohaku et al., 
2014; Tu et al., 2014; Tu et al., 2015). This paradigm shift in understanding of TSPO function has 
precipitated a need to reevaluate functional interpretations made for TSPO in previous studies [reviewed 
in (Selvaraj et al., 2015)]. 
Despite these recent findings that TSPO has no role in steroidogenesis, a new model for TSPO 
function explaining the reason for its high expression in steroidogenic cells is yet to be established 
(Selvaraj and Stocco, 2015). This gap in knowledge has led to speculations that a role in steroidogenic 
cell function, unrelated to mitochondrial cholesterol transport might still be relevant for TSPO (Fan et al., 
2015). Indeed high expression of TSPO in steroidogenic cells of the adrenals, testes and ovaries is evident 
from several studies (Bribes et al., 2004; De Souza et al., 1985), and has been reproducible (Morohaku et 
al., 2013; Tu et al., 2014). This correlation has been the basis of numerous studies attempting to link 
TSPO function to steroidogenesis, overshadowing the fact that TSPO expression is not particularly 
confined to steroidogenic cells within tissues (Morohaku et al., 2013). Expression of TSPO in many other 
cell types that do not produce steroids in tissues such as lungs, kidneys, livers, spleens and bone marrows 
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(Banati et al., 2014; Tu et al., 2014), suggest perhaps a broader function for TSPO in mitochondrial 
homeostasis, which remains to be explored in genetic models. 
In pharmacological studies, TSPO has been associated with almost all core mitochondrial 
functions. TSPO binding drugs have been shown to affect mitochondrial energy metabolism (Hirsch et 
al., 1989; Larcher et al., 1989), apoptosis (Furre et al., 2005; Maaser et al., 2005), intracellular calcium 
signaling (Campanella et al., 2008; Hong et al., 2006), and reactive oxygen species (ROS) production 
(Fennell et al., 2001; Zeno et al., 2012). However, interpreting effects observed using TSPO ligands have 
been confounded by inconsistencies due to inherent binding distinctions/affinities (Scarf et al., 2012), and 
potential alternate targets in the cell (Li et al., 2008; Seneviratne et al., 2012). As a result, these 
observations have not been relevant for advancing knowledge of the precise physiological function of 
TSPO. Another confounding factor of membrane-drug interactions of TSPO binding chemicals has also 
recently surfaced (Hatty et al., 2014; Scarf et al., 2012). Limitations of pharmacological studies were 
highlighted when the previously believed role for TSPO in mitochondrial permeability transition 
(Kinnally et al., 1993), could occur even after TSPO deletion (Sileikyte et al., 2014). Similarly, the 
prototypical TSPO binding drug PK11195 [N-butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-
carboxamide] that was used in demonstration of the first pharmacological basis for TSPO function in 
steroidogenesis (Mukhin et al., 1989), could stimulate steroid hormone production in TSPO deleted 
steroidogenic cells (Tu et al., 2015). Therefore, it has become important to clarify the different 
pharmacological effects reported on mitochondrial functions using Tspo gene deleted models to advance 
understanding of its physiological role in steroidogenic cells. 
Previously, we generated CRISPR/Cas9-mediated TSPO knockout MA-10 (MA-10:TspoΔ/Δ) 
Leydig cells and demonstrated that TSPO deletion did not have any effect on viability or steroidogenesis 
(Tu et al., 2015). In the present study, we examine the effect of TSPO deletion in this cell type on 
different mitochondrial functions. Our systematic investigation of mitochondrial properties led us to 
uncover that TSPO-deficient MA-10 cells increased fatty acid uptake, fatty acid oxidation (FAO), and 
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increased reactive oxygen species (ROS) production. Extending this observation in vivo, we found that 
TSPO deficiency in adrenal glands of global TSPO knockout (Tspo-/-) mice also resulted in upregulation 
of genes involved in FAO compared to the TSPO floxed (Tspofl/fl) controls. These results indicate that 
TSPO affects fatty acid metabolism, a function that positively correlates with high levels of TSPO 
expression observed in cell types active in lipid storage/metabolism. 
 
MATERIALS AND METHODS 
Cells and mice 
The MA-10 Leydig cell line (Ascoli, 1981), was used as a model for male steroidogenic cells. 
Two independent clones of TSPO knockout MA-10 cells (MA-10:TspoΔ/Δ) previously generated by 
CRISPR/Cas9-mediated targeting of Exon 2 of the Tspo gene were compared to intact MA-10 cells (MA-
10:Tspo+/+) in all experiments. Generation and characterization of Tspo mutations in these cells have 
been previously published (Tu et al., 2015). Cells were grown at 37˚C under 5% CO2 in Dulbecco’s 
modified eagle medium/DMEM high glucose (25 mM glucose, 1 mM pyruvate) containing 10% FBS and 
1% penicillin-streptomycin. Generation and validation of Tspofl/fl and Tspo-/- mice has been previously 
described (Tu et al., 2014); both male and female mice were sampled at 8-12 weeks of age. Animals were 
maintained in accordance with the National Institute of Health Guide for the Care and Use of Laboratory 
Animals. The Institutional Animal Care and Use Committee of Cornell University approved the 
experiment described.  
Progesterone assay 
For dibutyryl-cAMP (Bt2cAMP) stimulation experiments, 5 x 104 cells were plated per well in a 
96 well plate and allowed to attach overnight. Cells were then washed with PBS and incubated with 0.5 
mM Bt2cAMP in serum free media for 6 hrs. For both baseline and stimulation, supernatants were 
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collected and progesterone was measured as previously described (Tu et al., 2015), and normalized to 
total protein in each well. 
Measurement of mitochondrial respiration 
Mitochondrial respiration was calculated from oxygen consumption rates (OCR) under specific 
conditions using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). For quantifying 
mitochondrial respiration, MA-10:Tspo+/+ cells were paired with one of the MA-10:TspoΔ/Δ clones in 
different wells at a density of 50,000 cells in the same XF24 cell culture microplates in growth medium 
overnight. One hour before assay, cells were washed and incubated in XF assay medium (DMEM with no 
bicarbonate) supplemented with 25 mM glucose and 1 mM pyruvate at 37˚C in a CO2-free atmosphere. 
Changes to OCR were measured in real time every 3-5 minutes. Oligomycin, Carbonyl cyanide 4-
(trifluoromethoxy)phenylhydrazone (FCCP), Antimycin A and Rotenone were sequentially injected into 
each well to assess basal respiration, coupling of respiratory chain, proton leak and mitochondrial spare 
respiratory capacity. OCR values were used to calculate mitochondrial coupling efficiency, spare 
respiratory capacity and proton leak. Extracellular acidification rates (ECAR) as changes in mpH over 
time were simultaneously measured.  
Measurement of fatty acid oxidation 
Fatty acid oxidation (FAO) was calculated from OCR under specific conditions using an XF24 
Extracellular Flux Analyzer. For quantifying FAO, MA-10:Tspo+/+ and MA-10:TspoΔ/Δ cells were 
plated at a density of 50,000 cells in the XF24 cell culture microplates overnight. Cells were then starved 
in substrate-limited medium (DMEM containing 0.5 mM glucose, 1% FBS, 1 mM Glutamax and 0.5 mM 
carnitine) for 3 hours before it was replaced with FAO assay media (Krebs-Henseleit buffer supplemented 
with 2.5 mM glucose, 0.5 mM carnitine and 5 mM HEPES). Etomoxir (40 µM) was added 20 minutes 
before the assay. Bovine serum albumin (BSA) or Palmitate-BSA was added to specific wells right before 
starting the assay with sequential injections of Oligomycin, FCCP, Antimycin A and Rotenone, and 
changes to OCR were measured in real time every 3-5 minutes as described above. 
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Measurement of ATP 
MA-10:Tspo+/+ and MA-10:TspoΔ/Δ cells in growth phase at 60% confluence were maintained 
in either high glucose DMEM, or changed to no glucose DMEM, with or without 50 µM Etomoxir for 3 
hours. Cells were then collected and lysed in ice-cold trichloroacetic acid (0.5% final conc.) for 5 
minutes, and centrifuged at 10,000 x g to precipitate proteins. Supernatant containing ATP was collected 
and neutralized with 1 M Tris-acetate buffer, 1mM EDTA (pH 7.75), and kept on ice until measurement. 
ATP measurement was performed using a luciferin-luciferase method with an Enliten® ATP detection kit 
(Promega), and luminescence was measured using an Infinite® 200Pro reader (Tecan). Measured ATP 
values were normalized to total protein content for comparison between groups. 
Measurement of mitochondrial membrane potential (∆ψm) 
Cells in growth phase at 60% confluence were trypsinized and resuspended in phenol red-free 
high glucose DMEM, 10% FBS. Cells were then incubated with 100 nM Mitotracker® Green FM and 20 
nM tetramethylrhodamine methyl ester (TMRM) at 37˚C for 30 minutes in the dark. The labeled MA-10 
cells were examined separately using wavelengths 488/520 (excitation/emission) nm for Mitotracker® 
Green and 488/575 nm for TMRM with a Gallios flow cytometer (Beckman Coulter). Intensity of TMRM 
was normalized to that of Mitotracker® Green for comparison of ∆ψm among samples.   
Measurement of reactive oxygen species 
Production of reactive oxygen species and superoxide were directly monitored in live cells by 
flow cytometry using the total ROS/Superoxide detection kit (Enzo Life Science). Cells were grown 
overnight to 60% density, trypsinized and washed with phosphate buffered saline (PBS). Cells were then 
incubated with fluorescent dyes: oxidative stress detection reagent (green) for total ROS and reactive 
nitrogen species (RNS), and superoxide detection reagent (orange) for 30 minutes at 370C in the dark. The 
labeled MA-10 cells from both genotypes were examined using wavelengths 488/520 nm and 550/620 nm 
in a Gallios flow cytometer (Beckman Coulter). Positive controls (200 µM pyocyanin treatment) and 
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negative controls (5 mM N-acetyl-L-cysteine treatment) were used to confirm analytical methods. Mean 
fluorescence intensity was calculated from data collected from the two channels and values were 
compared between the two genotypes using Kaluza Flow Analysis software (Beckman Coulter).  
Lentiviral expression of TSPO in MA-10 cells 
Tspo cDNA was cloned in a lentiviral vector [pLenti CMV GFP Puro, (Campeau et al., 2009)] for 
expression in mammalian cells. Lentiviral particles were packaged using 293T cells by cotransfecting 
with helper plasmids encoding gag, pol and rev, and viral supernatants were collected at 48h and 72h. 
Unmodified pLenti vector was used to make GFP control viruses. MA-10:Tspo+/+ cells and the two MA-
10:TspoΔ/Δ clones were transduced using Tspo and control lentiviruses in medium supplemented with 6 
μg/ml Polybrene (Sigma) for 24 hours. Infection efficiency was analyzed visualizing GFP fluorescence or 
TSPO expression after 5 days and used for experiments.      
Gene expression 
Total RNA was extracted from MA-10 cells and adrenal glands using Trizol (Life Technologies). 
Reverse transcription was carried out using Multiscribe™ reverse transcriptase (Life Technologies). Gene 
expressions were quantified using a SYBR® Green detection method (Affymetrix) with validated primer 
sequences obtained from PrimerBank database (Spandidos et al., 2010). Primer specificity and 
amplification efficiency were confirmed and sequences are provided in Supplemental Table 1. All 
expression data were normalized to internal control genes, TATA-binding protein (Tbp) or 
Glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Relative quantification of fold-change was 
calculated using the 2-∆/∆Ct method (Livak and Schmittgen, 2001).  
Protein expression 
Total protein concentration in each sample was measured using the bicinchoninic acid (BCA) 
assay (Pierce). Proteins (cells: 30 µg and mouse tissues: 75 µg) were separated by SDS-PAGE and 
immunoblotted using rabbit monoclonal primary antibodies against TSPO (Abcam) and isocitrate 
81 
dehydrogenase 2 (IDH2) (Abcam), mouse monoclonal antibody against voltage-dependent anion channel 
1 (VDAC1) (Abcam), or rabbit polyclonal antibody against uncoupling protein 2 (UCP2) (Alpha 
Diagnostics). Each primary antibody was multiplexed with the loading control β-actin (ACTB) (Li-Cor). 
Simultaneous detection was performed using IRDye 700 and 800-labeled secondary antibodies under a 
laser fluorescence scanner (Li-Cor) and quantified using ImageJ as described previously (Morohaku et al., 
2014; Morohaku et al., 2013). 
Statistics 
Numeric differences of interval level data between groups were compared using a Student’s t-
test; comparisons for more than two groups were performed using ANOVA and post hoc Tukey’s test 
(p<0.05 was considered significant). All analyses were performed using Prism 5 (GraphPad). Data are 
represented as mean ± standard error of the mean and replicates are as indicated in figure legends. 
 
RESULTS 
TSPO deletion does not affect mitochondrial respiration in MA-10 cells 
Complete absence of TSPO in the two MA-10:TspoΔ/Δ clones, compared to high levels of TSPO 
expression in intact MA-10:Tspo+/+ cells (Figure 4.1A), make them excellent comparative models to 
investigate TSPO function. As demonstrated previously (Tu et al., 2015), deletion of TSPO in these cells 
had no effect on steroid hormone biosynthesis (Figure 4.1B). We confirmed using Western blots that loss 
of such an abundant mitochondrial protein did not affect expression of other mitochondrial markers in the 
two MA-10:TspoΔ/Δ clones: VDAC1, present in the outer mitochondrial membrane and IDH2, present in 
the mitochondrial matrix were not different between the two MA-10:TspoΔ/Δ clones and MA-10:Tspo+/+ 
cells (Figure 4.1A).  
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Figure 4.1. TSPO deletion does not alter mitochondrial bioenergetics in MA-10 cells. (A) 
Representative western blots of MA-10:Tspo+/+ and the two MA-10:TspoΔ/Δ clones showing that TSPO 
deletion did not affect expressions of mitochondrial proteins VDAC1 and IDH2. (B) TSPO deletion did 
not affect baseline or Bt2cAMP stimulated progesterone production in the two MA-10:TspoΔ/Δ clones 
compared to the intact MA-10:Tspo+/+ cells (For A-B, n=3/group). (C) Representative results from a 
paired assay showing that baseline oxygen consumption rate (OCR) and maximal OCR after addition of 
the protonophore FCCP were not different between MA-10:Tspo+/+ and MA-10:TspoΔ/Δ2 cells. OCR 
declined upon blocking ATP synthase activity using oligomycin, or inhibiting electron transport chain 
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using antimycin A and rotenone, but these were also not different between the two genotypes. (D) 
Calculated ATP production was not different between MA-10:Tspo+/+ and MA-10:TspoΔ/Δ cells. (E) 
Calculated mitochondrial coupling efficiency was not different between MA-10:Tspo+/+ and MA-
10:TspoΔ/Δ  cells. (F) Calculated spare respiratory capacity was significantly lower in MA-10:TspoΔ/Δ 
compared to MA-10:Tspo+/+ cells. (G) Calculated proton leak was not different between the two 
genotypes. (For C-G, n=10/group) (H) Normalized TMRM/Mitotracker® Green fluorescence intensity 
comparison between MA-10:Tspo+/+ and MA-10:TspoΔ/Δ cells showed no difference in baseline ∆ψm 
(n=5-6/group). (I) Total ATP levels were not different between MA-10:Tspo+/+ and MA-10:TspoΔ/Δ  
cells in high glucose medium (n=5/group). 
 
Direct measurements of baseline and maximal OCR showed no significant difference between 
MA-10:Tspo+/+ cells and both MA-10:TspoΔ/Δ clones; representative results from one paired assay 
comparing MA-10:Tspo+/+ cells and MA-10:TspoΔ/Δ1 clone is presented (Figure 4.1C). Calculated ATP 
production, oxidative phosphorylation coupling efficiency and proton leak were also unchanged in MA-
10:TspoΔ/Δ cells compared to MA-10:Tspo+/+ cells (Figure 4.1 D,E,G). The spare respiratory capacity 
was significantly reduced in MA-10:TspoΔ/Δ1 clone compared to MA-10:Tspo+/+ cells (Figure 4.1F), 
but the difference was very modest and not observed in MA-10:TspoΔ/Δ2 clone. All other results were 
consistent in the second MA-10:TspoΔ/Δ2 clone (data not shown). 
TSPO deletion does not affect ∆Ψm and ATP production in MA-10 cells 
Assessment of ∆Ψm using the membrane potential-dependent probe TMRM, normalized to 
Mitotracker® Green showed that MA-10:Tspo+/+ cells and the two MA-10:TspoΔ/Δ clones had similar 
baseline ∆Ψm (Figure 4.1H). Provided that oxygen consumption and ∆ψm were unchanged, ATP 
production was not expected to be different between MA-10:TspoΔ/Δ cells as compared to the intact MA-
10:Tspo+/+ cells. In corroboration, total ATP levels measured by luciferin-luciferase assay were not 
affected by TSPO deletion in the two MA-10:TspoΔ/Δ clones when compared to MA-10:Tspo+/+ cells 
when all cells were maintained in DMEM high glucose growth medium (Figure 4.1I). 
84 
 
Figure 4.2. Shift in substrate utilization for energy production in TSPO deficient MA-10 cells. (A) 
Baseline extracellular acidification rates (ECAR) and maximal ECAR after addition of oligomycin were 
significantly lower in MA-10:TspoΔ/Δ compared to MA-10:Tspo+/+ cells (n=10/group). (B) When cells 
were cultured in medium without glucose, ATP production was significantly higher in MA-10:TspoΔ/Δ 
cells compared to MA-10:Tspo+/+ cells. Treatment with etomoxir (Eto), a CPT1A inhibitor, resulted in 
decrease in ATP production in all cells to similar levels (n=4-6/group).  (C) Expression of Cd36, a key 
gene for fatty acid uptake is significantly higher in MA-10:TspoΔ/Δ  compared to MA-10:Tspo+/+ cells. 
Expression levels of key genes in mitochondrial β-oxidation pathway:  Cpt1a, Acadm, Acadl, and Hadha 
were significantly upregulated in MA-10:TspoΔ/Δ compared to MA-10:Tspo+/+ cells. There was no 
difference in the transcription factor Ppara and peroxisomal β-oxidation gene Acox1 between the two 
genotypes. Expression levels of key genes in lipogenesis pathway: Srebf1c, Fasn, Acaca were not 
different between MA-10:Tspo+/+ and MA-10:TspoΔ/Δ  cells, except that Srebf1c was significantly 
lower in one clone MA-10:TspoΔ/Δ1 but not in MA-10:TspoΔ/Δ2, compared to MA-10:Tspo+/+  cells 
(n=3/group; *p<0.05). 
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TSPO deletion increases mitochondrial fatty acid oxidation in MA-10 cells 
The extracellular acidification rates (ECAR), measured simultaneously with OCR were 
significantly lower in MA-10:TspoΔ/Δ cells compared to MA-10:Tspo+/+ cells (Figure 4.2A), which 
indicated a decrease in glycolysis associated with TSPO deletion. However, the fact that total ATP levels 
were not different in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells (Figure 4.1I), suggested 
a shift favoring substrate utilization from glucose to fatty acids. To directly examine the contribution of 
FAO to ATP production, MA-10:TspoΔ/Δ clones and MA-10:Tspo+/+ cells were incubated in no glucose 
DMEM medium to minimize ATP production through glycolysis and compared. Under this condition, 
ATP levels were then markedly higher (20-29%) in both MA-10:TspoΔ/Δ clones compared to intact MA-
10:Tspo+/+ cells (Figure 4.2B). When cells under this same condition (no glucose DMEM) were treated 
with etomoxir, an irreversible carnitine palmitoyltransferase I (CPT1A) inhibitor to block mitochondrial 
FAO, ATP in MA-10:TspoΔ/Δ clones decreased to levels almost identical to MA-10:Tspo+/+ cells 
(Figure 4.2B). This provided confirmation that the increase in ATP was associated with higher FAO in 
MA-10:TspoΔ/Δ clones. 
Expression levels of crucial genes involved in fatty acid metabolism indicated that MA-
10:TspoΔ/Δ clones had increased fatty acid uptake and utilization. Expression of the cluster of 
differentiation 36 (Cd36), also known as fatty acid translocase, was upregulated in MA-10:TspoΔ/Δ 
clones compared to MA-10:Tspo+/+ cells indicating higher fatty acid uptake in these cells (Figure 4.2C). 
Expressions of Cpt1a, acyl-CoA dehydrogenase medium chain (Acadm), acyl-CoA dehydrogenase long 
chain (Acadl) and hydroxyacyl-CoA dehydrogenase (Hadha), the key genes in mitochondrial FAO, were 
also significantly higher in MA-10:TspoΔ/Δ cells compared to MA-10:Tspo+/+ cells (Figure 4.2C). 
However, peroxisome proliferator-activated receptor alpha (Ppara) and the key peroxisomal FAO 
enzyme acyl-CoA oxidase 1 (Acox1) were not altered as a result of TSPO deletion (Figure 4.2C). 
Moreover, we observed that the upregulation of mitochondrial FAO is not attributed to higher 
lipogenesis, because expression of enzymes involved in the lipogenic pathway like fatty acid synthase 
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(Fasn), acetyl-CoA carboxylase alpha (Acaca) were not different in MA-10:TspoΔ/Δ clones compared to 
compared to MA-10:Tspo+/+ cells (Figure 4.2C). The sterol regulatory element-binding protein 1c 
(Srebf1c) was observed to be downregulated in clone MA-10:TspoΔ/Δ1 but not in clone MA-
10:TspoΔ/Δ2 (Figure 4.2C).  
 
Figure 4.3. TSPO deficiency increases fatty acid oxidation in MA-10 cells. (A) MA-10:Tspo+/+ and 
MA-10:TspoΔ/Δ cells were starved and given only BSA in FAO assay media. Etomoxir (Eto) was added 
to some wells 20 minutes before the assay. OCR was measured to indicate oxidation of endogenous fatty 
acids. (B) Quantification of endogenous FAO as the difference between conditions with or without 
Etomoxir treatment during starvation showed significantly higher maximal FAO in MA-10:TspoΔ/Δ cells 
compared to intact MA-10 cells. (C) MA-10:Tspo+/+ and MA-10:TspoΔ/Δ cells were starved and given 
BSA-palmitate. Etomoxir (Eto) was added to some wells 20 minutes before the assay. OCR was 
measured to indicate total FAO. (D) Quantification of total FAO as the difference between conditions 
with or without Etomoxir treatment, both containing BSA-palmitate showed higher baseline and maximal 
FAO in MA-10:TspoΔ/Δ cells. (For all panels: n=3/group; replicated 2 times, *p<0.05).  
 
Functional measurement of β-oxidation using substrate restricted media showed significantly 
higher endogenous β-oxidation rates in MA-10:TspoΔ/Δ1 cells compared to MA-10:Tspo+/+ cells (Figure 
4.3 A-B). When provided with an exogenous substrate in the form of palmitate, total mitochondrial β-
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oxidation (both endogenous and exogenous) of MA-10:TspoΔ/Δ1 cells were significantly higher at both 
baseline and maximal rates than MA-10:Tspo+/+ cells (Figure 4.3 C-D). These data confirmed that TSPO 
deletion increased mitochondrial FAO in MA-10 cells. 
 
 
 
Figure 4.4. TSPO deficiency increases ROS and UCP2 levels in MA-10 cells. (A) Superoxide 
production in both MA-10:TspoΔ/Δ cell clones was significantly higher compared to MA-10:Tspo+/+ 
cells (n=5-6/group). (B) Overlay plot showing higher fluorescence intensity for superoxide-responsive 
dye in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells. (C) Total reactive oxygen species and 
reactive nitrogen species (ROS/RNS) in both MA-10:TspoΔ/Δ cells were significantly higher compared 
to MA-10:Tspo+/+ cells (n=5-6/group). (D) Overlay plot showing higher fluorescence intensity of 
ROS/RNS-responsive dye in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells. (E) Gene 
expression of Ucp2 was upregulated in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells 
(n=3/group). (F) Representative Western blot for UCP2 showing increased expression in MA-10:TspoΔ/Δ 
clones compared to MA-10:Tspo+/+ cells (normalized numerical intensities to ACTB are indicated).   
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ROS and uncoupling protein 2 are upregulated in MA-10:TspoΔ/Δ cells 
As we observed an increase in FAO in MA-10:TspoΔ/Δ clones, we investigated if production of 
ROS was also increased in these cells compared to MA-10:Tspo+/+ cells. We detected that superoxide 
levels were significantly elevated in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells (Figure 
4.4 A-B). Total ROS/RNS levels, including hydrogen peroxide, peroxynitrite and hydroxyl radicals, were 
also significantly higher in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells (Figure 4.4 C-D). 
Changes in mitochondrial metabolism and ROS are known to affect expression of uncoupling proteins 
(UCPs). We observed that Ucp2 gene expression and UCP2 protein levels were significantly upregulated 
in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells (Figure 4.4 E-F). Ucp1 expression was not 
detected in MA-10 cells (not shown). 
TSPO overexpression decreases expression of FAO genes in MA-10 cells 
To examine if the effects of TSPO deficiency can be reversed by reintroducing TSPO expression 
in MA-10:TspoΔ/Δ cells, we infected cells with Tspo lentiviruses for stable expression. In the resulting 
cells, we observed strong TSPO overexpression after 5 days (Figure 4.5A). This TSPO overexpression 
did not perturb expression of VDAC1 in the OMM (Figure 4.5A). By examining the effect of TSPO 
overexpression on genes involved in FAO, we found that expression levels of Cpt1a and Hadha were 
significantly reduced (Figure 4.5B), indicating a reverse response to the TSPO deficient phenotype. 
However, expression of Cd36, Acadl and Acadm remained unchanged in TSPO overexpressing cells (not 
shown). 
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Figure 4.5. TSPO overexpression in TSPO deficient MA-10 cells downregulates genes involved in 
FAO. (A) Representative western blots of MA-10:Tspo+/+ cells and the two MA-10:TspoΔ/Δ clones 
showing TSPO, VDAC1 and ACTB expression after infection with Tspo lentivirus or GFP lentivirus 
(control). TSPO was overexpressed in intact MA-10:Tspo+/+ cells and the two MA-10: TspoΔ/Δ clones;  
expression of VDAC1 was not affected after TSPO overexpression. (B) Expression of Cpt1a and Hadha 
was significantly downregulated in TSPO-overexpressing MA-10:TspoΔ/Δ cells (n=3/group; a, b, c 
indicate significant differences between groups, p<0.05). 
 
Mitochondrial FAO genes are upregulated in Tspo-/- adrenal glands 
To investigate if in vitro effects of TSPO deficiency on FAO were discernible in vivo, we 
examined the adrenal glands of global Tspo-/- mice for expression of genes involved in FAO compared to 
the Tspofl/fl controls (Figure 4.6). We found that adrenal glands from Tspo-/- mice significantly upregulated 
expression of Cd36, suggesting higher fatty acid uptake in Tspo-/- adrenals compared to Tspofl/fl cohorts. 
Expressions of mitochondrial FAO genes Cpt1a and Acadl were also significantly upregulated in Tspo-/- 
adrenals compared to Tspofl/fl cohorts. Although Acadm and Hadha were found upregulated in Tspo-/- 
adrenals, the difference did not reach statistical significance. 
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Figure 4.6. Adrenals from Tspo-/- mice show upregulation of genes involved in FAO. (A) Expression 
of Cd36, Cpt1a and Acadl was significantly upregulated in adrenal glands from Tspo-/- mice compared to 
Tspofl/fl cohorts. Expression of Acadm and Hadha were also elevated in Tspo-/- adrenal glands but values 
did not reach statistical significance. (B) Expression of Tspo was confirmed to be absent in Tspo-/- adrenal 
glands. (For both panels: n=4/group, *p<0.05). 
 
TSPO is highly expressed in tissues active in lipid storage/metabolism 
In order to examine TSPO expression levels in different tissues, we examined a wider panel of 14 
murine tissues including brown adipose tissue (BAT) and epididymal white adipose tissue (WAT), in 
addition to brain, thymus, heart, lung, liver, spleen, adrenal, kidney, testis and ovary that we also studied 
previously (Tu et al., 2014). When 75 µg protein from each tissue separated by SDS-PAGE was used in 
Western blots, the results showed that TSPO could be detected in almost all tissues, albeit at different 
levels (Figure 4.7A). Note: Loading controls like ACTB showed significant variability in expression 
between tissues [as seen previously (Tu et al., 2014)]; use of a mitochondrial protein like IDH2 was also 
not applicable due to dramatic changes to functional characteristics of mitochondria in these tissues (not 
shown). Based on equal protein loading, TSPO expression was the highest in adrenal glands, followed by 
BAT and WAT. Expression levels were at the average in lung, kidney and spleen, and weaker in other 
tissues, with extremely low expression in the brain (Figure 4.7A). Testis showed relatively weak 
expression of TSPO because only a small population of cells in the testis, that comprise of Leydig and 
Sertoli cells express TSPO (Morohaku et al., 2013). TSPO expression in the ovary, a major steroidogenic 
tissue, was at similar levels to that seen in the liver. Adrenal glands, BAT and WAT had much higher 
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TSPO expression that was approximately 7-, 5- and 2.5-fold respectively compared to expression seen in 
the liver (Figure 4.7B). These results demonstrated that TSPO expression is not enriched specifically in 
steroid producing tissues, but rather in tissues that are active in lipid storage or metabolism as indicated 
by high lipid content.  
 
 
Figure 4.7. TSPO is highly expressed in tissues active in lipid metabolism. (A) Representative 
Western blot showing TSPO expression in 14 different tissues (75 µg protein/sample). TSPO was highly 
expressed in adrenal glands, followed by BAT, WAT, lung and kidney. TSPO expression was weaker in 
other tissues and extremely low in the brain. (B) Compared to liver (Lv), TSPO expression was similar, 
2.5-, 5- and 7- folds higher in ovary (Ov), WAT, BAT and adrenals (Ad) respectively. (n=4 
animals/group). 
 
DISCUSSION 
Several recent studies indicating that there is no physiological function for TSPO in 
steroidogenesis (Banati et al., 2014; Morohaku et al., 2014; Tu et al., 2014; Tu et al., 2015), have raised 
critical questions regarding the reason for its high levels of expression observed in steroidogenic 
mitochondria. By investigating different mitochondrial properties in TSPO-deficient steroidogenic MA-
10 cells, we identify that TSPO expression inversely affects mitochondrial FAO. Consistent with this 
finding, we observed upregulation of genes involved in mitochondrial FAO in the adrenal glands of Tspo-
/- mice. These findings indicate a novel TSPO function in modulating FAO that is broadly relevant for cell 
types that are active in lipid storage/metabolism. 
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In an early study that examined autoradiographic localization of TSPO in whole-body sections of 
neonatal rats, expression of TSPO was correlated to tissues that derive their metabolic energy primarily 
from oxidative phosphorylation (Anholt et al., 1985). Moreover, with the recent significant increase in 
obesity research and associated mouse models, use of quantitative trait loci analysis between inbred 
mouse strains identified Tspo as one of the six candidate genes that could influence triglyceride 
metabolism in mice (Leduc et al., 2011). Experimentally, we provide the first evidence linking TSPO and 
FAO by demonstrating that TSPO deletion induces a shift in substrate utilization from glucose to fatty 
acids for energy production in cells. Both endogenous and total mitochondrial FAO were significantly 
upregulated in MA-10:TspoΔ/Δ clones compared to MA-10:Tspo+/+ cells. 
Another study that explored novel transcripts associated with adipogenesis using differential 
display RT-PCR identified TSPO as one of the five candidate genes that showed a robust positive 
correlation with adipocyte differentiation (Wade et al., 2005), suggesting a direct involvement in this 
metabolic transition of pre-adipocytes. This was also consistent with observation that the TSPO-binding 
drugs PK11195 and Ro5-4864 could promote lipid deposition and adipocyte differentiation of 
mesenchymal stem cells (Lee et al., 2004). In a recent in vivo study, it was shown that TSPO-drug binding 
sites significantly decreased in both white and brown fat during diet-induced obesity in mice (Thompson 
et al., 2013). Moreover, significant downregulation of TSPO to almost half the baseline levels was also 
observed in the liver when animals were fed a high fat, high cholesterol diet (Dimitrova-Shumkovska et 
al., 2010), a condition that is known to overload fatty acid metabolism (Buettner et al., 2006). In 
conjunction with these observations, our detection of prominent TSPO expression in the WAT and BAT 
indicate that mitochondrial FAO regulation by TSPO might be of general relevance to lipid storage and/or 
metabolism in cells.  
On investigating MA-10:TspoΔ/Δ cells, we observed upregulation of genes involved in 
mitochondrial FAO, functional increase in OCR associated with FAO, and increased contribution of FAO 
to ATP production. For the genes analyzed for FAO, CPT1A is an integral OMM protein that converts 
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fatty acyl-CoA molecules to acylcarnitine and regulates its entry into the mitochondria (Fritz and Yue, 
1963), which is considered the rate-limiting step for long-chain fatty acids β-oxidation in mammalian 
cells. Upregulation of Cpt1a in MA-10:TspoΔ/Δ cells and reciprocal downregulation with TSPO 
overexpression indicates a correlation of TSPO and mitochondrial FAO. Inconsistency between the two 
MA-10:TspoΔ/Δ clones in Acadl and Srebf1c expressions, without effects on Cd36, Cpt1a, Acadm, 
Hadha, Ppara, Fasn and Acaca suggest that this is unconnected to TSPO. Regardless, complexities of 
interactions that regulate overall fatty acid metabolic homeostasis make such aberrances difficult to 
interpret. 
Although maximal total mitochondrial FAO in MA-10:TspoΔ/Δ cells increases more than 2-fold, 
the observation that this was a shift in cellular metabolic homeostasis without affecting overall ATP 
production suggests that the function mediated by TSPO could be compensated under physiological 
conditions, and perhaps regulation at multiple levels. This notion is supported by the fact that a 
phenotypic change in global Tspo-/- mice associated with this observation was not readily detected in 
recent studies (Banati et al., 2014; Tu et al., 2014). The observation that genes involved in FAO are 
consistently upregulated albeit modest in the adrenal glands of Tspo-/- mice suggests that further 
characterization and response to metabolic stress need to be investigated in the Tspo-/- mouse model. 
These results also suggest that contexts of TSPO overexpression in pathologies may indicate metabolic 
reprogramming as seen in innate immune cell activation (Shriver and Manchester, 2011; Vats et al., 
2006), and its overexpression in most cancer cells may also mark a response to the metabolic shift that 
occurs in these cells [(Pike et al., 2011; Samudio et al., 2010) and reviewed in (Carracedo et al., 2013)].  
On investigating oxidative phosphorylation, TSPO deficient mitochondria did not show any 
deficits in OCR, coupling efficiency or proton leak. There was a modest decrease in calculated spare 
respiratory capacity in MA-10:TspoΔ/Δ1, but not in MA-10:TspoΔ/Δ2; similarly, there was a decrease in 
calculated ATP production in MA-10:TspoΔ/Δ2, but not in MA-10:TspoΔ/Δ1. These endpoints are 
calculated from measured OCR values that were not different between the two clones on direct 
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comparison; such inconsistency between the clones also indicates that these observations are not a result 
of TSPO deficiency. It should be noted that directly measured ATP production was not different between 
the two MA-10:TspoΔ/Δ clones and MA-10:Tspo+/+ cells, indicating that an absolute interpretation of 
the above calculated values may not have physiological implications. This explanation is also supported 
by results showing that ∆ψm was not different between MA-10:TspoΔ/Δ clones and MA-10:Tspo+/+ 
cells. This result on ∆ψm was consistent with a previous study assessing mitochondrial respiration and 
∆ψm in mitochondria from primary hepatocytes of liver-specific TSPO conditional knockout mice 
(Sileikyte et al., 2014). However, other studies examining primary microglia (Banati et al., 2014), and 
fibroblasts (Zhao et al., 2015) isolated from global TSPO knockout (Tspo-/-) mice reported a significantly 
lower OCR (and a decrease in calculated ATP production). This dissimilarity that is based on cell type 
could be due to integral differences in mitochondrial and cellular properties; steroidogenic cells and 
hepatocytes are both active in lipid metabolism, whereas lipid metabolism is not prominent in microglia. 
It is possible that upregulation of FAO could be providing more substrates for oxidative phosphorylation, 
maintaining OCR after TSPO deletion in cells inherently capable of active lipid metabolism. 
Such metabolic effects mediated by TSPO might also explain the frequently made link between 
TSPO and oxidative stress. Although several studies indicate that high TSPO expression attenuated ROS 
production (Carayon et al., 1996; de Tassigny et al., 2013; Veenman et al., 2008), some studies also report 
the opposite effect (Gatliff et al., 2014; Klubo-Gwiezdzinska et al., 2012). We observed that cellular 
superoxides, as well as total ROS/RNS levels were elevated in the absence of TSPO. This could be linked 
to the increase in FAO, which can actively generate ROS independent of oxidative phosphorylation 
(Rosca et al., 2012; Schonfeld and Wojtczak, 2012). In concert, MA-10:TspoΔ/Δ cells significantly 
upregulated expression of UCP2, a protein that has been shown to decrease ROS/superoxide (Andrews et 
al., 2008; Pi and Collins, 2010). Recent evidence also suggests that UCP2 facilitates export of C4 
metabolites out of mitochondria (Vozza et al., 2014), and promotes mitochondrial utilization of FAO 
(Kukat et al., 2014), pertinent to our observation on increased FAO and suggesting a cellular response to 
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shift in energy homeostasis. Although the mechanism through which TSPO affects ROS production may 
be unclear, based on our observations in MA-10 cells, it is conceivable that TSPO affects mitochondrial 
ROS production via the modulation of FAO, without discounting other possible mechanisms of ROS 
regulation. 
The basis for TSPO effect on mitochondrial FAO could be due to a few different possibilities. 
First, proposed association between TSPO and acyl-CoA binding protein (ACBP, also known as the 
diazepam binding inhibitor/DBI or acyl-CoA binding domain containing protein 1/ACBD1) might be a 
direct link to the regulation of fatty acid metabolism. Like TSPO, ACBP is also a highly conserved 
protein (Burton et al., 2005) considered the endogenous ligand for TSPO (Bovolin et al., 1990), and 
previously thought to be involved in steroidogenesis (Papadopoulos et al., 1991). Subsequent examination 
of ACBP knockout mice indicated a direct involvement in fatty acid metabolism (Lee et al., 2007; Neess 
et al., 2011). Expression of ACBP in tissues mirrors TSPO expression (Tong et al., 1991; Toranzo et al., 
1994), and induction of ACBP during adipocyte differentiation (Mandrup et al., 1998), similar to TSPO 
(Wade et al., 2005), further indicates a functional relationship. Second, a functional association between 
TSPO and VDAC1 has been suggested (McEnery et al., 1992); VDAC1 is also known to associate with 
CPT1A and long chain acyl-CoA synthetase (ACSL), forming a fatty acid transfer complex at the OMM 
(Lee et al., 2011). It is possible that TSPO monitors or modulates activity of this transfer complex, 
affecting mitochondrial FAO and cellular metabolic homeostasis. Third, loss of an abundant cholesterol-
binding OMM protein like TSPO may lead to changes in physical membrane properties due to cholesterol 
modulation, which in turn could affect mitochondrial FAO. Although we did not observe such a physical 
effect on core mechanisms of oxidative phosphorylation and ∆Ψm, there is evidence that CPT1A could be 
regulated by changes in OMM lipid composition and molecular order (Rao et al., 2011). 
In conclusion, our results provide the first experimental evidence that links TSPO to 
mitochondrial FAO. The high correlation of TSPO levels and cells active in lipid metabolism provide a 
strong indication that its functional definition is not restricted to steroidogenic cells. We believe that this 
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discovery is the first step towards elucidating the precise physiological function of mammalian TSPO that 
will also advance understanding of the pathologic basis of its expression and its potential use as a 
diagnostic and therapeutic target in human medicine. 
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CHAPTER 5 
Mammalian TSPO Is a Tetrapyrrole Sequestering Protein 
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ABSTRACT 
Translocator protein (TSPO) is a highly conserved protein from bacteria to humans, suggesting a 
conserved evolutionary function beneficial for overall fitness. In mammals, TSPO is localized to the outer 
mitochondrial membrane and its expression has been dysregulated in many diseases. Since the model of 
TSPO and steroidogenesis was invalidated, many studies have proposed different functions for TSPO using 
different biological systems or tissue types but the exact molecular function of TSPO remains unclear. Our 
previous study provided the first evidence that high expression of mammalian TSPO is not restricted to 
steroidogenic tissues but in those that are rich in lipid droplets including white and brown adipose tissues. 
Using the MA-10 Leydig tumor cell line as an in vitro model, we demonstrated that TSPO suppresses fatty 
acid oxidation (FAO) and TSPO deletion induces a shift in substrate utilization from glucose to fatty acids 
for energy production. In this study, we examined metabolism in global TSPO knockout (Tspo-/-) mice. 
From studying their basal metabolic rate, performing metabolomics, and comparing gene expression 
changes, we discovered that Tspo-/- mice had overloaded FAO compared to control Tspofl/fl mice, similar to 
the phenotype reported for our MA-10 cell model. In a quest to pinpoint the exact molecular mechanism, 
we uncovered the biological function of TSPO in sequestering and preventing degradation of 
protoporphyrin IX (PPIX), the immediate tetrapyrrole precursor of heme. Linked to this process, we present 
a novel biological function of PPIX in lipid metabolism, which forms the basis for involvement of TSPO 
in regulating FAO.   
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INTRODUCTION 
Translocator protein (TSPO) is a highly conserved protein from bacteria to humans, suggesting a 
conserved function beneficial for evolutionary fitness. Particularly in human, TSPO has been implicated in 
several diseases such as inflammatory disorders, cancers and neuropsychiatric diseases. Hence, TSPO 
binding ligands emerge as promising diagnostic and therapeutic agents being tested in clinical trials for 
various indications. However, the exact molecular function of TSPO remains unknown, limiting its 
application in human medicine. 
In mammalian cells, TSPO is a transmembrane protein localized to the outer mitochondrial 
membrane (OMM). TSPO was linked to cholesterol translocation from cytosol into mitochondria, the rate 
limiting step for steroidogenesis. However, this model has been refuted by both recent genetic and 
pharmacological evidence, reproducible by at least 3 different laboratories, showing that complete absence 
of TSPO in mice and cells do not affect viability and steroid hormone production (Banati et al., 2014; 
Morohaku et al., 2014; Tu et al., 2014; Tu et al., 2015; Wang et al., 2016). The modest stimulating effect 
of some TSPO ligands on steroidogenesis, often used as the basis for the association of TSPO and 
steroidogenesis, was found to be non-specific and not mediated by TSPO (Tu et al., 2015). A structural 
study using high resolution NMR also found no evidence of potential side chains in mammalian TSPO to 
bind and translocate cholesterol (Jaremko et al., 2014). Moreover, this model had always failed to explain 
the conservation of TSPO throughout different kingdoms as cholesterol is not found in bacteria, and binding 
of TSPO to bacterial hopanoids, the functional analogue of cholesterol, was shown highly unlikely (Busch 
et al., 2017).  
Since the model of TSPO and steroidogenesis was invalidated, the exact molecular function of 
TSPO remains controversial. Many studies have proposed different functions for TSPO using different 
biological systems or tissue types. In bacteria, TSPO negatively regulated activity of coproporphyrinogen 
III oxidase in Rhodobacter sphaeroides (Yeliseev and Kaplan, 1995; Yeliseev and Kaplan, 1999); degraded 
protoporphyrin IX (PPIX) in a light and oxygen-dependent manner in Bacillus cereus (Guo et al., 2015) 
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and Chlorobium tepidum (Ginter et al., 2013). In plant, TSPO was a stress-induced porphyrin scavenger 
via an autophagy-dependent mechanism (Vanhee et al., 2011). In Drosophila, TSPO was an essential 
mediator of apoptosis and played a central role in controlling longevity (Lin et al., 2014). In zebrafish, 
TSPO played a key role in erythropoiesis (Rampon et al., 2009). In mammals, TSPO was implicated in 
regulation of adipose metabolism (Dimitrova-Shumkovska et al., 2010; Thompson et al., 2013); inhibited 
HIV-1 envelope protein synthesis in human CD4(+) T cell line (Zhou et al., 2014); and interacted with 
NADPH oxidase to maintain redox homeostasis in microglia (Guilarte et al., 2016). It is obvious that all 
the conclusions are restricted to an isolated system or model being studied and unable to provide a 
satisfactory explanation for the involvement of TSPO in another system. Although the ultimate biological 
effect in each system could be cell type-dependent, the function of a protein at the molecular level should 
be unified and yet undefined for TSPO.  
Our previous study provided the first evidence that high expression of mammalian TSPO is not 
restricted to steroidogenic tissues as previously claimed, but also in those that are rich in lipid droplets 
including white and brown adipose tissues (Tu et al., 2016), indicating a potential role of TSPO in lipid 
metabolism. Indeed, an unbiased quantitative trait loci analysis between inbred mouse strains identified 
Tspo as one of the 6 candidate genes that could influence triglyceride metabolism (Leduc et al., 2011). 
Another study using differential display RT-PCR identified TSPO as one of the 5 novel genes associated 
with adipogenesis (Wade et al., 2005). TSPO level was also significantly reduced in mouse liver and 
adipose tissues in different obesity models (Dimitrova-Shumkovska et al., 2010; Thompson et al., 2013), 
suggesting a direct regulation of TSPO in lipid homeostasis. In our previous study, we used MA-10 Leydig 
tumor cells as an in vitro model and demonstrated for the first time that TSPO supresses fatty acid oxidation 
(FAO) and TSPO deletion induces a shift in substrate utilization from glucose to fatty acids for energy 
production (Tu et al., 2016). In this study, we examined metabolic changes in global TSPO knockout (Tspo-
/-) mice. Our result showed that Tspo-/- mice had overloaded FAO compared to control Tspofl/fl mice, similar 
to the phenotype we reported for our MA-10 cell model. Investigation of the mechanism uncovered a novel 
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function for TSPO in sequestering PPIX and regulating its levels. PPIX has long been reproducibly 
demonstrated as the only endogenous ligand of TSPO throughout different kingdoms (Veenman et al., 
2016; Verma et al., 1987) but the significance of this interaction has not yet been characterized. 
Examination of the TSPO-PPIX relationship also led to the discovery of a novel biological function for 
PPIX in lipid metabolism, which unravels the basis for the involvement of TSPO in regulating FAO.   
 
MATERIALS AND METHODS 
Generation of mice, cells and bacteria 
Tspofl/fl and Tspo-/- mice in the C57BL/6 background previously generated (Tu et al., 2014), were 
sampled at 8-12 weeks of age for all experiments. Animals were maintained in accordance with the National 
Institute of Health Guide for the Care and Use of Laboratory Animals. The Institutional Animal Care and 
Use Committee of Cornell University approved the experiments described.  
MA-10 Leydig cancer cells were grown at 37˚C under 5% CO2 in Dulbecco’s modified eagle 
medium/DMEM high glucose (25 mM glucose, 1 mM pyruvate) containing 10% FBS and 1% penicillin-
streptomycin. TSPO knockout MA-10 cells (MA-10:TspoΔ/Δ) were generated by CRISPR/Cas9-mediated 
targeting of exon 2 of the Tspo gene (Tu et al., 2015). MA-10:TspoΔ/Δ cells were then transduced with 
Tspo lentiviruses to re-express TSPO (MA-10:TspoΔ/Δ+TSPO) as previously described (Tu et al., 2016). 
To generate MA-10 cells that express TSPO with HA and Flag tags, each tag was cloned at the C-terminal 
of Tspo gene in the same lentiviral vector (pLenti CMV GFP Puro) (Campeau et al., 2009). TSPO-HA and 
TSPO-Flag lentiviruses were packaged and MA-10:TspoΔ/Δ were transduced with both viruses to generate 
a cell line expressing both TSPO-HA and TSPO-Flag (MA-10:TspoΔ/Δ+TSPO-HA+TSPO-Flag).  
BL21 (DE3) competent E.coli bacteria (Thermo Fisher) were transformed with pET-21b(+) vector 
(Novagen) containing Tspo gene. Bacteria transformed with empty pET-21b(+) vector were used as the 
control. 3 colonies were picked for each group and plasmids were extracted and sequenced to confirm 
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successful transformation. Bacteria were then shaken at 370C in Luria-Bertani (LB) broth supplemented 
with 100 μg/mL Ampicillin until the optical density reached 0.6-0.8, indicating the log phase of growth. 
0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to LB broth and bacteria were shaken 
for another 4 hrs to induce TSPO expression. Bacteria expressing TSPO (BL21-TSPO) and control bacteria 
(BL21-CTRL) were used for subsequent analysis. 
Metabolic cages 
Activity, VO2, VCO2, heat production, and respiratory exchange ratio (RER) were measured for 
mice using the Oxymax Lab Animal Monitoring System CLAMS (Columbus Instruments). Mice were 
housed individually in metabolic cages in a room with constant temperature (22˚C) and a 14h: light-dark 
cycle (lights on from 0500-1900 hours). They were acclimatized to the cage environment for 24 hrs before 
data collection for the following 24 hrs. Analysis for 60 data points/hour for activity and 3 data points/hour 
recorded for other parameters was carried out using the Oxymax software (Columbus Instruments).  
Transmission electron microscopy 
Mice in the unfed state were euthanized and perfused with Karnovsky’s fixative (2.5% 
glutaraldehyde, 2% paraformaldehyde in 0.08 M phosphate buffer). Livers were dissected and fixed in the 
same fixative overnight at room temperature (RT). After fixation, tissues were processed for transmission 
electron microscopy as previously described (Tu et al., 2014). Stained sections were examined in a TecnaiTM 
T12 Spirit electron microscope (FEI), at 120 kV. High magnification images were acquired using a high-
resolution CCD camera Megaview III (Olympus Soft Imaging System). 
Glycogen quantification  
Mice were euthanized during both fed or unfed states and liver glycogen was determined as 
previously described (Passonneau and Lauderdale, 1974; Zhang, 2012). In brief, one set of 15-25 mg livers 
was minced and boiled in 0.5 mL of 2 M HCl for 1 h. Samples were cooled to RT and neutralized with 0.5 
mL of 2 M NaOH, and vortexed at 20,000 g for 10 mins. Total glucose in the supernatants was measured 
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using the glucose HK assay reagent (Sigma) according to manufacturer’s protocol. The second set of 15-
25 mg matching livers was minced and boiled in 0.5 mL of 2 M NaOH; in this condition, no glycogenolysis 
occurs. Samples were cooled to RT and neutralized with 0.5 mL of 2 M HCl, and vortexed at 20,000 g for 
10 mins. Free glucose in the supernatants was measured as mentioned above. The difference between total 
glucose and free glucose in the livers corresponds to the glycogen content, which was normalized to the 
liver weight. 
Metabolomics 
Mice were euthanized during the unfed state; livers and plasma were collected and stored at -80C 
until analysis. Lipid extracted phase from liver homogenates (6mg) and plasma (20uL) were processed for 
reverse-phase lipid chromatography–quadrupole/time-of-flight mass spectrometry (CSH–QTOF MS) 
analysis as previously described (Tu et al., 2017). In brief, lipids were detected and quantified using an 
Agilent 6550 iFunnel accurate mass quadrupole/time-of-flight (QTOF) mass spectrometer with a jet stream 
ESI source (Agilent). Method blanks and human pooled plasma samples were used as QC controls. MS-
DIAL software (Tsugawa et al., 2015) was used to process the raw data and annotations were made based 
on an in-house accurate mass and retention time lipid library created using LipidBlast, as described 
previously (Kind et al., 2013). Statistical analyses for all metabolites between Tspofl/fl and Tspo-/- mice were 
performed as previously described (Tu et al., 2017). False discovery rate-adjusted p values less than 0.05 
were considered significant. 
PPIX and heme quantification 
Tissues, cells and bacteria were lysed in 1% Triton X-100 in Tris-buffered saline. Samples were 
centrifuged at 5,000 g for 5 mins and the supernatant homogenates were collected. For PPIX quantification, 
1:1 methanol:1N perchloric acid (MeOH-PCA) was added to the homogenates in the volume ratio of 2:1. 
Samples were centrifuged at 10,000 g for 5 mins and the supernatants were ready for PPIX fluorescent 
measurement. For heme quantification, 2-5 μl of the homogenates was added to 500 μl of saturated (2 M) 
oxalic acid and boiled for 30 mins to produce PPIX from heme. Samples were then centrifuged at 10,000 g 
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for 10 mins at 4°C. PPIX fluorescence in the supernatant was measured as previously described (Zhao et 
al., 2016). Heme and PPIX values were normalized to protein content in each sample. 
Gene expression 
Total RNA was extracted from tissues of 8-12 week old Tspofl/fl and Tspo-/- mice using Trizol (Life 
Technologies). Reverse transcription was carried out using MultiscribeTM reverse transcriptase (Life 
Technologies). Gene expressions were quantified using a SYBR® Green detection method with validated 
primer sequences obtained from PrimerBank database (Spandidos et al., 2010). Primer specificity and 
amplification efficiency were confirmed and sequences are provided in Supplemental Table 1. All 
expression data were normalized to internal control gene, TATA box-binding protein (Tbp). Relative 
quantification of fold-change was performed using the 2-∆/∆Ct method (Livak and Schmittgen, 2001). 
Immunoblots 
Proteins were separated by SDS-PAGE and immunoblotted using rabbit monoclonal primary 
antibodies against TSPO (Abcam), isocitrate dehydrogenase 2 (IDH2) (Abcam), mouse monoclonal 
antibodies against voltage-dependent anion channel 1 (VDAC1) (Abcam), Flag tag (Sigma), rabbit 
polyclonal antibody against Hemagglutini (HA) tag (Thermo Fisher). Each primary antibody was 
multiplexed with the loading control β-actin (Li-Cor). Simultaneous detection was performed using IRDye 
700 and 800 labeled secondary antibodies under a laser fluorescence scanner (Li-Cor) and quantified using 
ImageJ as described previously (Tu et al., 2014). 
Crosslinking and co-immunoprecipitation  
L-photo-leucine (Thermo Fisher) was dissolved to final concentration of 1 mM in DMEM-limiting 
medium (Thermo Fisher) supplemented with 10% dialyzed FBS (Thermo Fisher), 30 mg/L L-Methionine 
and 1% penicillin-streptomycin. MA-10 cells were grown to 70% confluence, washed twice with PBS and 
incubated with L-photo-leucine containing medium for 24 hrs. The medium was then removed and replaced 
with PBS. Cells were irradiated with UV light at 345 nm for 10 mins to induce permanent crosslinking. For 
109 
all other crosslinkers, MA-10 cells were grown to 80% confluence and medium was replaced with PBS. 
Glutaraldehyde (GA) was added to final concentration of 2.5%, incubated for 6 mins at RT and quenched 
with 1 M glycine for 3 mins. Dithiobis(succinimidyl propionate) (DSP) (Thermo Fisher) 2 mM or Dimethyl 
3,3’-dithiobispropionimidate (DTBP) (Thermo Fisher) 5 mM was incubated with the cells for 30 mins at 
RT and quenched with 50 mM glycine for 15 mins. After crosslinking, cells were then lysed in NP-40 lysis 
buffer, and kept on ice for 15 mins. Samples were centrifuged at 1,000g for 5 mins to remove nuclei and 
debris. SDS was added to 0.8% final concentration to completely disrupt all membranes and denature 
proteins. Cell lysates were diluted 1:10 using PBS with 0.02% Tween-20 before being used for 
immunoprecipitation.  
Immunoprecipitation was done using Dynabeads Protein G (Thermo Fisher) for TSPO antibody or 
Dynabeads protein A (Thermo Fisher) for Flag antibody according to manufacturer’s protocol. In brief, 8 
ug of antibodies was incubated with every 50 mg of beads for 2 hrs at 40C. The bead-antibody complex was 
then washed using PBS with 0.02% Tween-20 to remove unbound antibodies. Diluted cell lysates 
mentioned above was added to the bead-antibody complex, and rotated overnight at 40C. The bead-
antibody-antigen complex was washed 3 times with PBS and the antigen was eluted from the beads using 
50 mM glycine pH 2.8 supplemented with 1% SDS.    
Statistics 
Numeric differences between groups were compared using a Student’s t-test; comparisons for more 
than two groups were performed using ANOVA and post hoc Tukey’s test (p<0.05 was considered 
significant). All analyses were performed using Prism 5 (GraphPad). 
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RESULTS 
Deletion of TSPO increases mitochondrial FAO   
To examine if absence of TSPO caused any metabolic disturbances, we assessed Tspofl/fl and Tspo-
/- mice in metabolic cages for continuous 24 hr monitoring. Tspo-/- mice showed significantly lower oxygen 
consumption rate (OCR) than the control group, during both light and dark cycles which correspond to 
unfed and fed states in mice respectively (Figure 5.1A). The respiratory exchange ratio (RER), an indicator 
of which fuel source is being metabolized by the body, was significantly lower in Tspo-/- mice than in Tspofl/fl 
mice during the light cycle or unfed state (Figure 5.1B). A lower RER indicates more active utilization of 
fatty acids rather than glucose for energy production in Tspo-/- mice in the unfed state. RER in the dark cycle 
or fed state was similar between Tspofl/fl and Tspo-/- mice (Figure 5.1B). There was no difference in the 
ambulatory and total activities between the two genotypes in both light and dark cycles (not shown). 
Since our Tspo-/- mice are a global knockout model, the metabolic phenotype observed could be the 
result of many altered inputs from different metabolic tissues where TSPO is expressed. Therefore, to 
confirm that absence of TSPO indeed causes more active utilization of fatty acids to produce energy through 
FAO, we decided to examine liver, the chief metabolic organ that reflects the changes to whole body 
metabolism. Gene expression analysis every 6 h showed that critical genes involved in fatty acid synthesis: 
sterol regulatory element-binding protein 1c (Srebp1c), fatty acid synthase (Fasn), acetyl-coA carboxylase 
α (Acaca) and genes involved in mitochondrial FAO: carnitine palmitoyltransferase 1a (Cpt1a), 
trifunctional enzyme subunit α (Hadha) were highly elevated in Tspo-/- liver compared to the control group 
at various time points (Figure 5.1C). This indicates that Tspo-/- liver synthesize and utilize more fatty acids 
for energy production than Tspofl/fl liver. The magnitude of the difference was particularly prominent late 
in the light cycle or unfed state. The difference in gene expression in the dark cycle was not as consistent 
and noticeable among different genes as compared to those in the light cycle. This result agrees with our 
metabolic cage data where Tspo-/- mice displayed significantly lower RER only in the unfed state, 
particularly towards the end of the light cycle.  
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Transmission electron microscopy of livers in the unfed state revealed noticeably more glycogen 
granules deposited in the Tspo-/- hepatocytes than the control group (Figure 5.1D). In the physiological 
unfed state, fatty acids are not the primary source of fuel as mice preferentially deplete glycogen store in 
the liver first before mobilizing fat. We then quantified the liver glycogen content and found that in the fed 
state (dark cycle) when glycogen is mainly synthesized and stored, there was no difference in the glycogen 
content between Tspofl/fl and Tspo-/- liver (Figure 5.1E). However, in the unfed state (light cycle) when 
glycogen is broken down for energy, Tspo-/- mice utilized significantly less glycogen and therefore had 
significantly more glycogen stored in the liver compared to the Tspofl/fl mice (Figure 5.1E). These results 
again support our conclusion that Tspo-/- mice indeed spared glucose and utilized more lipids for energy 
production compared to Tspofl/fl mice. 
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Figure 5.1. Deletion of TSPO increases mitochondrial FAO. (A) Monitoring oxygen consumption (VO2) 
over a 24-hour period in Tspofl/fl and Tspo-/- mice showed that VO2 was significantly decreased in both light 
and dark cycles in Tspo-/- mice compared to Tspofl/fl cohorts. (B) Monitoring respiratory exchange ratio 
(RER) over a 24-hour period in Tspofl/fl and Tspo-/- mice showed that RER was significantly decreased in 
the light cycle, and remained the same in the dark cycle in Tspo-/- mice compared to Tspofl/fl cohorts 
(n=12/group). (C) Gene expression analysis every 6 h showed that critical genes involved in fatty acid 
synthesis: sterol regulatory element-binding protein 1c (Srebp1c), fatty acid synthase (Fasn), acetyl-coA 
carboxylase α (Acaca) and genes involved in mitochondrial FAO: carnitine palmitoyltransferase 1a 
(Cpt1a), trifunctional enzyme subunit α (Hadha) were highly elevated in Tspo-/- liver compared to the 
control group (n=5-6 mice/group/time point). (D) Transmission electron micrographs of the livers in unfed 
state showed significantly more glycogen granules (arrow) in Tspo-/- mice compared to Tspofl/fl cohorts. (E) 
Quantification of glycogen content confirmed significantly more glycogen in livers of Tspo-/- mice 
compared to Tspofl/fl cohorts in the unfed state (light cycle). Level of glycogen was similar between the two 
genotypes in the fed state (dark cycle) (n=5-9 mice/group). (F) Lipidomic analysis of the livers in the unfed 
state showed no difference in the total levels of cholesterol (Chol), triglycerides (TG) and free fatty acids 
(FFA) between the two genotypes. Total level of acylcarnitines (AC) was almost doubled in Tspo-/- livers 
compared to Tspofl/fl group (n=8/group). (G) Levels of all long-chain ACs, except AC(18:1), were 
significantly elevated in Tspo-/- livers compared to Tspofl/fl group (n=8/group). (H) Lipidomic analysis of 
the plasma in the unfed state showed no difference in the total levels of Chol, TG and FFA between the two 
genotypes. Total level of AC was significantly higher in Tspo-/- plasma compared to Tspofl/fl group 
(n=8/group). (I) Levels of all long-chain ACs examined were elevated in Tspo-/- plasma compared to Tspofl/fl 
group (n=8/group). 
 
To further characterize metabolic changes as a result of TSPO deletion, liquid chromatograph/mass 
spectrometry-based profiling of the liver and plasma metabolomes were performed in mice at the unfed 
state. No significant changes were observed in total cholesterol (Chol), triglycerides (TG) and free fatty 
acids (FFA) levels between the livers of Tspofl/fl and Tspo-/- mice (Figure 5.1F). However, the total level of 
acylcarnitines (AC), the committed form of fatty acids for FAO, was almost doubled in Tspo-/- livers 
compared to Tspofl/fl group (Figure 5.1F). Analysis of long-chain ACs revealed marked increase in ACs of 
palmitic acid (16:0), stearic acid (18:0) and linoleic acid (18:2) in Tspo-/- livers compared to Tspofl/fl group 
(Figure 5.1G). AC of oleic acid (18:1) was also elevated in Tspo-/- livers but the value did not reach statistical 
significance. In the plasma, similar to the liver, there were no significant changes in the total levels of Chol, 
TG, FFA between Tspofl/fl and Tspo-/- mice (Figure 5.1H). Levels of all examined long-chain ACs were 
significantly elevated in Tspo-/- plasma compared to Tspofl/fl group (Figure 5.1I). Such accumulation of ACs 
often indicates highly active or overloaded mitochondrial FAO, causing the excessive secretion of ACs into 
plasma. This supports our conclusion that Tspo-/- mice indeed have increased FAO. In addition to liver and 
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plasma, we also found no changes in total cholesterol level, both free cholesterol and cholesterol esters, in 
the adrenal glands and brown adipose tissues of Tspo-/- mice (not shown). These are tissues where TSPO is 
the most highly expressed, and such similarity between the two genotypes rules out the possibility of any 
involvement of TSPO in cholesterol homeostasis, including translocation.    
Taken together, our results suggest that TSPO has an inhibitory effect on mitochondrial FAO, and 
loss of TSPO causes the flux of fatty acids in the form of ACs into mitochondria for β-oxidation.  
TSPO dimerization is induced by protoporphyrin IX (PPIX) 
It has not been documented in the literature whether TSPO could bind FFA or interact with any 
proteins directly involved in FAO. In the previous study (Tu et al., 2016), we proposed 3 possible 
mechanisms for how TSPO could affect FAO: 1/ binding to acyl-coA-binding protein (ACBP) (Bovolin et 
al., 1990), which has been shown to be directly involved in fatty acid metabolism (Lee et al., 2007; Neess 
et al., 2011); 2/ binding to VDAC1 (McEnery et al., 1992), which forms FFA transfer complex with CPT1a 
at the OMM (Lee et al., 2011); 3/ changing physical membrane properties or lipid compositions of the 
OMM. Now we find the third option unlikely as our lipidomics comparing Tspofl/fl and Tspo-/- livers did not 
detect any shifts in compositions of membrane phospholipids including all classes of sphingophospholipids 
and glycerophospholipids (not shown). In order to examine the other two possibilities, we performed co-
immunoprecipitation to identify interacting partners of TSPO. TSPO is a transmembrane protein; and 
traditional co-immunoprecipitation using a weak- or non- denaturing condition to lyse cells is very prone 
to false positives as micelle-like vesicles formed under this condition entrap nonspecific membrane proteins 
nearby. Hence, we used crosslinkers to covalently link interacting proteins and then disrupted membranes 
completely under a strong denaturing condition with SDS. Crosslinkers with different chemistry (L-photo-
leucine linking Leu to Leu; GA, DSP, DTBP linking primary amines), different spacer arm lengths, 
different reactivity and hydrophobicity were used to avoid artifacts. Western blot result showed only one 
consistent band of a TSPO complex at 30-32 kDa across all the crosslinkers used (Figure 5.2A). However, 
immunoprecipitation using a monoclonal TSPO antibody followed by proteomics did not detect any other 
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protein at 14-16 kDa in this complex (not shown), suggesting the complex to be a homodimer of TSPO. 
We then expressed TSPO-HA and TSPO-Flag proteins in MA-10:TspoΔ/Δ cells. TSPO-HA protein was 
readily detected in the complex pulled down by a monoclonal anti-Flag antibody, confirming the 
dimerization of TSPO (Figure 5.2B).  
 
Figure 5.2. TSPO dimerization is induced by PPIX. (A) Western blot result showed one consistent band 
of a TSPO complex at 30-32 kDa across all the crosslinkers used in MA-10 cells. (B) Co-
immunoprecipitation was carried out with lysates prepared from MA-10:TspoΔ/Δ cells expressing TSPO-
Flag and TSPO-HA. Cells were incubated with DSP to crosslink interacting proteins. Immunoblots (IB) of 
the input using anti-Flag and anti-HA antibodies detected both monomer and dimer bands at 16 and 30kDa 
respectively. Cell lysates were then immunoprecipitated (IP) with anti-Flag antibody and then blotted using 
anti-HA antibody. The presence of TSPO-HA in the complex pulled down by anti-Flag antibody confirmed 
the formation of a homodimer. (C) MA-10 cells were treated with different chemicals and TSPO dimer 
formation was evaluated. cAMP, cholesterol, palmitic acid, H2O2 and pyocyanin did not affect dimer 
formation. ALA and PPIX strikingly increased TSPO dimer formation. 
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To investigate whether the dimerization of TSPO is a random physical association or of significant 
biological relevance, several conditions were applied to MA-10 cells to identify any changes in the dimer 
formation. Interestingly, only 5-aminolevulinic acid (ALA) and protoporphyrin IX (PPIX) strikingly 
increased the dimerization of TSPO (Figure 5.2C). ALA is the precursor of PPIX while PPIX is the 
immediate precursor of heme. PPIX is the only endogenous ligand of TSPO that has been reproducible 
across different studies and systems. All other tested stimuli including cAMP, different forms of lipids 
(cholesterol, palmitic acid) and reactive oxygen species (H2O2, pyocyanin) failed to alter the dimerization 
of TSPO (Figure 5.2C). Other conditions such as starvation, serum supplementation and hypoxia also did 
not have any effect on TSPO dimer formation (not shown). Specificity of PPIX in inducing dimerization of 
TSPO was compared with other porphyrin derivatives. PPIX was found to be the strongest inducer while 
iron-containing porphyrins including heme were either much weaker or had no effect at all (not shown). 
TSPO regulates the level of PPIX in cells and tissues   
The effect of TSPO deletion and overexpression on PPIX and heme levels was examined in three 
different systems: mouse tissues, MA-10 cells and BL21 E.coli. First, total levels of PPIX and heme were 
quantified in various mouse tissues. As demonstrated in our previous study (Tu et al., 2016), tissues rich in 
lipid droplets such as Harderian glands, adrenal glands and brown adipose tissues (BAT) have the highest 
TSPO expression (Figure 5.3A). Expression of VDAC1, another protein in the OMM, does not correlate 
with the lipid content of tissues like TSPO (Figure 5.3A). Strikingly, we noticed the same strong correlation 
that these lipid-rich tissues also had a very high level of free PPIX compared to other tissues (Figure 5.3A). 
This trend was not observed with the total level of heme (not shown). Comparing level of free PPIX between 
Tspofl/fl and Tspo-/- mice, no differences between the two genotypes were found in tissues with low-moderate 
level of TSPO expression such as brain, spleen, liver, and bone marrow, agreeing with our previous findings 
(Zhao et al., 2016). However, in tissues with very high level of TSPO expressions, absence of TSPO 
significantly reduced the level of PPIX (Figure 5.3A), but not heme (not shown). These data suggest that 
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binding of TSPO to PPIX increases the availability of PPIX in tissues, potentially by protecting it from 
degradation or bioconversion.  
 
Figure 5.3. TSPO regulates the level of PPIX in cells and tissues. (A) Various mouse tissues were 
examined for TSPO expression and PPIX content. Tissues low in TSPO expression such as brain, spleen, 
liver and bone marrow had low level of PPIX. Tissues high in TSPO expression such as brown adipose 
tissue (BAT), adrenal glands, Harderian glands had high level of PPIX. In tissues high in PPIX and TSPO 
expression, Tspo-/- have significantly lower level of PPIX compared to Tspofl/fl group (n=6-8/group). (B) 
MA-10:TspoΔ/Δ cells had significantly lower level of PPIX at baseline compared to control MA-10 cells. 
Re-expressing TSPO in MA-10:TspoΔ/Δ cells rescued level of PPIX to the similar level in MA-10 cells 
(n=3/group). Treatment with ALA increased intracellular PPIX level in all cells wover time. MA-
10:TspoΔ/Δ+TSPO cells accumulated much more PPIX at 1, 2, 4 hr time points compared to MA-
10:TspoΔ/Δ cells (n=3/group). (C) BL21 bacteria was induced to express mammalian TSPO and the 
expression was confirmed by the 16kDa band in western blot. Crosslinking with DSP showed the same 
band of TSPO dimer at 30kDa. Treatment with ALA increased intracellular PPIX level in the bacteria over 
time. Bacteria expressing TSPO accumulated significantly more PPIX at 0.5, 1, 2 hr time points compared 
to control bacteria. Bacteria expressing TSPO with A147T polymorphism accumulated the same level of 
PPIX as bacteria expressing wild type TSPO (n=3/group). 
 
In MA-10 cells, TSPO knockout MA-10:TspoΔ/Δ cells showed significantly lower baseline PPIX 
level than the wild type MA-10 cells (Figure 5.3B). When the knockout clone was re-expressed TSPO, the 
level of PPIX was rescued in these cells and became comparable to that in the control MA-10 cells (Figure 
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5.3B). To avoid misinterpretation as the result of any clonal effect when comparing the knockout clone and 
the wild type heterogeneous MA-10 cell population, we decided to use the TSPO knockout clone and the 
TSPO re-expressing cells from the same clone for further analysis. When these two groups of cells were 
challenged with ALA for PPIX production, the difference observed in PPIX level at baseline was further 
exacerbated with time. Cells with TSPO (Δ/Δ+TSPO) accumulated significantly more PPIX than cells 
without TSPO (Δ/Δ) at all examined time points (Figure 5.3B), substantiating our observation in mouse 
tissues.  
To rule out possibilities of interference or compensation from other biological systems that might 
mediate the changes in intracellular PPIX level, we introduced mammalian TSPO into BL21 E.coli bacteria 
that do not have any other mammalian machinery. Western blot result confirmed successful IPTG induction 
of mammalian TSPO expression in the bacteria (Figure 5.3C). Crosslinking with DSP showed the same 
TSPO dimer band at 30 kDa (Figure 5.3C), suggesting proper folding of the protein in bacteria. When the 
bacteria were challenged with ALA, we observed the exact same trend that bacteria expressing mammalian 
TSPO accumulated significantly more PPIX over time compared to the control bacteria (Figure 5.3B). 
Bacteria expressing mammalian TSPO with A147T polymorphism performed the same as those expressing 
wild type TSPO (Figure 5.3C), indicating that this polymorphism did not affect the function of TSPO. The 
above experiment was performed in the dark condition, simulating the dark environment in mammalian 
tissues.  
TSPO binding protects PPIX from degradation or bioconversion 
TSPO synthetic ligands: PK11195, Ro5-4864 and Etifoxine were added to MA-10 cells to displace 
bound PPIX from TSPO. Levels of PPIX in wild type MA-10 cells treated with PK11195 and Ro5-4864 
significantly reduced and reached similar levels to TspoΔ/Δ cells (Figure 5.4A). Etifoxine did not have any 
effect on the level of PPIX, most probably due to the inability to displace PPIX from its binding to TSPO. 
The effects of PK1115 and Ro5-4864 were specific and mediated by TSPO as no changes in PPIX level 
were observed when these ligands were added to TspoΔ/Δ cells (Figure 5.4A). PPIX displaced from TSPO 
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by the ligands was likely to be degraded or converted into an unknown metabolite as total level of heme 
remained constant after all treatments (not shown). Interestingly, when bound PPIX was displaced by 
PK1115 and Ro5-4864, baseline TSPO dimers also dissociated as shown in the western blot (Figure 5.4B), 
substantiating our conclusion that TSPO dimerization was indeed only triggered by PPIX binding to TSPO.  
 
 
Figure 5.4. TSPO binding protects PPIX from degradation. (A) MA-10 cells were treated with TSPO 
ligands PK11195, Etifoxine and Ro5-4864. Levels of PPIX in MA-10 cells treated with PK11195 and Ro5-
4864 significantly reduced and reached similar level of PPIX in TspoΔ/Δ cells. Etifoxine did not have any 
effect on the level of PPIX in MA-10 cells (n=4/group). (B) MA-10 cells were treated with TSPO ligands 
and crosslinked with GA. No dimer form was detected in western blot after PK11195 and Ro5-4864 
treatment while Etifoxine did not affect dimer formation. (C) TspoΔ/Δ and TspoΔ/Δ+TSPO cells were 
treated with ALA to accumulate PPIX for 6 hr. ALA was removed and level of PPIX quickly went down 
over time. At time 0, TspoΔ/Δ+TSPO cells accumulated 41% more PPIX than TspoΔ/Δ cells. The difference 
reduced to 21% and 11% after 1 and 3 hr respectively. (D) MA-10 cells were treated with ALA for 6 h to 
accumulate PPIX. ALA was then removed and cell lysates were crosslinked with GA to examine dimer 
formation at 1, 2, 3 hr time points. Western blot showed diminishing presence of TSPO dimer over time.  
 
To examine whether the binding and protection of TSPO to PPIX is permanent, we treated MA-10 
cells with ALA for 6 h to induce non-physiologically high level of PPIX accumulation in the cells. ALA 
was then removed to stop further PPIX synthesis and PPIX levels were measured over time in TspoΔ/Δ and 
TspoΔ/Δ+TSPO cells. At time 0 when ALA was just removed, TspoΔ/Δ+TSPO cells accumulated 41% 
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more PPIX than TspoΔ/Δ cells (Figure 5.4C). However, after 1 h of ALA removal, total level of PPIX 
dropped drastically in both groups, indicating that PPIX is actively and quickly removed from cells. The 
difference in PPIX level between the 2 genotypes reduced by half to only 21% after 1 h and to 11% after 3 
h of ALA removal (Figure 5.4C), which is attributed to the release of bound PPIX from TSPO over time 
for degradation. The reduction in PPIX binding also corresponded to the dissociation of TSPO dimers over 
time (Figure 5.4D). Together, this data show that binding of PPIX to TSPO is a reversible, dynamic process 
and under regulation of cellular demand.  
First evidence of biological effect of PPIX on lipid metabolism 
We reported for the first time that PPIX, not heme is highly enriched in lipid-rich tissues, suggesting 
a potential role of PPIX in lipid homeostasis. However, very limited research has been done to examine if 
PPIX could have any independent physiological effects besides being converted to heme. In this 
experiment, mice were injected with 25 mg/kg ALA to transiently and acutely increase PPIX levels in all 
the tissues. After 4 hrs, lipid metabolism was examined in the livers of both Tspofl/fl and Tspo-/- mice to 
determine whether such global surge in PPIX level has any biological effect and whether the effect is TSPO-
dependent. Oil Red O (ORO) staining showed that Tspofl/fl livers had neutral lipid deposits while these were 
much less noticeable and mostly absent in Tspo-/- livers (Figure 5.5A). Quantification of the ORO staining 
confirmed significantly smaller liver areas in Tspo-/- mice having lipid deposits compared to the Tspofl/fl 
group (Figure 5.5B). Gene expression analysis showed that Acaca, the gene catalyzing the rate-limiting 
step in fatty acid synthesis was significantly downregulated only in Tspofl/fl mice after ALA injection (Figure 
5.5C). Other genes involved in lipid synthesis: Srebp1c and Fasn were not affected in both genotypes. Most 
intriguingly, genes involved in FAO: Cpt1a and Hadha were both severely downregulated after ALA 
injection in both genotypes (Figure 5.5C), indicating that a surge in PPIX level in the body could markedly 
inhibit FAO. The inhibitory effect was much more prominent in the presence of TSPO due to higher PPIX 
level: Cpt1a and Hadha were downregulated by 80% and 55% respectively in Tspofl/fl mice while they were 
downregulated only by 40% and 25% respectively in Tspo-/- mice. This explains why unmetabolized lipids 
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started to accumulate more in Tspofl/fl livers compared to the Tspo-/- mice as shown in ORO staining. To 
extrapolate further, this also explains why our Tspo-/- mice having lower PPIX level at baseline would 
upregulate the FAO machinery compared to Tspofl/fl mice. 
 
Figure 5.5. PPIX inhibits liver FAO. Mice were injected ALA 25mg/kg and livers were examined after 4 
hrs. (A) Oil Red O (ORO) staining showed that Tspofl/fl livers had neutral lipid deposits (red color), while 
these were mild or mostly absent in Tspo-/- livers. (B) Quantification of the ORO stained area confirmed 
significantly smaller liver areas in Tspo-/- mice having lipid deposits compared to the Tspofl/fl group (n=5-7 
mice/group). (C) Gene expression analysis showed that after ALA injection, Srebp1c and Fasn were not 
affected in both genotypes while Acaca was significantly downregulated only in Tspofl/fl livers. After ALA 
injection, Cpt1a and Hadha were strikingly downregulated by 80% and 55% respectively in Tspofl/fl livers 
while they were downregulated only by 40% and 25% respectively in Tspo-/- livers (n=4 mice/group). 
 
DISCUSSION 
PPIX and tetrapyrroles are the only endogenous ligands of TSPO that have been demonstrated in 
almost all kingdoms (Veenman et al., 2016). Functional characterization of TSPO binding to PPIX has been 
reported in several studies in bacteria and plants but extremely limited in mammals, possibly due to the 
daunting old model of TSPO in steroidogenesis. Our study concludes that mammalian TSPO binds 
reversibly to sequester PPIX in the form of a dimer and prevents PPIX from quick degradation or 
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bioconversion in cells. Hence, cells expressing high level of TSPO have a larger reservoir of PPIX, which 
can be released for biological actions on demand. We propose that this mechanism is also conserved for 
TSPO in other species. Indeed, the most systematic and extensive functional characterization of TSPO and 
PPIX interaction was done in Rhodobacter sphaeroides (Yeliseev and Kaplan, 1995; Yeliseev and Kaplan, 
1999) and shared many similar findings with ours. When TSPO was absent, bacteria accumulated 
significantly less PPIX compared to wild type bacteria (Yeliseev and Kaplan, 1999); instead they produced 
more Mg-protoporphyrins (Yeliseev and Kaplan, 1999) and bacteriochlorophylls (Yeliseev and Kaplan, 
1995), the downstream enzymatic products of PPIX in photosynthetic bacteria. In Arabidopsis thaliana, 
TSPO was found to be a scavenger for porphyrins including heme and PPIX although the binding affinity 
for PPIX was weaker than heme (Vanhee et al., 2011). When treated with ALA to induce porphyrins 
accumulation, transgenic plant cells overexpressing TSPO could sequester markedly more porphyrins 
compared to wild type plant cells. High level of TSPO protected cells from porphyrin-induced phototoxicity 
and when TSPO was degraded by autophagy, excess porphyrins were also removed (Vanhee et al., 2011). 
From these studies, it seems that the ultimate effects of TSPO-PPIX interaction vary in different biological 
systems, but sequestering and shielding PPIX or tetrapyrroles is the conserved biological function of TSPO. 
A recent structural study in Bacillus cereus by Guo et al, however, concluded that TSPO actively degraded 
PPIX but only when UV light and oxygen were present (Guo et al., 2015). Although it is arguable that this 
is the unique function of TSPO in bacteria, it is hard to comprehend such important enzymatic activity is 
lost during evolution of a small protein like TSPO. This result also contradicts the study in Rhodobacter 
sphaeroides where no TSPO corresponded to a low level of PPIX (Yeliseev and Kaplan, 1999). We 
speculate that the use of albumin protein as the negative control for TSPO in the Guo et al study was not 
adequate. Bacterial TSPO is particularly rich in tryptophan residues, which are highly photoexcitable and 
the emission wavelength spectrum of tryptophan significantly overlaps with the absorption spectrum of 
PPIX (Shaw and Pal, 2008). That could explain why TSPO altered PPIX absorption spectrum only in the 
presence of UV light. A tryptophan-rich protein would serve as a better negative control than albumin to 
determine if the effect is indeed mediated by bacterial TSPO.   
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TSPO has been found to interact with several proteins and hence placed in different unrelated 
functional models (Gatliff et al., 2014; Guilarte et al., 2016; Rone et al., 2012). These interactions were 
concluded from experiments performed under a non- or weak- denaturing condition that is prone to produce 
false positives for transmembrane proteins due to incomplete disruption of lipid membranes. In our study, 
we used different crosslinkers to covalently link interacting proteins and preserve the interactions when 
cells are lysed in a strong denaturing condition. We only observed a single band of TSPO dimer at 30-
32kDa, and no other band up to 250kDa. This agreed with the glutaraldehyde crosslinking result of TSPO 
in Rhodobacter sphaeroides (Yeliseev and Kaplan, 2000). Although TSPO dimerization has been reported 
in literature, it is often not based on definitive experimental evidence. For instance, TSPO was reported to 
exist in several forms of oligomers since multiple bands were detected in a western blot using TSPO 
polyclonal antisera (Delavoie et al., 2003). These extra bands are likely nonspecific as they have not been 
reported in studies using TSPO monoclonal antibodies (Morohaku et al., 2014; Tu et al., 2014). 
Crystallographic studies of bacterial TSPO concluded that purified TSPO formed a highly stable dimer 
(Guo et al., 2015; Li et al., 2015) while the NMR structure of mouse TSPO was found to be a monomer 
(Jaremko et al., 2014). Moreover, the dimerization interface was completely different between Bacillus 
cereus and Rhodobacter sphaeroides TSPO (Guo et al., 2015; Li et al., 2015), raising questions why the 
dimerization sites are not conserved and whether the dimerization itself is an artifact due to hydrophobic 
aggregation of TSPO during purification and/or crystallization. Our study not only confirmed TSPO 
dimerization but also demonstrated that the dimer form is likely to have biological significance. TSPO 
dimerization is greatly induced or stabilized only by porphyrins, particularly PPIX, suggesting that 
shielding PPIX from degradation or bioconversion requires TSPO in the dimer form. However, the exact 
dimerization interface remains to be investigated. 
Level of free PPIX in cells and tissues is directly regulated by TSPO and correlates with the level 
of TSPO expression. Therefore, we speculate that cell type-dependent biological effects of TSPO reported 
in literature are mediated by biological actions of PPIX, rather than directly by TSPO. PPIX is believed to 
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be committed to heme synthesis and has no other function in cells. However, early reports showed that level 
of free PPIX is readily detectable in many tissues at varying degrees under different pathological conditions. 
In neoplastic diseases and chronic circulatory disorders, free PPIX was abundant in many tissues but highest 
in adrenal glands, with values up to 100 and 200 times higher than in normal adrenals respectively 
(Zawirska, 1978). In adrenal tumorous diseases without hyperplastic lesions, level of PPIX was even 4 
times higher than adrenals of patients with porphyria (Zawirska, 1977), a disorder that causes severe build-
up of porphyrins in the body. Interestingly, this marked elevation only applied to PPIX, not copro- or uro- 
porphyrins, suggesting a specific regulation for PPIX in the tissues. When rats were starved for 24 hrs, 
activity of ALA synthase, the rate-limiting enzyme to synthesize porphyrins, doubled in the adrenal glands 
but stayed the same in the liver. This led to accumulation of PPIX in adrenals that was surprisingly not 
accompanied by any changes in the heme content of the tissue (Condie et al., 1976). These data clearly 
indicate unknown biological functions of PPIX that are tightly regulated under physiological and 
pathological conditions. Our study reports for the first time a strong correlation between PPIX level and 
lipid-rich tissues. When mice were injected with ALA to induce PPIX production in the whole body, 
mitochondrial FAO was strikingly inhibited in the liver and the effect was more prominent when PPIX was 
preserved in the presence of TSPO. This also explains why TSPO, by binding and maintaining high level 
of PPIX in the OMM, has an inhibitory effect on FAO and deletion of TSPO in the mice and MA-10 cells 
lifts up this inhibitory mechanism, causing a surge in mitochondrial FAO as observed in both systems. 
Although evidence for biological functions of PPIX is extremely limited, there has been direct 
evidence that PPIX could bind to several proteins such as soluble guanylate cyclase (Ignarro et al., 1982), 
transferases (Smith et al., 1985), beta lactoglobulin (Dufour et al., 1990), hemoglobin and myoglobin (Sil 
et al., 2004). The binding site could be the same as heme due to their similarity in structure, or distinct. 
Some of these bindings have been characterized to have biological significance as they modify protein 
functions. PPIX, but not other structural analogs, is a strong activator of soluble guanylate cyclase (Ignarro 
et al., 1982), hence significantly increased cGMP-mediated relaxation of bovine pulmonary arteries 
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(Mingone et al., 2006). Furthermore, among all naturally occurring porphyrins, PPIX was found to be the 
strongest inhibitor of glutathione S-transferase isozymes (Smith et al., 1985), the key detoxifying enzymes 
important for cellular metabolism. Other biological effects reported for PPIX with unknown molecular 
mechanism include inhibition of HIV virus replication, not due to inhibition of viral enzyme reverse 
transcriptase (Asanaka et al., 1989); and induction of Heme-binding protein 23kDa (HBP23) mRNA 
expression to a similar level elicited by heme (Immenschuh et al., 1997). Interestingly, the inhibitory effect 
of PPIX on HIV virus replication could underlie the inhibitory effect of TSPO on HIV-1 replication in 
human CD4(+) T cell line (Zhou et al., 2014). From these studies, we speculate that PPIX could have 
diverse biological functions, including inhibition of FAO, but the molecular mechanism of action is a brand-
new area to investigate. A few possible mechanisms are: 1/ PPIX inserts into different lipid membranes due 
to its high hydrophobicity and alters functions of membrane proteins; 2/ similar to heme, PPIX directly 
binds to proteins, changes protein conformation and functions; 3/ PPIX is converted to some other 
metabolites that have bioactivities.  
Our study concludes that TSPO sequesters PPIX, protects it from degradation or bioconversion, 
and therefore directly regulates level of free PPIX in cells. Similar to TSPO, PPIX is enriched in tissues 
rich in lipid droplets and has an inhibitory effect on mitochondrial FAO. Although the range of biological 
functions for PPIX remain elucidated, reported effects of TSPO in various systems needs careful 
interpretation as they could be mediated through PPIX. TSPO, therefore, maybe better known as a the 
Tetrapyrrole Sequestering PrOtein. 
 
 
 
 
 
126 
REFERENCES 
Asanaka, M., T. Kurimura, H. Toya, J. Ogaki, and Y. Kato. 1989. Anti-HIV activity of protoporphyrin. 
AIDS (London, England). 3:403-404. 
Banati, R.B., R.J. Middleton, R. Chan, C.R. Hatty, W.W. Kam, C. Quin, M.B. Graeber, A. Parmar, D. 
Zahra, P. Callaghan, S. Fok, N.R. Howell, M. Gregoire, A. Szabo, T. Pham, E. Davis, and G.J. Liu. 
2014. Positron emission tomography and functional characterization of a complete PBR/TSPO 
knockout. Nature communications. 5:5452. 
Bovolin, P., J. Schlichting, M. Miyata, C. Ferrarese, A. Guidotti, and H. Alho. 1990. Distribution and 
characterization of diazepam binding inhibitor (DBI) in peripheral tissues of rat. Regulatory peptides. 
29:267-281. 
Busch, A.W., Z. WareJoncas, and B.L. Montgomery. 2017. Tryptophan-Rich Sensory Protein/Translocator 
Protein (TSPO) from Cyanobacterium Fremyella diplosiphon Binds a Broad Range of Functionally 
Relevant Tetrapyrroles. Biochemistry. 56:73-84. 
Campeau, E., V.E. Ruhl, F. Rodier, C.L. Smith, B.L. Rahmberg, J.O. Fuss, J. Campisi, P. Yaswen, P.K. 
Cooper, and P.D. Kaufman. 2009. A versatile viral system for expression and depletion of proteins in 
mammalian cells. PloS one. 4:e6529. 
Condie, L.W., T.R. Tephly, and J. Barbon. 1976. Studies on heme synthesis in the rat adrenal. Ann Clin 
Res. 8 Suppl 17:83-88. 
Delavoie, F., H. Li, M. Hardwick, J.C. Robert, C. Giatzakis, G. Peranzi, Z.X. Yao, J. Maccario, J.J. 
Lacapere, and V. Papadopoulos. 2003. In vivo and in vitro peripheral-type benzodiazepine receptor 
polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry. 42:4506-
4519. 
Dimitrova-Shumkovska, J., L. Veenman, T. Ristoski, S. Leschiner, and M. Gavish. 2010. Chronic high fat, 
high cholesterol supplementation decreases 18 kDa Translocator Protein binding capacity in association 
with increased oxidative stress in rat liver and aorta. Food and chemical toxicology : an international 
journal published for the British Industrial Biological Research Association. 48:910-921. 
Dufour, E., M.C. Marden, and T. Haertle. 1990. Beta-lactoglobulin binds retinol and protoporphyrin IX at 
two different binding sites. FEBS letters. 277:223-226. 
Gatliff, J., D. East, J. Crosby, R. Abeti, R. Harvey, W. Craigen, P. Parker, and M. Campanella. 2014. TSPO 
interacts with VDAC1 and triggers a ROS-mediated inhibition of mitochondrial quality control. 
Autophagy. 10:2279-2296. 
Ginter, C., I. Kiburu, and O. Boudker. 2013. Chemical catalysis by the translocator protein (18 kDa). 
Biochemistry. 52:3609-3611. 
Guilarte, T.R., M.K. Loth, and S.R. Guariglia. 2016. TSPO Finds NOX2 in Microglia for Redox 
Homeostasis. Trends in pharmacological sciences. 
Guo, Y., R.C. Kalathur, Q. Liu, B. Kloss, R. Bruni, C. Ginter, E. Kloppmann, B. Rost, and W.A. 
Hendrickson. 2015. Protein structure. Structure and activity of tryptophan-rich TSPO proteins. Science 
(New York, N.Y.). 347:551-555. 
Ignarro, L.J., K.S. Wood, and M.S. Wolin. 1982. Activation of purified soluble guanylate cyclase by 
protoporphyrin IX. Proceedings of the National Academy of Sciences of the United States of America. 
79:2870-2873. 
Immenschuh, S., C. Nell, S. Iwahara, N. Katz, and U. Muller-Eberhard. 1997. Gene regulation of HBP 23 
by metalloporphyrins and protoporphyrin IX in liver and hepatocyte cultures. Biochem Biophys Res 
Commun. 231:667-670. 
Jaremko, L., M. Jaremko, K. Giller, S. Becker, and M. Zweckstetter. 2014. Structure of the mitochondrial 
translocator protein in complex with a diagnostic ligand. Science (New York, N.Y.). 343:1363-1366. 
Kind, T., K.H. Liu, Y. Lee do, B. DeFelice, J.K. Meissen, and O. Fiehn. 2013. LipidBlast in silico tandem 
mass spectrometry database for lipid identification. Nature methods. 10:755-758. 
127 
Leduc, M.S., R.S. Hageman, R.A. Verdugo, S.W. Tsaih, K. Walsh, G.A. Churchill, and B. Paigen. 2011. 
Integration of QTL and bioinformatic tools to identify candidate genes for triglycerides in mice. Journal 
of lipid research. 52:1672-1682. 
Lee, K., J. Kerner, and C.L. Hoppel. 2011. Mitochondrial carnitine palmitoyltransferase 1a (CPT1a) is part 
of an outer membrane fatty acid transfer complex. The Journal of biological chemistry. 286:25655-
25662. 
Lee, L., C.A. DeBono, D.R. Campagna, D.C. Young, D.B. Moody, and M.D. Fleming. 2007. Loss of the 
acyl-CoA binding protein (Acbp) results in fatty acid metabolism abnormalities in mouse hair and skin. 
The Journal of investigative dermatology. 127:16-23. 
Li, F., J. Liu, Y. Zheng, R.M. Garavito, and S. Ferguson-Miller. 2015. Protein structure. Crystal structures 
of translocator protein (TSPO) and mutant mimic of a human polymorphism. Science (New York, N.Y.). 
347:555-558. 
Lin, R., A. Angelin, F. Da Settimo, C. Martini, S. Taliani, S. Zhu, and D.C. Wallace. 2014. Genetic analysis 
of dTSPO, an outer mitochondrial membrane protein, reveals its functions in apoptosis, longevity, and 
Ab42-induced neurodegeneration. Aging cell. 13:507-518. 
Livak, K.J., and T.D. Schmittgen. 2001. Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif.). 25:402-408. 
McEnery, M.W., A.M. Snowman, R.R. Trifiletti, and S.H. Snyder. 1992. Isolation of the mitochondrial 
benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine 
nucleotide carrier. Proceedings of the National Academy of Sciences of the United States of America. 
89:3170-3174. 
Mingone, C.J., S.A. Gupte, J.L. Chow, M. Ahmad, N.G. Abraham, and M.S. Wolin. 2006. Protoporphyrin 
IX generation from delta-aminolevulinic acid elicits pulmonary artery relaxation and soluble guanylate 
cyclase activation. Am J Physiol Lung Cell Mol Physiol. 291:L337-344. 
Morohaku, K., S.H. Pelton, D.J. Daugherty, W.R. Butler, W. Deng, and V. Selvaraj. 2014. Translocator 
protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. 
Endocrinology. 155:89-97. 
Neess, D., M. Bloksgaard, S. Bek, A.B. Marcher, I.C. Elle, T. Helledie, M. Due, V. Pagmantidis, B. Finsen, 
J. Wilbertz, M. Kruhoffer, N. Faergeman, and S. Mandrup. 2011. Disruption of the acyl-CoA-binding 
protein gene delays hepatic adaptation to metabolic changes at weaning. The Journal of biological 
chemistry. 286:3460-3472. 
Passonneau, J.V., and V.R. Lauderdale. 1974. A comparison of three methods of glycogen measurement in 
tissues. Analytical biochemistry. 60:405-412. 
Rampon, C., M. Bouzaffour, M.A. Ostuni, P. Dufourcq, C. Girard, J.M. Freyssinet, J.J. Lacapere, G. 
Schweizer-Groyer, and S. Vriz. 2009. Translocator protein (18 kDa) is involved in primitive 
erythropoiesis in zebrafish. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology. 23:4181-4192. 
Rone, M.B., A.S. Midzak, L. Issop, G. Rammouz, S. Jagannathan, J. Fan, X. Ye, J. Blonder, T. Veenstra, 
and V. Papadopoulos. 2012. Identification of a dynamic mitochondrial protein complex driving 
cholesterol import, trafficking, and metabolism to steroid hormones. Mol Endocrinol. 26:1868-1882. 
Shaw, A.K., and S.K. Pal. 2008. Resonance energy transfer and ligand binding studies on pH-induced 
folded states of human serum albumin. J Photochem Photobiol B. 90:187-197. 
Sil, S., T. Bose, D. Roy, and A.S. Chakraborti. 2004. Protoporphyrin IX-induced structural and functional 
changes in human red blood cells, haemoglobin and myoglobin. J Biosci. 29:281-291. 
Smith, A., I. Nuiry, and Y.C. Awasthi. 1985. Interactions with glutathione S-transferases of porphyrins 
used in photodynamic therapy and naturally occurring porphyrins. Biochem J. 229:823-831. 
Spandidos, A., X. Wang, H. Wang, and B. Seed. 2010. PrimerBank: a resource of human and mouse PCR 
primer pairs for gene expression detection and quantification. Nucleic acids research. 38:D792-799. 
Thompson, M.M., H.C. Manning, and K.L. Ellacott. 2013. Translocator protein 18 kDa (TSPO) is regulated 
in white and brown adipose tissue by obesity. PloS one. 8:e79980. 
128 
Tsugawa, H., T. Cajka, T. Kind, Y. Ma, B. Higgins, K. Ikeda, M. Kanazawa, J. VanderGheynst, O. Fiehn, 
and M. Arita. 2015. MS-DIAL: data-independent MS/MS deconvolution for comprehensive 
metabolome analysis. Nature methods. 12:523-526. 
Tu, L.N., K. Morohaku, P.R. Manna, S.H. Pelton, W.R. Butler, D.M. Stocco, and V. Selvaraj. 2014. 
Peripheral benzodiazepine receptor/translocator protein global knock-out mice are viable with no 
effects on steroid hormone biosynthesis. The Journal of biological chemistry. 289:27444-27454. 
Tu, L.N., M.R. Showalter, T. Cajka, S. Fan, V.V. Pillai, O. Fiehn, and V. Selvaraj. 2017. Metabolomic 
characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci Rep. 
7:6120. 
Tu, L.N., A.H. Zhao, M. Hussein, D.M. Stocco, and V. Selvaraj. 2016. Translocator Protein (TSPO) Affects 
Mitochondrial Fatty Acid Oxidation in Steroidogenic Cells. Endocrinology. 157:1110-1121. 
Tu, L.N., A.H. Zhao, D.M. Stocco, and V. Selvaraj. 2015. PK11195 effect on steroidogenesis is not 
mediated through the translocator protein (TSPO). Endocrinology. 156:1033-1039. 
Vanhee, C., G. Zapotoczny, D. Masquelier, M. Ghislain, and H. Batoko. 2011. The Arabidopsis multistress 
regulator TSPO is a heme binding membrane protein and a potential scavenger of porphyrins via an 
autophagy-dependent degradation mechanism. The Plant cell. 23:785-805. 
Veenman, L., A. Vainshtein, N. Yasin, M. Azrad, and M. Gavish. 2016. Tetrapyrroles as Endogenous TSPO 
Ligands in Eukaryotes and Prokaryotes: Comparisons with Synthetic Ligands. International journal of 
molecular sciences. 17. 
Verma, A., J.S. Nye, and S.H. Snyder. 1987. Porphyrins are endogenous ligands for the mitochondrial 
(peripheral-type) benzodiazepine receptor. Proceedings of the National Academy of Sciences of the 
United States of America. 84:2256-2260. 
Wade, F.M., C. Wakade, V.B. Mahesh, and D.W. Brann. 2005. Differential expression of the peripheral 
benzodiazepine receptor and gremlin during adipogenesis. Obesity research. 13:818-822. 
Wang, H., K. Zhai, Y. Xue, J. Yang, Q. Yang, Y. Fu, Y. Hu, F. Liu, W. Wang, L. Cui, H. Chen, J. Zhang, 
and W. He. 2016. Global Deletion of TSPO Does Not Affect the Viability and Gene Expression Profile. 
PloS one. 11:e0167307. 
Yeliseev, A.A., and S. Kaplan. 1995. A sensory transducer homologous to the mammalian peripheral-type 
benzodiazepine receptor regulates photosynthetic membrane complex formation in Rhodobacter 
sphaeroides 2.4.1. The Journal of biological chemistry. 270:21167-21175. 
Yeliseev, A.A., and S. Kaplan. 1999. A novel mechanism for the regulation of photosynthesis gene 
expression by the TspO outer membrane protein of Rhodobacter sphaeroides 2.4.1. The Journal of 
biological chemistry. 274:21234-21243. 
Yeliseev, A.A., and S. Kaplan. 2000. TspO of rhodobacter sphaeroides. A structural and functional model 
for the mammalian peripheral benzodiazepine receptor. The Journal of biological chemistry. 275:5657-
5667. 
Zawirska, B. 1977. Porphyrins and morphology of the adrenals in some endocrinologic syndromes and 
other diseases. Mater Med Pol. 9:26-33. 
Zawirska, B. 1978. Organ Porphyrins in Human Circulatory Disorders and Neoplastic Disease.  Diagnosis 
and Therapy of Porphyrias and Lead Intoxication. Diagnosis and Therapy of Porphyrias and Lead 
Intoxication. 
Zhang, P. 2012. Analysis of Mouse Liver Glycogen Content. Bio-protocol. 2:e186. 
Zhao, A.H., L.N. Tu, C. Mukai, M.P. Sirivelu, V.V. Pillai, K. Morohaku, R. Cohen, and V. Selvaraj. 2016. 
Mitochondrial Translocator Protein (TSPO) Function Is Not Essential for Heme Biosynthesis. The 
Journal of biological chemistry. 291:1591-1603. 
Zhou, T., Y. Dang, and Y.H. Zheng. 2014. The mitochondrial translocator protein, TSPO, inhibits HIV-1 
envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation 
pathway. Journal of virology. 88:3474-3484. 
129 
CHAPTER 6 
Final Conclusions and Future Directions 
130 
 
My studies and 25 years of TSPO research  
The highly prevalent model linking TSPO to steroidogenesis was presumptively built on extensive 
pharmacological and genetic studies. Although it is not our intention to criticize, we are under obligation 
to point out that almost all mechanistic studies emanated from a single research group led by Papadopoulos 
and their collaborators. This model has apparently misled the field of TSPO research for the past 25 years, 
and acceptance of these results prevented the search for the true function of TSPO. Their early reports 
claiming that deletion of TSPO caused embryonic lethality in mice (Papadopoulos et al., 1997a) and 
severely decreased viability in cells (Papadopoulos et al., 1997b) discouraged further attempts to generate 
genetic tools to rigorously evaluate TSPO as a pharmacological target and its precise function. Our careful 
reappraisal of 25-year TSPO literature revealed serious inconsistencies and limitations in these studies that 
led to the inaccurate association of TSPO and steroidogenesis (Selvaraj et al., 2015). Our lab also generated 
the first global Tspo-/- mice and showed that TSPO is not required for survival and development as the  
Tspo-/- mice were healthy with no apparent abnormalities (Tu et al., 2014). Both knocking-down and 
knocking-out of TSPO in different steroidogenic cell lines did not affect cell viability (Tu et al., 2014; Tu 
et al., 2015). Furthermore, steroid hormone production was not affected in Tspo-/- mice as well as 
steroidogenic cells lacking TSPO compared to the controls (Tu et al., 2014; Tu et al., 2015). These findings, 
reproduced by 2 other independent laboratories (Banati et al., 2014; Wang et al., 2016), refuted the 25-year 
old dogma and removed TSPO as being a component of the steroid biosynthetic machinery associated with 
the mitochondria.  
The modest stimulating effects of some TSPO binding chemicals on steroid hormone production 
are often cited as the early evidence linking TSPO and steroidogenesis (Krueger and Papadopoulos, 1990; 
Papadopoulos et al., 1990; Papadopoulos et al., 1991). The proposed therapeutic applications of these 
chemicals in human medicine are also based on the theory that they could stimulate de novo steroid hormone 
synthesis at the target sites (Nothdurfter et al., 2012). Since TSPO is shown not involved in steroidogenesis, 
the use of these chemicals becomes questionable due to unclear mechanism of action. Moreover, potential 
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off-target effects of TSPO binding chemicals have not been seriously examined, although there are reports 
in the literature of TSPO-independent actions of several chemicals, particularly PK11195 (Gonzalez-Polo 
et al., 2005; Hans et al., 2005; Seneviratne et al., 2012). Using the TSPO knock out MA-10 Leydig cancer 
cells, I performed the very first target validation demonstrating that PK11195 considered the prototypical 
TSPO binding drug could induce steroid hormone production to the same extent regardless of the presence 
or absence of TSPO (Tu et al., 2015). This indicated that the effect of PK11195 on steroidogenesis may be 
mediated through binding to an unidentified cellular target other than TSPO in steroid hormone producing 
cells. Such rigorous target validation studies were not previously possible as it was widely believed that 
TSPO-deleted cells would not be viable. These findings hence raise immediate concerns over the use of 
TSPO binding drugs in clinical trials due to the lack of a known target function and unpredictable side 
effects.   
Although TSPO is not involved in steroidogenesis, its high expression in steroidogenic tissues such 
as the adrenal glands is irrefutable. Upon extensive tissue profiling, I found that TSPO is enriched in tissues 
rich in lipid droplets including adipose tissues, suggesting a role in lipid metabolism instead of 
steroidogenesis (Tu et al., 2016). Using both TSPO knockout MA-10 cells and Tspo-/- mice as the models, 
I demonstrated that deletion of TSPO increased mitochondrial fatty acid oxidation (FAO). In searching for 
a mechanism underlying this phenotype, I performed co-immunoprecipitation to identify interacting 
partners of TSPO that are involved in regulating FAO. Interestingly, my study demonstrated that TSPO did 
not have any interacting partners, but formed a dimer, which could be induced or stabilized by 
protoporphyrin IX (PPIX), the endogenous ligand of TSPO. Level of PPIX was found to be high in tissues 
rich in lipid droplets and directly regulated by TSPO. This study is the first to report such correlation 
between free PPIX level and lipid-rich tissues. Although TSPO-PPIX interaction has long been documented 
in the literature, the biological significance especially in mammalian systems has not been characterized in 
depth. Moreover, my findings suggest that conclusions from studies in which TSPO was placed in different 
models interacting with different proteins (Gatliff et al., 2014; Guilarte et al., 2016; Rone et al., 2012) or 
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shown to form dimers and oligomers (Delavoie et al., 2003; Guo et al., 2015; Li et al., 2015) were likely 
misinterpreted due to artifacts and technical limitations. TSPO indeed dimerizes to sequester PPIX but the 
dimerization interface remains to be examined.  
TSPO has been demonstrated to have many biological effects in different systems and organisms 
(Gatliff et al., 2014; Guilarte et al., 2016; Rone et al., 2012) but these effects are unrelated and no studies 
have attempted to connect them or unify them by providing the exact molecular mechanism of TSPO. I 
proposed that throughout different kingdoms, sequestering PPIX and increasing its availability is the 
primary conserved function of TSPO, and the reported cell type-dependent biological effects for TSPO are 
mediated by biological actions of PPIX in cells rather than directly by TSPO. However, studies on PPIX 
function are extremely limited, making it challenging to provide satisfactory explanations to all biological 
effects reported for TSPO. My study attempted to find a mechanism how TSPO inhibits FAO in cells and 
mice and found that this effect could be attributed to the biological action of PPIX. The finding that high 
level of PPIX could severely inhibit FAO is novel and serves as very first evidence for one of PPIX 
functions in cells.   
In conclusion, my studies help correct the current model of TSPO function in steroidogenesis and 
identify the true function of TSPO in sequestering and protecting PPIX from degradation, without any 
“translocator” function. Therefore, TSPO needs to be renamed as the Tetrapyrrole Sequestering PrOtein, 
so that the gene and protein nomenclature provides a relationship to function. 
  
Future directions 
Since TSPO is now removed from the steroidogenic machinery, it paves the way for active research 
in the field of steroidogenesis to elucidate the mechanism of how cholesterol is delivered from the cytosol 
or OMM to IMM. The steroidogenic acute regulatory protein (STAR) is a strong candidate as its expression 
in steroidogenic cells in the absence of hormone stimulation resulted in an increase in steroid biosynthesis 
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(Clark et al., 1994). Mutations in the Star gene were responsible for the potentially fatal lipoid congenital 
adrenal hyperplasia (lipoid CAH), a disease in which severely afflicted individuals are unable to synthesize 
steroids (Lin et al., 1995). Currently, STAR has been modeled to deliver cholesterol to the OMM and TSPO 
carried out the mitochondrial cholesterol import process. Since we now know such cooperation does not 
exist, re-examining the exact mode of action of STAR or identify other partners that assist STAR in this 
process will shed light on the mechanism of cholesterol transport for steroidogenesis.  
Binding of TSPO to PPIX has long been documented but the binding site of PPIX to TSPO remains 
to be characterized. It is also important to determine if PPIX binding site is close to or the same as that of 
other TSPO binding chemicals and how interaction with the binding chemicals affects the function of TSPO 
in PPIX sequestering. This will help to interpret or predict the biological effects of the TSPO binding 
chemicals more accurately once we understand the biological actions of PPIX in cells. In addition, structural 
studies on TSPO dimerization are not yet conclusive. Recent crystallographic studies of bacterial TSPO 
presented different dimerization interfaces between Bacillus cereus and Rhodobacter sphaeroides TSPO 
(Guo et al., 2015; Li et al., 2015); this could be artefactual due to a forced conformation that may be needed 
a transmembrane protein like TSPO to crystalize. Dimerization was not found in an NMR study of murine 
TSPO (Jaremko et al., 2014). Perhaps examining membrane-bound TSPO structure in the presence of PPIX 
using high resolution NMR would provide us with more precise information on TSPO dimerization and the 
structural interface mediating this process.   
Since TSPO directly regulates the level of PPIX in cells, the ultimate biological effects by targeting 
TSPO would largely depend on PPIX actions in cells. Therefore, elucidating biological functions of PPIX 
is critical to interpret biological effects reported for TSPO, such as its upregulation in neuroinflammation 
and other diseases.  This would certainly be an interesting new research area in the future. And until more 
information about PPIX actions is uncovered, the potential of TSPO as a therapeutic target may not be 
realized in human medicine.  
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